record_id,name,DOI,year,journal,cancer_type,stage,comparison_arms,discusses_irAE,irAE_subgroup_analysis,irAE_grading_reported,irAE_organs_reported,reports_OS,reports_PFS,study_design,sample_size,immunotherapy_agent,followup_median_months,irAE_incidence_any_grade,irAE_incidence_grade3plus,biomarker_reported,quality_score,eligibility_decision,treatment_line,combination_regimen,prior_immunotherapy,geographic_region,specific_irAE_incidence,irAE_management_summary,specific_biomarker_status,study_type,ECOG_status,PROs_related_irAE
1,Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial,10.1016/j.ejca.2025.115431,2025,European Journal of Cancer,Melanoma,Advanced,"['Pembrolizumab monotherapy', 'Pembrolizumab + intermittent dabrafenib + trametinib']",yes,yes,yes,no,yes,yes,Randomized controlled trial,32,Pembrolizumab,73,,,BRAFV600E/K-mutated,,eligible,Treatment-naïve,Dabrafenib + Trametinib,no,,"{'grade3plus_cohort1': 12, 'grade3plus_cohort2': 12, 'grade3plus_cohort3': 38, 'grade3plus_cohort4': 63}",,BRAFV600E/K-mutated,,,
2,"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study",10.1016/j.ejca.2025.115381,2025,European Journal of Cancer,Melanoma,IIB or IIC,"['Pembrolizumab', 'Placebo']",yes,no,no,no,no,yes,"Randomized, controlled, phase III",976,Pembrolizumab,52.8,,,no,,eligible,Adjuvant,no,no,,{},,,Clinical Trial,,
3,A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial,10.1016/j.annonc.2024.12.014,2025,Annals of Oncology,pleural mesothelioma,advanced,"['atezolizumab + bevacizumab + carboplatin-pemetrexed (ABC)', 'bevacizumab + carboplatin-pemetrexed (BC)']",yes,no,yes,no,yes,yes,"randomized, open-label, phase III",400,atezolizumab,35,,55,histology,,yes,first-line,bevacizumab + carboplatin-pemetrexed,no,,,,epithelioid; non-epithelioid,clinical trial,65% ECOG PS 1,yes
4,A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM),10.1016/j.esmoop.2025.104554,2025,ESMO Open,squamous cell carcinoma of the head and neck,recurrent/metastatic,"['durvalumab + monalizumab', ""physician's choice (control)""]",yes,no,yes,no,yes,yes,"phase II, randomized, open-label substudy",66,"monalizumab, durvalumab",,,9.0,no,,eligible,second or third line,durvalumab + monalizumab,anti-PD(L)1,,,,,clinical trial,,
5,,10.1136/jitc-2024-011314,2025,Journal for ImmunoTherapy of Cancer,Triple-negative breast cancer,Metastatic,"['bevacizumab 7.5 mg/kg', 'bevacizumab 15 mg/kg']",yes,no,no,yes,yes,yes,Phase II trial,30,tislelizumab,,,,yes,,eligible,First-line,"bevacizumab, tislelizumab, nab-paclitaxel",no,,{'Hypothyroidism': 30.0},,"interleukin (IL)-1α, IL-2, vascular endothelial growth factor-A, insulin-like growth factor binding protein-7",,,
6,First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study,10.1007/s12325-024-03069-4,2025,Advances in Therapy,Gastric or gastroesophageal junction cancer,Locally advanced or metastatic,"['Pembrolizumab plus chemotherapy', 'Placebo plus chemotherapy']",yes,no,yes,no,yes,yes,"Randomized, phase 3",236,Pembrolizumab,24.7,,,HER2,,eligible,First-line,Chemotherapy (fluoropyrimidine- and platinum-containing),no,Mainland China,,manageable toxicity,HER2-negative,Subgroup analysis,,
7,"A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial",10.1016/j.lungcan.2025.108454,2025,Lung Cancer,NSCLC,,"['atezolizumab + bevacizumab + carboplatin/paclitaxel', 'atezolizumab + bevacizumab + pemetrexed']",yes,no,yes,no,yes,yes,"randomised, non-comparative, phase II",95,atezolizumab,19,,,EGFR mutation,,yes,,atezolizumab + bevacizumab + chemotherapy,,,,,EGFR-mutant,Clinical Trial,,
8,First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia,10.1093/jjco/hyae182,2025,Japanese Journal of Clinical Oncology,Renal Cell Carcinoma,Metastatic,"['pembrolizumab-axitinib', 'sunitinib']",yes,no,yes,no,yes,yes,"Phase 3, open-label, randomized",130,Pembrolizumab,,,69.4,no,,eligible,First-line,Pembrolizumab + Axitinib,no,"East Asia (Japan, South Korea, Taiwan)",,,,Subgroup analysis,,
9,Efficacy and safety of tislelizumab combined with platinum-based drugs in treatment of advanced non-small cell lung cancer,10.3760/cma.j.cn115355-20240108-00018,2025,Cancer Research and Clinic,non-small cell lung cancer,advanced,"['platinum-based drugs combined with tislelizumab', 'platinum-based drugs']",yes,no,no,yes,no,no,randomized controlled study,86,tislelizumab,,,,yes,,yes,,platinum-based drugs,no,China,"{'skin itching': 23.3, 'rash': 20.9, 'diarrhea': 48.8}",,programmed death receptor ligand 1 expression,prospective,,
10,Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action,10.1016/j.jid.2024.03.048,2025,Journal of Investigative Dermatology,,,"['tebentafusp', ""investigator's choice""]",yes,yes,no,yes,yes,no,randomized phase 3 trial,378,Tebentafusp,,,,yes,,eligible,,,,,,,"gp100, HLA-A*02:01",,,
11,"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial",10.1016/S1470-2045(24)00757-5,2025,The Lancet Oncology,Breast Cancer,"I, II, III","['nivolumab lead-in group', 'concurrent nivolumab group']",yes,no,yes,no,no,no,"randomized, open-label, phase 2",108,Nivolumab,12,,65,no,,eligible,neoadjuvant,"carboplatin, paclitaxel",no,"Australia, New Zealand, Italy",,,,clinical trial,0-1,
12,Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN),10.1016/S1556-0864(25)00382-X,2025,Journal of Thoracic Oncology,NSCLC,II-IIIB (N2),"['durvalumab + neoadjuvant CT', 'placebo + neoadjuvant CT']",yes,no,no,no,no,no,"double-blind, PBO-controlled study",,durvalumab,,,,,,eligible,perioperative,neoadjuvant platinum-based chemotherapy,no,,,,,clinical trial,0/1,yes
13,Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial,10.1038/s41591-024-03360-5,2025,Nature Medicine,Rectal cancer,Locally advanced,"['neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade', 'neoadjuvant chemoradiation alone']",yes,no,no,no,no,no,Randomized phase 2 trial,186,PD-1 blockade,,,,Mismatch repair status,,yes,Neoadjuvant,Chemoradiation,no,Beijing,,,proficient mismatch repair and deficient mismatch repair,Clinical Trial,,no
14,Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma,10.1016/j.jhep.2024.07.017,2025,Journal of Hepatology,Hepatocellular Carcinoma,Unresectable,"['STRIDE (Single Tremelimumab Regular Interval Durvalumab)', 'Durvalumab monotherapy', 'Sorafenib']",yes,no,yes,no,yes,no,Randomized controlled trial,479,"Tremelimumab, Durvalumab",,,19.9,no,,eligible,,Tremelimumab + Durvalumab,no,"Asia (Hong Kong, India, South Korea, Taiwan, Thailand, Vietnam)",,,,Clinical Trial,,
15,,10.1016/S2213-2600(24)00264-9,2025,The Lancet Respiratory Medicine,non-small-cell lung cancer,IV,"['nivolumab plus ipilimumab', 'platinum-based doublet chemotherapy']",yes,no,yes,yes,yes,yes,"randomised, open-label, phase 3",217,"nivolumab, ipilimumab",,,,no,,eligible,first-line,nivolumab plus ipilimumab,no,France,"{'endocrine disorders': 0.05, 'cardiac disorders': 0.1, 'gastrointestinal disorders': 0.11}",,,clinical trial,0-2,
16,Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma,10.1016/j.clgc.2024.102264,2025,Clinical Genitourinary Cancer,Renal Cell Carcinoma,Advanced,"['lenvatinib plus pembrolizumab', 'lenvatinib plus everolimus', 'sunitinib']",no,no,no,no,no,no,Markov model,,pembrolizumab,,,,no,,eligible,First-line,lenvatinib plus pembrolizumab; lenvatinib plus everolimus,no,China; United States,,,,Cost-effectiveness analysis,,
17,Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy,10.1016/j.jtho.2024.10.012,2025,Journal of Thoracic Oncology,squamous NSCLC,IV,"['pembrolizumab plus olaparib', 'pembrolizumab plus placebo']",no,no,no,no,yes,yes,"randomized, double-blind, phase 3 trial",591,pembrolizumab,33.4,,,,,eligible,first-line,pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel (induction); pembrolizumab + olaparib/placebo (maintenance),no,,,,,Clinical Trial,,
18,Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study,10.1016/j.esmoop.2024.104107,2025,ESMO Open,Gastric cancer and gastroesophageal junction cancer,Advanced/metastatic,"['nivolumab + ipilimumab', 'nivolumab + relatlimab', 'nivolumab + IDO1i']",yes,no,yes,no,no,yes,"randomized, open-label, phase II adaptive-design trial",162,Nivolumab,50.2,,,no,,eligible,Previously treated,"nivolumab + ipilimumab, nivolumab + relatlimab, nivolumab + IDO1i",anti-programmed death-(ligand) 1/anti-CTLA-4-naïve and -experienced,,,,,Clinical Trial,,
19,The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC,10.1016/j.jtho.2024.10.026,2025,Journal of Thoracic Oncology,Nonsquamous NSCLC,Metastatic,"['pembrolizumab plus olaparib', 'pembrolizumab plus pemetrexed']",yes,no,yes,no,yes,yes,Phase 3 randomized controlled trial,672,Pembrolizumab,39.9,,,no,,yes,Maintenance therapy,Pembrolizumab + Olaparib; Pembrolizumab + Pemetrexed,no,,,,,Clinical Trial,,
20,"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study",10.1016/S1470-2045(24)00679-X,2025,The Lancet Oncology,Hepatocellular carcinoma,Locally advanced or metastatic,"['tiragolumab + atezolizumab + bevacizumab', 'atezolizumab + bevacizumab']",yes,no,yes,yes,no,no,"Randomized, open-label, phase 1b-2 umbrella study",59,"Tiragolumab, Atezolizumab",20.6,100,,"PD-L1, TIGIT",,eligible,First-line,Tiragolumab + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab,no,"China, France, Israel, New Zealand, South Korea, Taiwan, USA","{'pruritis': 50, 'arthralgia': 33, 'diarrhoea': 30, 'hypertension_grade3-4': 15, 'aspartate_aminotransferase_increased_grade3-4': 8, 'proteinuria_grade3-4': 5}","Not explicitly detailed, but states 'no new safety signals were identified' and 'addition of tiragolumab did not appear to result in a substantial worsening of treatment-related or immune-mediated adverse events'.",,Clinical Trial,0-1,no
21,"Real-Life Feasibility Of Multiple-Drugs Regimens Including Pembrolizumab In The Treatment Of Persistent, Recurrent Or Metastatic Cervical Cancer",10.1016/j.ijgc.2024.100535,2025,International Journal of Gynecological Cancer,Cervical Cancer,"Recurrent, Persistent, or Metastatic","['CT+B+P', 'CT+P']",yes,no,yes,yes,yes,yes,Prospective observational study,16,Pembrolizumab,10,,55,no,,eligible,,Chemotherapy + Bevacizumab + Pembrolizumab; Chemotherapy + Pembrolizumab,no,Italy,"{'G4 seizure': 6.25, 'G4 immune-related colitis': 6.25, 'G3 allergic reaction': 6.25}",Three patients (18.7%) had a SAE requiring to definitely stop the therapy.,,Observational Study,<=2,
22,"Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)",10.1200/JCO.2025.43.4_suppl.570,2025,Journal of Clinical Oncology,"Extrahepatic cholangiocarcinoma (ECC), Gallbladder cancer (GBC)",resectable,"['chemoradiation-anti-PD-1 group (Camrelizumab + concurrent Capecitabine and radiotherapy)', 'observation group']",yes,no,yes,no,yes,yes,"multicenter, phase 2, randomized controlled trial",93,Camrelizumab,,,,no,,eligible,adjuvant,Camrelizumab + Capecitabine + radiotherapy,no,,,,,RCT,,
23,,10.1200/JCO.2025.43.5_suppl.525,2025,Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['ipilimumab 12-weekly + nivolumab', 'ipilimumab 3-weekly + nivolumab']",yes,yes,yes,no,no,no,Randomized Phase 2,192,"Ipilimumab, Nivolumab",,,,no,,eligible,1st line,Ipilimumab + Nivolumab,no,,,,,Clinical Trial,,yes
25,A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Assess the Risk of Immune-Related Adverse Effects (irAEs) in Patients with Locally Advanced Nasopharyngeal Carcinoma Treated with Immune Checkpoint Inhibitors,10.1158/2326-6074.IO2025-B043,2025,Cancer Immunology Research,Nasopharyngeal Carcinoma,Locally Advanced,"['ICI arm', 'control arm']",yes,yes,yes,yes,no,no,Meta-analysis of RCTs,572,"sintilimab, toripalimab",,57.47,10.39,no,,yes,,Chemoradiation therapy,no,East and Southeast Asia,"{'hypothyroidism_grade1_2': 27.6, 'rash_any_grade': 25, 'rash_high_grade': 5.52, 'pruritus_any_grade': 25, 'allergic_reaction_any_grade': 3.25}",Early detection and appropriate supportive care is essential.,,Systematic Review and Meta-Analysis,,yes
26,,10.1016/S0140-6736(24)02551-0,2025,The Lancet,Hepatocellular Carcinoma,,"['TACE + Durvalumab + Bevacizumab', 'TACE + Durvalumab + Placebo', 'TACE + Placebo']",yes,no,yes,no,yes,yes,"multiregional, randomised, double-blind, placebo-controlled, phase 3",616,"Durvalumab, Bevacizumab",27.9,,,no,,eligible,,TACE,no,multiregional (18 countries),,,,Clinical Trial,0 or 1,
27,"A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer",10.1158/1078-0432.CCR-24-1728,2025,Clinical Cancer Research,Urothelial Cancer,Advanced,"['atezolizumab alone', 'atezolizumab with CYT107']",yes,no,yes,no,no,no,Randomized Phase II,47,Atezolizumab,,,,yes,,yes,after platinum chemotherapy,CYT107,no,,,,"CCL4, VEGFA, TNF",Clinical Trial,,
28,"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence after Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial",10.1200/JCO.24.00773,2025,Journal of Clinical Oncology,Renal Cell Carcinoma,"Localized, high risk of recurrence","['nivolumab', 'placebo', 'nivolumab plus ipilimumab']",yes,no,yes,no,no,yes,"Randomized, placebo-controlled, phase III",825,Nivolumab,27,,,no,,yes,Adjuvant,"Nivolumab monotherapy, Nivolumab plus ipilimumab",no,,,,,Clinical Trial,,
29,Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma,10.1056/NEJMoa2401726,2025,New England Journal of Medicine,Urothelial Carcinoma,Muscle-invasive,"['Pembrolizumab', 'Observation']",yes,no,yes,no,yes,yes,"Phase 3, randomized",702,Pembrolizumab,44.8,,50.6,PD-L1,,eligible,Adjuvant,,no,,,,,Clinical Trial,,
30,Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial,10.1038/s41591-024-03411-x,2025,Nature Medicine,Melanoma,IIIB-D,"['pembrolizumab plus vibostolimab', 'pembrolizumab plus gebasaxturev', 'pembrolizumab monotherapy']",yes,no,yes,no,no,no,"Phase 1/2, adaptive-design",66,"Pembrolizumab, Vibostolimab, Gebasaxturev",,,,yes,,eligible,Neoadjuvant,"Pembrolizumab + Vibostolimab, Pembrolizumab + Gebasaxturev",no,,,,"tumor mutational burden, 18-gene T cell-inflamed gene expression profile",Clinical Trial,,
31,Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials,10.3389/fphar.2025.1535444,2025,Frontiers in Pharmacology,Hepatocellular Carcinoma,advanced or unresectable,"['PD-1/PD-L1 inhibitors combined with TKIs', 'first-line monotherapy or TKI monotherapy']",yes,no,yes,no,yes,yes,meta-analysis of RCTs,2174,PD-1/PD-L1 inhibitors,,,,no,,yes,first-line,PD-1/PD-L1 inhibitors + TKIs,no,Asia,,,,RCT,,
32,Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study,10.1080/14796694.2025.2491297,2025,Future Oncology,small-cell lung cancer,extensive-stage,"['durvalumab + platinum-etoposide (EP)', 'EP']",no,no,no,no,yes,yes,Phase III,537,durvalumab,,,,no,,eligible,first-line,platinum-etoposide,no,,,,,clinical trial,,yes
33,Subcutaneous versus intravenous nivolumab for renal cell carcinoma,10.1016/j.annonc.2024.09.002,2025,Annals of Oncology,Renal cell carcinoma,Advanced/metastatic,"['Subcutaneous nivolumab', 'Intravenous nivolumab']",yes,no,no,no,no,no,"Phase III, open-label, multicenter, noninferiority trial",495,Nivolumab,8,,,no,,eligible,,no,,,{},,,Clinical Trial,,
34,"Increasing Incidence Of Myocarditis Associated With Nivolumab/relatlimab (opdualag), A Retrospective Analysis Of FDA Adverse Event Reporting System Database",10.1016/j.cardfail.2024.10.122,2025,Journal of Cardiac Failure,Melanoma,Unresectable or metastatic,,yes,yes,no,yes,no,no,Retrospective analysis,310,Nivolumab/Relatlimab,,,,no,,eligible,,Nivolumab + Relatlimab,,,"{'myocarditis': 0.0452, 'immune-mediated myocarditis': 0.0258}",,,Post-marketing surveillance,,
35,Tebentafusp (IMCgp100) in the treatment of uveal melanoma — from preclinical evidence to clinical practice,10.5603/njo.104457,2025,Nowotwory,Uveal melanoma,Advanced/metastatic,"['Tebentafusp', ""Investigator's choice (mainly pembrolizumab)""]",yes,no,no,yes,yes,no,Randomized phase III study,378,Tebentafusp,,,,yes,,eligible,untreated,,no,,,,HLA-A*02:01 positive,,,
36,Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial,10.1200/JCO.24.00668,2024,Journal of Clinical Oncology,Ovarian Cancer,Recurrent,"['Atezolizumab + carboplatin doublet + maintenance niraparib', 'Placebo + carboplatin doublet + maintenance niraparib']",yes,no,no,no,no,yes,multicenter placebo-controlled double-blind randomized phase III,417,Atezolizumab,28.6,,,"BRCA status, PD-L1 status",,eligible,one or two previous CT lines,"carboplatin doublet, niraparib",no,,,,,Clinical Trial,,
37,Time-dependent efficacy analysis of first-line immunotherapies for advanced non–small cell lung cancer,10.1186/s12885-024-12439-8,2024,BMC Cancer,non-small cell lung cancer,advanced,"['nivolumab plus ipilimumab', 'pembrolizumab']",no,no,no,no,yes,yes,network meta-analysis,,"nivolumab, ipilimumab, pembrolizumab",,,,yes,,eligible,first-line,nivolumab plus ipilumab,no,,,,PD-L1 expression,RCT,,
38,"The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial",10.1186/s13063-024-08234-2,2024,Trials,renal cell carcinoma,metastatic,"['upfront CN', 'deferred CN', 'systemic therapy (ST) only']",yes,no,no,no,yes,yes,"open-label, multi-center, parallel, prospective, randomized, interventional clinical study",55,nivolumab plus ipilimumab,,,,yes,,eligible,,nivolumab plus ipilimumab,no,,,,"genetic mutation profiles of the tumor tissue, circulating tumor DNA, urine tumor DNA, and tumor-infiltrating lymphocytes. The gut and urine microbial communities",interventional clinical study,,
39,Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial,10.1038/s41467-024-51105-2,2024,Nature Communications,esophageal squamous cell carcinoma,advanced,[],yes,no,yes,no,yes,yes,single-arm phase 2 trial,33,Toripalimab,,,,yes,,eligible,first-line,"chemotherapy, radiotherapy",no,,{},,"CD8 + T cells, CD11c+ dendritic cells, CD68+ macrophages",interventional,,
42,,10.1007/s10147-024-02633-w,2024,International Journal of Clinical Oncology,renal cell carcinoma,advanced,,yes,no,yes,no,yes,yes,retrospective observational study,50,pembrolizumab,,100,66,no,,eligible,first-line,lenvatinib and pembrolizumab,no,Japan,,,,real-world evidence,,
43,Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients,10.1186/s13063-024-08619-3,2024,Trials,squamous cell carcinoma,,"['1% topical sirolimus', 'placebo']",no,no,no,no,no,no,randomized double-blind placebo-controlled trial,146,sirolimus,24,,,,,eligible,,,,,,,,chemoprevention,,
44,Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes,10.1186/s40780-024-00403-4,2024,Journal of Pharmaceutical Health Care and Sciences,,,,yes,no,no,no,yes,no,Review,,nivolumab,,,,,,eligible,,,,,,Pharmacist management of AEs was shown to improve treatment response. Management of AEs is an important role for pharmacists aiming to improve patient QOL and treatment efficacy.,,,,
45,"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial",10.1016/S1470-2045(24)00504-7,2024,The Lancet Oncology,Nasopharyngeal carcinoma,III–IVa,"['Toripalimab + concurrent chemoradiotherapy', 'Placebo + concurrent chemoradiotherapy']",yes,no,yes,no,no,yes,"Randomized, single-center, double-blind, placebo-controlled, phase 2 trial",150,Toripalimab,37.8,,10.0,EBV DNA,,yes,Neoadjuvant and adjuvant,Concurrent chemoradiotherapy,no,China,,,EBV DNA concentration of at least 1500 copies per mL,Interventional,0–1,no
46,Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39,10.1016/j.annonc.2024.10.289,2024,Annals of Oncology,Urothelial Carcinoma,Locally advanced or metastatic,"['Enfortumab vedotin plus pembrolizumab (EV+P)', 'Chemotherapy (gemcitabine with cisplatin or carboplatin)']",yes,no,yes,yes,yes,yes,"Phase III, randomized",886,"Enfortumab vedotin, Pembrolizumab",15.6,,64.9,no,,eligible,First-line,Enfortumab vedotin + Pembrolizumab,no,"Pan-Asian (China, Japan, Korea, Singapore, Thailand, Taiwan)","{'maculopapular rash (G≥3)': 11.7, 'hyperglycemia (G≥3)': 10.6, 'peripheral sensory neuropathy (G≥3)': 7.4, 'skin reactions (G≥3)': 27.7, 'peripheral neuropathy (G≥3)': 8.5, 'severe skin reactions (G≥3)': 18.1, 'pneumonitis (G≥3)': 6.4}",Safety profile was generally manageable.,,Clinical Trial,,
47,"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial",10.1016/S1470-2045(24)00507-2,2024,The Lancet Oncology,Head and neck squamous cell carcinoma (HNSCC),III–IVB p16-negative HNSCC or unfavourable stage I–III p16-positive oropharyngeal or unknown primary carcinoma,"['durvalumab', 'cetuximab']",yes,no,yes,no,no,yes,"open-label, multicentre, parallel-group, randomised, phase 2/3 trial",186,durvalumab,27.6,,,p16 status,,eligible,,Radiotherapy with concurrent and adjuvant durvalumab or cetuximab,no,North America,,,"p16-negative, p16-positive",Clinical Trial,ECOG performance status 2,no
48,"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial",10.1016/j.esmoop.2024.104073,2024,ESMO Open,renal cell carcinoma,advanced,"['Nivolumab + Relatlimab', 'Nivolumab + Ipilimumab']",yes,no,yes,no,no,yes,"randomized, open-label, phase II",60,"Nivolumab, Relatlimab, Ipilimumab",48.6,,,yes,,eligible,IO-naive,"Nivolumab + Relatlimab, Nivolumab + Ipilimumab",no,multi-country (6 countries),,,"LAG-3, PD-L1",clinical trial,,
49,Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer,10.1056/NEJMoa2402141,2024,New England Journal of Medicine,Colorectal Cancer,Metastatic,"['nivolumab plus ipilimumab', 'nivolumab alone', 'chemotherapy with or without targeted therapies']",yes,no,yes,no,no,yes,Phase 3 open-label trial,303,"Nivolumab, Ipilimumab",31.5,,23,MSI-H/dMMR,,eligible,First-line,Nivolumab plus Ipilimumab,no,,,,MSI-H or dMMR,Clinical Trial,,no
50,"Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial",10.1007/s10120-024-01535-0,2024,Gastric Cancer,Gastric/Gastroesophageal junction cancer,Advanced/Recurrent,"['Nivolumab + chemotherapy', 'Placebo + chemotherapy']",yes,no,no,no,yes,yes,"Randomized, double-blind, placebo-controlled, phase 3 trial",717,Nivolumab,36,,,HER2,,yes,First-line,Chemotherapy (SOX or CAPOX),no,"Japan, South Korea, Taiwan",,,HER2-negative,Clinical Trial,,
51,,10.1016/j.annonc.2024.07.727,2024,Annals of Oncology,renal cell carcinoma,advanced,"['Nivolumab plus ipilimumab', 'Sunitinib']",yes,no,no,no,yes,yes,Randomized Controlled Trial,1096,"Nivolumab, Ipilimumab",99.1,,,no,,eligible,first-line,Nivolumab + Ipilimumab,no,,,,,clinical trial,,
52,"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis",10.1016/S1470-2045(24)00457-1,2024,The Lancet Oncology,Hepatocellular Carcinoma,A,[],no,no,no,no,no,yes,Pooled analysis of phase 1 and 2 clinical trials and observational protocols,111,ICI combinations,27.2,,,no,,eligible,Neoadjuvant,ICI combinations,no,"USA, UK, Taiwan",{},,,Clinical Trial,0-1,
53,CISPLATIN VS CARBOPLATIN-BASED CHEMOTHERAPY COMBINED WITH IMMUNE CHECKPOINT INHIBITOR (ICI)- META-ANALYSIS OF EFFICACY AND TOXICITIES IN RANDOMIZED CLINICAL TRIALS,10.1136/jitc-2024-SITC2024.0486,2024,Journal for ImmunoTherapy of Cancer,"Urothelial, Lung, Esophageal, and other cancers",,"['CIS-based chemotherapy + ICI', 'CAR-based chemotherapy + ICI']",yes,yes,yes,no,yes,yes,Meta-analysis of phase 3 trials,29276,"PD1 inhibitor, PD-L1 inhibitor, CTLA4 inhibitor, PD1 plus CTLA4 inhibitor",,,0.07,no,,eligible,,Chemotherapy (Cisplatin or Carboplatin) + ICI,,"Global, Asian",,,,Meta-analysis,,
54,A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma,10.1158/1078-0432.CCR-24-0499,2024,Clinical Cancer Research,Pancreatic Ductal Adenocarcinoma,Metastatic,"['GnP (arm A1)', 'oleclumab (RP2D) with GnP (arm A2)', 'oleclumab (RP2D) with durvalumab plus GnP (arm A3)']",yes,no,yes,no,yes,yes,Phase Ib/II randomized clinical trial,170,"Oleclumab, Durvalumab",,,,yes,,eligible,untreated or previously received gemcitabine-based chemotherapy,Chemotherapy (gemcitabine plus nab-paclitaxel or modified FOLFOX),no,,,,CD73 expression,Clinical Trial,,no
55,Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma,10.1007/s12072-024-10690-6,2024,Hepatology International,Hepatocellular Carcinoma,Advanced,"['HAIC plus camrelizumab and apatinib (TRIPLET protocol)', 'camrelizumab and apatinib (C–A protocol)']",yes,no,yes,no,yes,yes,Retrospective,416,camrelizumab,,,,no,,eligible,,HAIC + camrelizumab + apatinib,no,,,,,,,
56,"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial",10.1038/s41591-024-03132-1,2024,Nature Medicine,extensive-stage small-cell lung cancer (ES-SCLC),extensive-stage,"['benmelstobart and anlotinib plus etoposide/carboplatin (EC)', 'placebo and anlotinib plus EC', ""double placebo plus EC ('EC alone')""]",yes,no,yes,no,yes,yes,"multicenter, double-blind, randomized, placebo-controlled phase 3 trial",738,benmelstobart (PD-L1 inhibitor),,,93.1,no,,yes,first-line,benmelstobart + anlotinib + etoposide/carboplatin,no,,,tolerable and manageable,,clinical trial,,
57,Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations,10.1007/s10147-024-02583-3,2024,International Journal of Clinical Oncology,Urothelial Carcinoma,Advanced or Metastatic,"['erdafitinib', 'docetaxel/vinflunine']",no,no,no,no,yes,yes,Randomized controlled trial,27,no,,,,FGFR alterations,,yes,post-anti-PD-(L)1,,yes,Japan,,,FGFR altered,Subgroup analysis,,
59,Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis,10.3390/cancers16203458,2024,Cancers,Hepatocellular Carcinoma,Unresectable,"['Lenvatinib + Pembrolizumab', 'Atezolizumab + Bevacizumab']",yes,no,no,no,yes,yes,Retrospective analysis with propensity score matching,121,"Pembrolizumab, Atezolizumab",,,,,,eligible,First-line,"Lenvatinib + Pembrolizumab, Atezolizumab + Bevacizumab",no,,,,,Observational,,
60,"Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC",10.1016/j.jtho.2024.05.005,2024,Journal of Thoracic Oncology,NSCLC,Locally advanced or metastatic,"['atezolizumab subcutaneously', 'atezolizumab intravenously']",yes,no,no,no,yes,yes,Randomized Phase III,371,Atezolizumab,9.5,,,no,,yes,,,,,{},,,Clinical Trial,,
61,Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer,10.1016/j.lungcan.2024.107859,2024,Lung Cancer,non-small cell lung cancer,IV,"['atezolizumab-containing therapy', 'platinum-doublet chemotherapy']",no,no,no,no,yes,yes,exploratory integrated analysis of randomized Phase III trials,1224,atezolizumab,,,,,,eligible,chemotherapy-naïve,platinum-based chemotherapy,no,,,,,clinical trial,,
62,Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH),10.1200/JCO.23.02261,2024,Journal of Clinical Oncology,Rectal Cancer,Locally Advanced,"['Group A: SCRT + consolidation immunochemotherapy (capecitabine, oxaliplatin, toripalimab)', 'Group B: Induction immunochemotherapy + SCRT + remaining immunochemotherapy']",yes,no,yes,no,no,no,"Randomized, open-label, phase II",121,Toripalimab,19,,,Mismatch repair status (pMMR/MSS),,yes,Neoadjuvant,Immunochemotherapy,no,,,,pMMR/MSS,Clinical Trial,,
63,SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1,10.1016/j.jtho.2024.09.041,2024,Journal of Thoracic Oncology,NSCLC,locally advanced/metastatic,"['Tislelizumab + Sitravatinib', 'Docetaxel']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 3",377,Tislelizumab,8,,,no,,yes,previously treated (<=2 lines of systemic chemotherapy and anti-PD-(L)1 antibodies),Tislelizumab + Sitravatinib,yes,,"{'hypertension_grade3plus': 0.134, 'pneumonia_grade3plus': 0.091, 'palmar-plantar erythrodysesthesia syndrome_grade3plus': 0.065, 'hypokalemia_grade3plus': 0.054}",,,Clinical Trial,<=1,no
64,,10.1016/j.annonc.2024.07.505,2024,Annals of Oncology,Head and neck squamous cell carcinoma (HNSCC),recurrent or metastatic,"['pembrolizumab-chemotherapy', 'cetuximab-chemotherapy']",no,no,no,no,yes,no,systematic review,882,pembrolizumab,,,,no,,eligible,first-line,chemotherapy,,,,,,,,
65,Prospective screening and proposed treatment algorithm for immune checkpoint inhibitor induced myositis in neoadjuvant-treated rectal cancer patients: data from the phase II CHINOREC trial,10.1093/eurheartj/ehae666.3209,2024,European Heart Journal,Rectal Cancer,Intermediate to locally advanced,"['neoadjuvant CRT alone', 'neoadjuvant CRT + IPI/NIVO']",yes,no,no,yes,no,no,"Prospective, randomized, open-label, multicenter, phase II investigator-initiated trial",80,"Ipilimumab, Nivolumab",,12,,yes,,eligible,Neoadjuvant,Chemoradiotherapy,no,,{'Myositis': 12},"Glucocorticoids (GC) with concomitant intravenous immunoglobulin (IVIG). If myotoxicity biomarkers did not improve, patients received infliximab (INFLIXI) and/or plasma exchange (PLEX).","cTnT, cTnI, CK, MB",Clinical Trial,,no
66,"Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial",10.1038/s41591-024-03077-5,2024,Nature Medicine,Melanoma,III,"['pembrolizumab alone', 'sequential therapy (dabrafenib plus trametinib followed by pembrolizumab)', 'concurrent (triple) therapy']",yes,no,no,no,yes,yes,"randomized, phase 2",60,pembrolizumab,,75,,BRAFV600-mutant,,yes,neoadjuvant,"dabrafenib, trametinib",no,,,,BRAFV600-mutant,clinical trial,,
67,Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial,10.1038/s41591-024-03086-4,2024,Nature Medicine,Renal Cell Carcinoma,Metastatic,"['cabozantinib and nivolumab with CBM588', 'cabozantinib and nivolumab without CBM588']",yes,no,no,no,no,yes,"Randomized, open-label, investigator-initiated, phase 1",30,Nivolumab,,,,yes,,eligible,first-line,Cabozantinib and Nivolumab,no,,,,Bifidobacterium spp.,Interventional,,
68,Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial,10.1038/s41591-024-03088-2,2024,Nature Medicine,Breast cancer,Metastatic,"['metronomic vinorelbine (NVB) monotherapy', 'NVB plus anti-PD-1 toripalimab', 'anti-angiogenic bevacizumab, NVB and toripalimab', 'conventional cisplatin, NVB and toripalimab', 'metronomic cyclophosphamide, capecitabine, NVB and toripalimab (VEX cohort)']",no,no,no,no,no,yes,Bayesian adaptive randomized phase 2 trial,97,toripalimab,,,,no,,eligible,first or second line,yes,no,,,,,Clinical Trial,,
69,ABCL-588 Incidence of Pseudoprogression During Nivolumab Plus R-DA-EPOCH Treatment for Primary Mediastinal B-Cell Lymphoma,10.1016/S2152-2650(24)01538-6,2024,"Clinical Lymphoma, Myeloma and Leukemia",Primary Mediastinal B-cell Lymphoma (PMBCL),,"['Nivolumab plus R-DA-EPOCH', 'R-DA-EPOCH alone']",yes,no,no,yes,yes,no,Randomized controlled trial,45,Nivolumab,,13,,no,,yes,First-line,R-DA-EPOCH,no,,{'Pseudoprogression': 13},,,Prospective randomized study,,
70,Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study,10.1016/j.esmoop.2024.103690,2024,ESMO Open,Urothelial Carcinoma,Metastatic,"['Induction avelumab followed by avelumab in combination with carboplatin-gemcitabine followed by avelumab maintenance (arm A)', 'Carboplatin-gemcitabine (arm B)']",yes,no,yes,no,yes,yes,"Randomized, open-label phase II study",85,Avelumab,,,,PD-L1,,eligible,First-line,Carboplatin-gemcitabine,no,,,,,Clinical Trial,0-2,no
72,"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study",10.1200/JCO.23.02736,2024,Journal of Clinical Oncology,Colorectal Cancer,Metastatic,"['lenvatinib plus pembrolizumab', 'regorafenib or trifluridine/tipiracil (SOC)']",yes,no,yes,no,yes,no,"Randomized, Controlled, Open-Label, Phase III",480,Pembrolizumab,18.6,,58.4,yes,,eligible,previously treated,lenvatinib plus pembrolizumab,no,international,,,pMMR or not MSI-H,Clinical Trial,,
73,Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09),10.1200/JCO.23.02082,2024,Journal of Clinical Oncology,Clear Cell Renal Cell Carcinoma,Advanced/metastatic,"['Bempegaldesleukin plus Nivolumab', 'Sunitinib', 'Cabozantinib']",yes,no,yes,no,yes,no,Phase III Randomized Controlled Trial,623,"Bempegaldesleukin, Nivolumab",,,,no,,eligible,First-line,Bempegaldesleukin plus Nivolumab,no,,"{'pyrexia_any_grade': 32.6, 'pruritus_any_grade': 31.3}",,,Interventional,,
74,LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity,10.1016/j.cell.2024.07.016,2024,Cell,Melanoma,,,no,no,no,no,no,no,Preclinical study (mouse models),,"Nivolumab (anti-PD-1), Relatlimab (anti-LAG-3)",,,,"PD-1, LAG-3, IFN-γ, TOX",,no,,Nivolumab + Relatlimab,,,,,,Preclinical,,
75,GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial,10.1016/j.eclinm.2024.102716,2024,eClinicalMedicine,Cervical Cancer,Recurrent or advanced,,yes,no,yes,no,yes,yes,"Open-label, single-arm, phase II trial",65,Pembrolizumab,14.72,33.8,6.2,yes,,eligible,,GX-188E vaccine + Pembrolizumab,,South Korea,,,"HPV 16/18 positive, PD-L1 positive/negative",Clinical Trial,0 or 1,no
76,"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study",10.1016/S1470-2045(24)00211-0,2024,The Lancet Oncology,renal cell carcinoma,T2 or greater or Tany N+,"['nivolumab plus surgery', 'surgery only followed by surveillance']",yes,no,yes,yes,no,yes,"open-label, randomised, phase 3 trial",819,nivolumab,30.4,,,no,,yes,first-line,nivolumab + surgery,no,"USA, Canada","{'elevated lipase grade 3-4': 0.05, 'anaemia grade 3-4': 0.02, 'increased alanine aminotransferase grade 3-4': 0.03, 'abdominal pain grade 3-4': 0.01, 'increased serum amylase grade 3-4': 0.02}",,,clinical trial,0-1,no
77,"Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in highrisk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial",10.1200/JCO.2024.42.23_suppl.138,2024,Journal of Clinical Oncology,Nasopharyngeal Carcinoma,Locoregionally advanced (T4N1M0 or T1-4N2-3M0),[],yes,no,yes,yes,yes,yes,"Single-arm, phase II clinical trial",152,Nivolumab,43,,7.2,no,,eligible,,Nivolumab + induction chemotherapy (gemcitabine + cisplatin) + intensity-modulated radiotherapy + adjuvant nivolumab,no,China,"{'rash': 2.0, 'dermatitis': 2.0}",,,Clinical Trial,,
78,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer after a Checkpoint Inhibitor and Chemotherapy,10.1200/JCO.23.02166,2024,Journal of Clinical Oncology,Non-Small Cell Lung Cancer,Metastatic,"['Atezolizumab + Cabozantinib', 'Docetaxel']",no,no,no,no,yes,yes,"Multicenter, open-label, phase III randomized trial",366,Atezolizumab,10.9,,,no,,eligible,Second-line or later,Atezolizumab + Cabozantinib,yes,,,,,Clinical Trial,,
79,"Randomized Placebo-Controlled, BiomarkerStratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity",10.1158/2159-8290.CD-24-0066,2024,Cancer Discovery,Melanoma,Metastatic,"['SER-401 arm (oral vancomycin-preconditioning/SER-401 alone/nivolumab + SER-401)', 'placebo arm [placebo antibiotic/placebo microbiome modulation (PMM)/nivolumab + PMM]']",yes,no,no,no,no,no,"Randomized, placebo-controlled, biomarker-stratified phase I trial",14,Nivolumab,,,,yes,,yes,,SER-401 + nivolumab,ICB-naïve,,,,Ruminococcaceae abundance,Interventional,,
80,"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)",10.1186/s12885-023-10971-7,2024,BMC Cancer,Renal Cell Carcinoma,Metastatic,"['pembrolizumab plus epacadostat', 'sunitinib or pazopanib']",yes,no,yes,no,no,no,"Randomized, open-label, parallel-group, multicenter, phase 3",129,Pembrolizumab,10.3,,34.4,yes,,eligible,First-line,Pembrolizumab + Epacadostat,no,,,,kynurenine levels,Clinical Trial,,
81,,10.1016/j.radonc.2024.110320,2024,Radiotherapy and Oncology,,,"['steroid taper + nintedanib', 'placebo + steroid taper']",no,no,no,no,no,no,randomized clinical trial,30,,,,,yes,,no,,,,,,,"TGF-β1, MCP-1, PDGF, IL-5, TNFSF12, EGF",,,
82,Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study,10.1016/j.esmoop.2024.103622,2024,ESMO Open,oesophago-gastric adenocarcinoma,advanced,"['active surveillance', 'maintenance durvalumab']",yes,no,no,no,yes,yes,randomized phase II,205,durvalumab,,,,PD-L1 CPS,,eligible,first-line maintenance,no,no,,,,HER2-negative,clinical trial,,
83,"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial",10.1016/S0140-6736(24)00594-4,2024,The Lancet,Nasopharyngeal Carcinoma,III-IVa,"['sintilimab group', 'standard therapy group']",yes,no,yes,no,no,yes,"Randomized, controlled, phase 3 trial",425,Sintilimab,41.9,,0.1,no,,yes,First-line,Chemoradiotherapy,no,China,,,,Clinical Trial,,
84,"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial",10.1200/JCO.23.01601,2024,Journal of Clinical Oncology,"Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma",Advanced or metastatic,"['nivolumab plus chemotherapy', 'chemotherapy']",yes,no,yes,no,yes,yes,Phase III,,Nivolumab,36.2,,,PD-L1 CPS,,eligible,First-line,Chemotherapy,no,,,,PD-L1 CPS ≥5,Clinical Trial Update,,
85,"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer",10.1200/JCO.23.01940,2024,Journal of Clinical Oncology,Breast Cancer,Metastatic,"['fulvestrant (F)', 'fulvestrant plus palbociclib (F + P)', 'fulvestrant plus palbociclib and avelumab (F + P + A)']",no,no,no,no,no,yes,Randomized Phase II,220,Avelumab,,,,yes,,yes,,Fulvestrant + Palbociclib + Avelumab,no,,,,ESR1 and PIK3CA alterations,Interventional,,
86,"Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer",10.1002/cncr.35222,2024,Cancer,Ovarian cancer,,"['cobimetinib + niraparib', 'cobimetinib + niraparib + atezolizumab']",no,no,no,no,no,yes,Phase 1b,74,atezolizumab,,,,yes,,eligible,1 or 2 prior lines,cobimetinib + niraparib +/- atezolizumab,no,,,,"BRCA wild-type, HRDsig-positive, HRDsig-negative, NF1 mutation, MKNK1 mutation",Clinical Trial,,
87,Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial,10.1038/s41591-024-02965-0,2024,Nature Medicine,non-small-cell lung cancer,resectable,"['nivolumab', 'nivolumab and relatlimab']",yes,no,yes,no,yes,yes,randomized phase 2 trial,60,"nivolumab, relatlimab",12,,,no,,eligible,neoadjuvant,nivolumab + relatlimab,no,,,,,interventional,,
88,"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial",10.1016/j.jtho.2023.12.023,2024,Journal of Thoracic Oncology,NSCLC,IV,"['lenvatinib plus pembrolizumab', 'placebo plus pembrolizumab']",yes,no,yes,no,yes,yes,"Randomized, Double-Blind, Phase 3 Trial",623,Pembrolizumab,15.9,,57.9,PD-L1 TPS,,eligible,First-line,Lenvatinib plus Pembrolizumab,no,,,,PD-L1 TPS >= 1%,Clinical Trial,,
89,The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial),10.1016/j.ejso.2024.108265,2024,European Journal of Surgical Oncology,Melanoma,,"['Nivolumab + ILP', 'Placebo + ILP']",yes,no,yes,no,yes,yes,Randomized double-blind placebo-controlled trial,20,Nivolumab,,90,40,no,,eligible,,Isolated Limb Perfusion (ILP),no,,,,,Phase Ib/II trial,,
90,Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D,10.1016/j.clcc.2024.03.001,2024,Clinical Colorectal Cancer,Colorectal Cancer,Metastatic,"['Pembrolizumab + 5-fluorouracil, leucovorin, oxaliplatin (mFOLFOX7)', 'Pembrolizumab + 5-fluorouracil, leucovorin, irinotecan (FOLFIRI)']",yes,no,yes,no,no,no,Phase 1b,63,Pembrolizumab,31.85,,,yes,,yes,,Chemotherapy,no,,,,"Microsatellite stable, Mismatch repair-proficient, KRAS, PD-L1, T-cell-inflamed gene expression profiles, HER2, Tumor mutational burden",,,
91,Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer,10.1158/2326-6066.CIR-22-0306,2024,Cancer Immunology Research,Prostate Cancer,Metastatic Castration-resistant,"['Radium-223 + Pembrolizumab', 'Radium-223']",yes,no,no,no,yes,yes,Randomized Phase II,42,Pembrolizumab,,,,yes,,eligible,,Radium-223,no,,,,"CD4+ T-cell, CD8+ T-cell, CTLA-4, Ki67+ T cells, myeloid cells, TIM-3+ T cells",Clinical Trial,,
92,"Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study",,2024,Journal of Clinical Oncology,colorectal cancer,IIB-III,"['IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody)', 'sintilimab (anti-PD-1 antibody)']",yes,no,yes,yes,no,no,"randomized, open-labeled, phase Ib study",101,"IBI310, sintilimab",,,,MSI-H/dMMR,,eligible,neoadjuvant,IBI310 + sintilimab,no,,"{'any_grade_arm_A': 42.3, 'any_grade_arm_B': 36.7, 'grade3plus_arm_A': 3, 'grade3plus_arm_B': 4, 'hypothyroidism_grade2_arm_A': 1, 'hyperthyroidism_grade1_arm_A': 1, 'immune-mediated myocarditis_grade3plus_arm_A': 1, 'ileus_grade3plus_arm_A': 1, 'enteritis_grade3plus_arm_A': 1, 'alanine aminotransferase increased_grade3plus_arm_B': 1, 'rash_grade3plus_arm_B': 1, 'hypothyroidism_grade3plus_arm_B': 1, 'myocarditis_grade3plus_arm_B': 1}",manageable,MSI-H/dMMR,clinical trial,ECOG PS 1: 54.5%,no
93,A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRCLUN18- 153,,2024,Journal of Clinical Oncology,NSCLC,I,"['Pembrolizumab', 'observation']",yes,no,no,no,yes,yes,Randomized Phase II,244,Pembrolizumab,,,,PD-L1,,eligible,adjuvant,no,no,US,,,,interventional,,
95,"Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma",,2024,Journal of Clinical Oncology,"Colorectal cancer, Head and neck squamous cell carcinoma",Metastatic,"['TTX-080 alone', 'TTX-080 + Cetuximab', 'TTX-080 + Pembrolizumab']",yes,no,no,no,no,yes,"Phase 1a/1b, 3+3 design",202,"TTX-080, Pembrolizumab",,,,yes,,eligible,,"TTX-080 + Cetuximab, TTX-080 + Pembrolizumab",,,,,"HLA-G, RAS/BRAF WT, HER2-Neg, HPV-Neg",Clinical Trial,,
96,"Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial",,2024,Journal of Clinical Oncology,Nasopharyngeal Carcinoma,Locoregionally advanced (T4N1M0 or T1-4N2-3M0),[],yes,no,yes,yes,yes,yes,"Single-arm, phase II clinical trial",152,Nivolumab,39,,7.2,no,,yes,,Nivolumab + induction chemotherapy (gemcitabine + cisplatin) + intensity-modulated radiotherapy + adjuvant nivolumab,no,China,"{'hepatic (aspartate aminotransferase increased)': 3.3, 'skin (rash/dermatitis)': 2.0}",,,Clinical Trial,,
97,Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy,,2024,Journal of Clinical Oncology,dedifferentiated liposarcoma,resectable,"['nivolumab + ipilimumab', 'nivolumab']",yes,no,no,yes,no,no,"randomized, phase II, non-comparative trial",5,"nivolumab, ipilimumab",,,,no,,eligible,neoadjuvant,nivolumab + ipilimumab,no,,,,,qualitative,,yes
98,A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma,10.1158/1078-0432.CCR-23-3249,2024,Clinical Cancer Research,Head and Neck Squamous Cell Carcinoma (HNSCC),Locally advanced but resectable,"['Durvalumab (D)', 'Durvalumab (D) + Tremelimumab (T)']",yes,no,yes,no,no,yes,"Phase II, Open-Label, Randomized Clinical Trial",48,"Durvalumab, Tremelimumab",,,,yes,,eligible,Neoadjuvant,Durvalumab + Tremelimumab,no,,,,"AI-powered spatial distribution analysis of tumor-infiltrating lymphocytes, high-dimensional profiling of circulating immune cells",Clinical Trial,,
99,"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial",10.1002/cam4.7235,2024,Cancer Medicine,esophageal squamous cell carcinoma,"advanced, recurrent, or metastatic","['nivolumab plus chemotherapy', 'nivolumab plus ipilimumab', 'chemotherapy']",yes,no,yes,no,yes,yes,"randomized, open-label, phase III trial",970,"nivolumab, ipilimumab",29,,,PD-L1,,eligible,first-line,"nivolumab plus chemotherapy, nivolumab plus ipilimumab",no,,,no new safety signals identified,tumor cell PD-L1 expression of ≥1%,clinical trial,,
100,,10.1016/j.ejca.2024.113973,2024,European Journal of Cancer,pleural mesothelioma,,"['ipilimumab and nivolumab alone (arm B)', 'ipilimumab and nivolumab combined with UV1 (arm A)']",no,no,no,no,yes,yes,"randomized, open-label, phase 2",118,"ipilimumab, nivolumab, UV1 telomerase vaccine",17.3,,,,,eligible,second-line,ipilimumab + nivolumab +/- UV1,no,,,,,clinical trial,,
102,"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial",10.1016/S1470-2045(24)00082-2,2024,The Lancet Oncology,Biliary tract cancer,"Advanced, unresectable, locally advanced, or metastatic","['Durvalumab + gemcitabine + cisplatin', 'Placebo + gemcitabine + cisplatin']",no,no,no,no,yes,no,"Randomized, double-blind, placebo-controlled, phase 3",685,Durvalumab,9.9,,,no,,eligible,Previously untreated,"Gemcitabine, Cisplatin",no,,,,,Clinical Trial,0 or 1,yes
103,ARDS Following Steroid Refractory ICI-Pneumonitis: A Case Report,,2024,American Journal of Respiratory and Critical Care Medicine,bladder carcinoma,,[],yes,no,no,yes,no,no,case report,1,Nivolumab,,,,no,,eligible,,,,,,"ICI treatment was discontinued, and a one-month trial of oral corticosteroids was initiated. Immunosuppression was escalated with mycophenolate mofetil (MMF) and a single dose of infliximab at 5 mg/kg.",,,,
104,"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)",10.1200/JCO.23.01891,2024,Journal of Clinical Oncology,Non-small-cell lung cancer,,"['ABCP (atezolizumab plus bevacizumab, paclitaxel, and carboplatin)', 'PC (pemetrexed plus carboplatin or cisplatin)']",yes,no,no,no,yes,yes,"Randomized, open-label, multicenter, phase III",228,Atezolizumab,26.1,,,yes,,eligible,,Atezolizumab + Bevacizumab + Chemotherapy,no,Republic of Korea,,,"EGFR-mutated, ALK-translocated, PD-L1 expression",Interventional,,no
106,Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302,10.1007/s10388-023-01040-w,2024,Esophagus,Esophageal squamous cell carcinoma (ESCC),Advanced/metastatic,"['Tislelizumab', 'Chemotherapy (paclitaxel/docetaxel)']",yes,no,yes,no,yes,yes,"Randomized, open-label, phase 3",50,Tislelizumab,,,24,PD-L1,,yes,Second-line,,no,Japan,,,PD-L1 score ≥ 10%,Subgroup analysis,,
107,,10.1002/cam4.6980,2024,Cancer Medicine,solid tumors,advanced,"['retifanlimab monotherapy', 'INCB001158 monotherapy', 'retifanlimab + INCB001158 combination']",yes,no,yes,yes,no,no,Phase I,18,retifanlimab,,,,no,,eligible,,retifanlimab + INCB001158,,Japan,{'thyroid disorder': 1},,,,,
108,,10.1016/j.ejca.2024.113585,2024,European Journal of Cancer,Melanoma,III,"['Pembrolizumab', 'Placebo']",yes,yes,no,no,no,yes,Randomized Controlled Trial,1019,Pembrolizumab,,,,no,,yes,Adjuvant,,no,,,,,Clinical Trial,,
109,"Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial",10.1016/j.eururo.2023.08.012,2024,European Urology,Urothelial Carcinoma,Advanced,"['pembrolizumab + lenvatinib', 'pembrolizumab + placebo']",yes,no,yes,no,yes,yes,"Randomized, Double-Blind, Phase 3",487,Pembrolizumab,12.8,,,no,,eligible,First-line,Lenvatinib,no,,,,,Clinical Trial,,
110,Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer,10.3802/jgo.2024.35.e40,2024,Journal of Gynecologic Oncology,Endometrial cancer,Advanced/recurrent,"['lenvatinib + pembrolizumab', 'treatment of physician’s choice chemotherapy (doxorubicin or paclitaxel)']",yes,no,yes,no,yes,yes,Randomized controlled trial,155,Pembrolizumab,34.3,97,74,Mismatch repair proficient (pMMR),,yes,Previously treated,Lenvatinib + Pembrolizumab,no,East Asia,,manageable safety,pMMR,Subgroup analysis,,
111,Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy,10.1093/ofid/ofad694,2024,Open Forum Infectious Diseases,,,"['cemiplimab', 'placebo']",yes,no,yes,yes,no,no,"phase 1/2, randomized (4:1), double-blind, placebo-controlled study",5,cemiplimab,12,,,HIV-1-specific polyfunctional CD4+ and CD8+ T-cell responses,,eligible,,,,,"{'thyroiditis_grade2': 1, 'hepatitis_grade3': 1}",,,clinical trial,,
112,,10.1158/1538-7445.AM2024-6411,2024,Cancer Research,Melanoma,III or IV,"['adjuvant nivolumab plus ipilimumab', 'adjuvant nivolumab']",no,no,no,no,no,yes,"randomized, double-blind, phase III adjuvant trial",674,"nivolumab, ipilimumab",,,,Gut microbiome,,eligible,adjuvant,nivolumab plus ipilimumab,no,"three continents, five distinct regions",,,"Eubacterium, Ruminococcus, Clostridium, Firmicutes",clinical trial,,
113,,10.1136/ijgc-2024-ESGO.34,2024,International Journal of Gynecological Cancer,Endometrial Cancer,Primary advanced or recurrent,"['Dostarlimab + Carboplatin-Paclitaxel', 'Placebo + Carboplatin-Paclitaxel']",yes,no,yes,no,yes,yes,Randomized 1:1,487,Dostarlimab,,38.2,12.4,no,,eligible,,Carboplatin-Paclitaxel,no,,,"63.5% of irAEs in dostarlimab arm treated with steroids, immunosuppressants and/or thyroid therapy; 73.6% resolved (median 10.0 days). 80.0% resolved (median 8.0 days) in patients not receiving these treatments.",,Clinical Trial,,
114,"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study",10.1016/S0140-6736(23)02268-7,2024,The Lancet,Melanoma,IIIB-IV,"['mRNA-4157 plus pembrolizumab', 'pembrolizumab monotherapy']",yes,no,yes,no,no,yes,"Randomized, open-label, phase 2b",157,Pembrolizumab,23,,25,no,,eligible,Adjuvant,mRNA-4157,no,"USA, Australia",,,,Clinical Trial,,
116,"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study",10.1016/j.annonc.2023.09.3108,2024,Annals of Oncology,renal cell carcinoma,advanced,"['toripalimab plus axitinib', 'sunitinib']",yes,no,yes,no,yes,yes,"randomized, open-label, phase III",421,toripalimab,14.6,,61.5,no,,yes,first-line,toripalimab plus axitinib,no,,{},,,clinical trial,,
117,Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence,10.1016/j.clgc.2023.11.001,2024,Clinical Genitourinary Cancer,Renal Cell Carcinoma,advanced,,no,no,no,no,yes,yes,Systematic Literature Review,11000,cabozantinib,,,,no,,eligible,all,monotherapy,,North America and/or Europe,,,,retrospective,,
118,"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study",10.1016/S1470-2045(23)00541-7,2024,The Lancet Oncology,gastric or gastro-oesophageal adenocarcinoma,"locally advanced, resectable","['pembrolizumab plus cisplatin-based chemotherapy', 'placebo plus cisplatin-based chemotherapy', 'pembrolizumab plus FLOT-based chemotherapy', 'placebo plus FLOT-based chemotherapy']",yes,no,yes,no,yes,yes,"multicentre, randomised, placebo-controlled, double-blind, phase 3",1007,pembrolizumab,47.7,,,no,,eligible,neoadjuvant and adjuvant,chemotherapy,no,multi-country,,,,clinical trial,0-1,no
119,Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population,,2024,Journal of Clinical Oncology,Renal Cell Carcinoma,Metastatic,"['Ipilimumab/Nivolumab', 'Axitinib/Pembrolizumab']",yes,no,no,yes,yes,yes,Retrospective,547,"Ipilimumab, Nivolumab, Pembrolizumab",30,,,no,,yes,First-line,"Ipilimumab/Nivolumab, Axitinib/Pembrolizumab",no,Canada,,Adverse events led to a dose or schedule change in 61.7% of I/N patients and 79.1% of A/P patients.,,Observational Study,,
120,SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer,10.1200/JCO.23.01363,2024,Journal of Clinical Oncology,Small-cell lung cancer,Extensive-stage,"['tiragolumab + atezolizumab + carboplatin + etoposide', 'placebo + atezolizumab + carboplatin + etoposide']",yes,no,yes,no,yes,yes,Phase III,490,"Tiragolumab, Atezolizumab",14.3,54.4,7.9,no,,yes,First-line,Chemotherapy,no,,,,,Clinical Trial,,
121,Perioperative Toripalimab Plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial,10.1001/jama.2023.24735,2024,JAMA,Non-small cell lung cancer,II or III resectable,"['Toripalimab + platinum-based chemotherapy', 'Placebo + platinum-based chemotherapy']",yes,no,yes,no,no,yes,Randomized clinical trial,501,Toripalimab,18.3,,,no,,yes,Perioperative,Chemotherapy,no,China,,,,Interventional,,
122,"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial",10.1016/S0140-6736(23)02405-4,2024,The Lancet,cervical cancer,"metastatic (stage IVB), persistent, or recurrent","['atezolizumab + cisplatin/carboplatin + paclitaxel + bevacizumab', 'cisplatin/carboplatin + paclitaxel + bevacizumab']",yes,no,yes,no,yes,yes,"randomised, open-label, phase 3 trial",410,atezolizumab,,,,no,,eligible,first-line,chemotherapy + anti-VEGF + immunotherapy,no,"Europe, Japan, USA",,,,interventional,,no
123,"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial",10.1016/S2468-1253(23)00316-3,2024,The Lancet Gastroenterology and Hepatology,oesophageal squamous cell carcinoma,oligometastatic,"['systemic therapy alone', 'combined systemic and local therapy']",no,no,no,no,no,yes,"randomized, open-label, multicentre, phase 2 trial",104,anti-PD-1 antibodies,30.5,,,,,eligible,,chemotherapy plus anti-PD-1 antibodies,,China,,,,clinical trial,,
124,SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,10.1016/j.annonc.2023.10.004,2024,Annals of Oncology,non-small-cell lung cancer,advanced,"['sitravatinib + nivolumab', 'docetaxel']",no,no,no,no,yes,yes,randomized controlled trial,577,nivolumab,17.1,,,,,yes,second-line or later,sitravatinib + nivolumab,yes,,,,,clinical trial,,
125,,10.1016/j.radonc.2023.109941,2024,Radiotherapy and Oncology,Pancreatic cancer,,"['SBRT + Pembrolizumab + Trametinib', 'SBRT + Gemcitabine']",yes,no,yes,no,yes,no,"Randomized, open-label, phase 2 trial",170,Pembrolizumab,,,,yes,,eligible,,SBRT + Pembrolizumab + Trametinib,no,,,,"PD-L1, TILs, mutant KRAS",,,
126,A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor,10.1177/10732748241244586,2024,Cancer Control,,,"['multi-TKI monotherapy', 'multi-TKI plus ICI combination therapy']",yes,yes,no,yes,no,no,Systematic Review and Meta-Analysis,7951,ICI,,,,no,,eligible,,multi-TKI plus ICI,,,"{'diarrhea': 1.24, 'hypothyroidism': 1.44, 'rash': 1.71}",This would help optimize the management of toxicities caused by multi-TKI plus ICI combination therapy.,,,,
127,The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies,10.1080/14796694.2024.2343272,2024,Future Oncology,advanced solid tumors and hematological malignancies,advanced,,yes,no,no,no,no,no,,,"vibostolimab, pembrolizumab",,,,,,eligible,,vibostolimab + pembrolizumab,,,,,,program overview,,
128,Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma,10.1177/17588359241274625,2024,Therapeutic Advances in Medical Oncology,Hepatocellular Carcinoma,Unresectable,"['durvalumab plus tremelimumab', 'sorafenib']",no,no,no,no,yes,yes,Markov model-based cost-effectiveness analysis,,"durvalumab, tremelimumab",,,,yes,,eligible,First-line,durvalumab plus tremelimumab,no,US,,,"HBV-related HCC, high alpha-fetoprotein levels",Cost-effectiveness analysis,,
129,"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)",10.1177/17588359241277656,2024,Therapeutic Advances in Medical Oncology,Endometrial Cancer,Primary advanced or recurrent,"['Dostarlimab + Carboplatin-Paclitaxel', 'Placebo + Carboplatin-Paclitaxel']",yes,no,yes,no,yes,yes,"Phase III, randomized, double-blind, multicenter",487,Dostarlimab,,58.5,,no,,eligible,,Carboplatin-Paclitaxel,no,,,irAE management was described,,Clinical Trial,,
130,Comparative efficacy of chemo-immunotherapy combination regimens in the frontline setting for NSCLC based on reconstructed patient data : Efficacy of first-line chemo-immuno in NSCLC,10.1080/1120009X.2024.2417600,2024,Journal of Chemotherapy,NSCLC,metastatic,"['cemiplimab + CT', 'pembrolizumab + CT', 'nivolumab + ipilimumab + CT', 'CT alone']",no,no,no,no,yes,no,reconstructed patient data from Kaplan-Meier curves of phase III randomised clinical trials,,"cemiplimab, pembrolizumab, nivolumab, ipilimumab",,,,PD-L1,,eligible,first-line,chemotherapy,no,,,,"PD-L1 expression ≥50%, PD-L1 < 1%, PDL-1 ≥ 1%",reconstructed data analysis,,
131,,10.2147/PTT.S478352,2024,Psoriasis: Targets and Therapy,,,,no,no,no,no,no,no,real-world study,848,,,,,,,no,,,,,,,,,,
132,Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas,10.1080/2162402X.2024.2432728,2024,OncoImmunology,High-grade gliomas,Newly diagnosed Grade 3 and Grade 4,,yes,no,yes,yes,yes,yes,Phase I study,15,"Nivolumab, Ipilimumab",,,,yes,,eligible,prior to standard radiotherapy,Nivolumab + Ipilimumab,no,,"{'lipase increased': 2, 'anorexia': 1, 'pruritus': 1, 'rash': 3, 'cerebral edema': 1}",,"LAG-3, TGF-β, ERBB2, ERBB3, ERBB4, PPAR, MGMT promoter methylated",Clinical Trial,,
133,Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial,10.1001/jamaoncol.2023.4003,2023,JAMA Oncology,Hepatocellular carcinoma,unresectable,"['tislelizumab', 'sorafenib tosylate']",yes,no,yes,no,yes,yes,randomized clinical trial,674,tislelizumab,33,96.2,22.2,no,,eligible,first-line,no,no,global,,,,clinical trial,1 or less,
134,"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial",10.1016/S0140-6736(23)01613-6,2023,The Lancet,Pleural Mesothelioma,Advanced,"['Chemotherapy alone', 'Chemotherapy with pembrolizumab']",yes,no,yes,no,yes,no,Randomized controlled trial,440,Pembrolizumab,16.2,,27.0,no,,yes,First-line,Chemotherapy (cisplatin/carboplatin + pemetrexed),no,"Canada, Italy, France",,,,Interventional,0 or 1,no
135,Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma,10.1056/NEJMoa2304753,2023,New England Journal of Medicine,Uveal Melanoma,Metastatic,"['Tebentafusp', ""Investigator's choice (pembrolizumab, ipilimumab, or dacarbazine)""]",yes,no,yes,yes,yes,no,"Open-label, phase 3, randomized controlled trial",,"Tebentafusp, Pembrolizumab, Ipilimumab",36,,,yes,,eligible,Previously untreated,,no,,"{'rash_any_grade': 83, 'pyrexia_any_grade': 76, 'pruritus_any_grade': 70, 'hypotension_any_grade': 38}",,HLA-A*02:01-positive,Clinical Trial,,
136,First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the NeoCheckRay trial,10.1136/jitc-2023-007279,2023,Journal for ImmunoTherapy of Cancer,Breast Cancer,Early-stage,[],yes,no,yes,yes,no,no,"Open-label, single-arm trial",6,"durvalumab, oleclumab",24,,,"PD-L1, CD73, Ki67",,eligible,neo-adjuvant,"paclitaxel, doxorubicin, cyclophosphamide, durvalumab, oleclumab, SBRT",no,,{'pericarditis_grade3': 1},corticosteroids for pericarditis,,clinical trial,,
138,A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma,10.1038/s41467-023-39196-9,2023,Nature Communications,Pancreatic Adenocarcinoma,Resectable,"['Pancreatic cancer GVAX vaccine with low-dose cyclophosphamide alone (Arm A)', 'Pancreatic cancer GVAX vaccine with low-dose cyclophosphamide and anti-PD-1 antibody nivolumab (Arm B)', 'Pancreatic cancer GVAX vaccine with low-dose cyclophosphamide, nivolumab, and anti-CD137 agonist antibody urelumab (Arm C)']",yes,no,no,no,yes,yes,Platform trial,40,"GVAX, Nivolumab, Urelumab",,,,yes,,eligible,Neoadjuvant and adjuvant,GVAX + cyclophosphamide; GVAX + cyclophosphamide + nivolumab; GVAX + cyclophosphamide + nivolumab + urelumab,no,,,,"IL17A expression, CD8+ CD137+ cells",Clinical Trial,,no
139,"Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial",10.1016/j.jtho.2023.08.018,2023,Journal of Thoracic Oncology,NSCLC,advanced,"['bintrafusp alfa', 'pembrolizumab']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 3",304,"bintrafusp alfa, pembrolizumab",14.3,,42.4,PD-L1,,eligible,first-line,,no,,,,PD-L1–high,clinical trial,,
140,Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass),10.1016/j.eururo.2023.09.004,2023,European Urology,Renal Cell Carcinoma,Metastatic,"['Nivolumab maintenance', 'TKI maintenance (sunitinib or pazopanib)']",yes,no,yes,no,yes,yes,Open-label phase 2 randomized clinical trial,49,Nivolumab,,,56,no,,yes,,,no,Germany,,,,Clinical Trial,0-2,yes
141,"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial",10.1016/S1470-2045(23)00469-2,2023,The Lancet Oncology,Hepatocellular carcinoma,Advanced,"['lenvatinib plus pembrolizumab', 'lenvatinib plus placebo']",yes,no,yes,no,yes,yes,"Randomized, double-blind, phase 3",794,Pembrolizumab,32.1,,,no,,yes,First-line,Lenvatinib,no,Global,,,,Clinical Trial,0 or 1,no
142,"An open-label, randomised, controlled trial on the benefit of hmb, L-arginine, and L-glutamine beverages and locomotion training as supportive care in the treatment of unresectable advanced hepatocellular carcinoma using lenvatinib: Hello study",10.1016/j.clnesp.2023.09.076,2023,Clinical Nutrition ESPEN,Hepatocellular Carcinoma,Advanced,"['HMB/L-arginine/L-glutamine and locomotion training', 'Control']",no,no,no,no,no,no,Randomized Controlled Trial,20,,,,,,,no,,,,,,,,,,
143,Systematic Literature Review of Health-Related Quality of Life in Advanced or Metastatic Esophageal Cancer,10.1016/j.jval.2023.09.135,2023,Value in Health,Esophageal cancer,Advanced or metastatic,,no,no,no,no,no,no,Systematic Literature Review,,"tislelizumab, camrelizumab, nivolumab",,,,no,,eligible,,,,,,,,Systematic Review,,yes
144,Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study,10.1159/000535501,2023,Liver Cancer,Hepatocellular Carcinoma,Unresectable,"['Bevacizumab skipped due to AESIs (Group A-1)', 'Bevacizumab not skipped (Group A-2)']",yes,yes,yes,no,yes,yes,Exploratory analysis of a phase III study,210,Atezolizumab,,,,no,,eligible,,Atezolizumab + Bevacizumab,no,,,Skipping bevacizumab due to AESIs,,Clinical Trial,,no
145,"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial",10.1016/S0140-6736(23)01796-8,2023,The Lancet,Hepatocellular carcinoma,High-risk resected or ablated,"['Atezolizumab plus bevacizumab', 'Active surveillance']",yes,no,yes,no,yes,yes,"Randomized, open-label, multicentre, phase 3 trial",668,Atezolizumab,17.4,,41.0,no,,eligible,Adjuvant,Atezolizumab plus bevacizumab,no,Global (26 countries in four WHO regions),,Both atezolizumab and bevacizumab were discontinued because of adverse events in 29 patients (9%) who received atezolizumab plus bevacizumab.,,Clinical Trial,,
146,,10.1056/NEJMoa2309457,2023,New England Journal of Medicine,NSCLC,advanced,"['selpercatinib', 'platinum-based chemotherapy with or without pembrolizumab']",yes,no,no,no,no,yes,randomized phase 3 trial,261,pembrolizumab,,,,RET fusion-positive,,eligible,first-line,chemotherapy + pembrolizumab,no,,,,RET fusion-positive,clinical trial,,
147,Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.,10.1056/NEJMoa2309863,2023,New England Journal of Medicine,Urothelial Carcinoma,Advanced,"['Nivolumab plus Gemcitabine-Cisplatin', 'Gemcitabine-Cisplatin alone']",yes,no,yes,no,yes,yes,"Phase 3, multinational, open-label, randomized controlled trial",608,Nivolumab,33.6,,,no,,eligible,First-line,Gemcitabine-Cisplatin,no,,,,,Clinical Trial,,
148,Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020,10.1111/cts.13641,2023,Clinical and Translational Science,Oncology (general),,,no,no,no,no,no,no,Narrative Synthesis,119,,,,,yes,,no,,,,Europe,,,,Regulatory Review,,
149,Adjuvant nivolumab shows promise in MCC,10.1038/s41571-023-00810-w,2023,Nature Reviews Clinical Oncology,Merkel cell carcinoma,,[],yes,no,no,no,no,no,,,nivolumab,,,,,,eligible,adjuvant,,,,{},,,,,
150,Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial,10.1158/2159-8290.CD-23-0436,2023,Cancer Discovery,non-small cell lung cancer,resectable,"['durvalumab monotherapy', 'durvalumab plus oleclumab', 'durvalumab plus monalizumab', 'durvalumab plus danvatirsen']",yes,no,no,no,no,no,"randomized, multidrug platform trial",83,durvalumab,,,,yes,,eligible,neoadjuvant,"durvalumab plus oleclumab, durvalumab plus monalizumab, durvalumab plus danvatirsen",no,,,,"PD-L1, CD73, NKG2A, STAT3",clinical trial,,
151,"Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study",10.1016/S1470-2045(23)00459-X,2023,The Lancet Oncology,cutaneous squamous cell carcinoma,II–IV (M0),[],yes,no,yes,yes,yes,yes,"single-arm, multicentre, phase 2 study",79,cemiplimab,18.7,,0.25,no,,yes,neoadjuvant,cemiplimab + surgery,no,,"{'increased blood potassium': 0.06, 'traumatic limb amputation': 0.06, 'cardiomyopathy': 0.06, 'hypophysitis': 0.06}",,,clinical trial,0 or 1,no
152,OA09.05 A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004),10.1016/j.jtho.2023.09.058,2023,Journal of Thoracic Oncology,squamous non-small-cell lung cancer,IIIB/IIIC or IV,"['serplulimab + chemotherapy', 'placebo + chemotherapy']",yes,no,yes,yes,yes,yes,"randomized, double-blind, international multicenter phase 3",537,serplulimab,31.1,,,PD-L1 expression level,,eligible,first-line,chemotherapy (carboplatin and nab-paclitaxel),no,international,"{'hypothyroidism': 6.4, 'rash': 5.0, 'immune-mediated lung disease': 4.2}",,,clinical trial,,
153,"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial",10.1016/S1470-2045(23)00451-5,2023,The Lancet Oncology,Prostate Cancer,metastatic castration-resistant,,yes,no,yes,yes,no,no,"open-label, dose-expansion, phase 1",43,pembrolizumab,16.5,,5.0,PSMA,,yes,,177Lu-PSMA-617 + pembrolizumab,no,USA,"{'arthritis': 3, 'pneumonitis': 3}",,PSMA-avid lesions,clinical trial,0 or 1,no
154,OA12.04 Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial,10.1016/j.jtho.2023.09.069,2023,Journal of Thoracic Oncology,Non-small cell lung cancer,IA/IIB,"['SABR alone', 'I-SABR (SABR + nivolumab)']",yes,no,yes,yes,no,yes,Randomized Phase II,141,Nivolumab,33,,,PD-L1,,eligible,first-line,SABR,no,,"{'grade 3 immunologic adverse events': 10, 'grade 2 immunologic adverse events': 16, 'grade 3 pneumonitis': 0, 'grade 2 pneumonitis': 2}",,PD-L1-negative,clinical trial,,
155,MA20.08 Prediction of Immune-Related Adverse Events Based on Th17 Cell Differentiation Pathway,10.1016/j.jtho.2023.09.265,2023,Journal of Thoracic Oncology,NSCLC,advanced,"['sintilimab plus chemotherapy', 'placebo plus chemotherapy']",yes,yes,yes,no,yes,no,randomized controlled phase 3 study,266,sintilimab (anti-PD-1 antibody),,46.2,6.4,yes,,eligible,,chemotherapy,no,,,earlier detection and intervention,"Th17 cell differentiation pathway, IL2RG, IL6R, JAK2, LAT, RORA expression",Post hoc analysis,,
156,"P2.09-08 Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial",10.1016/j.jtho.2023.09.582,2023,Journal of Thoracic Oncology,NSCLC,III,[],no,no,no,no,yes,yes,"single arm, open label, multi-center phase II trial",15,gefitinib,28.8,,,EGFR mutation,,eligible,maintenance,gefitinib after CCRT,no,,,,EGFR mutant,clinical trial,,
157,MO71-5 Pembrolizumab effectiveness in platinum-resistant ovarian carcinoma: Systematic review,10.1016/j.annonc.2023.09.328,2023,Annals of Oncology,Ovarian cancer,,,no,no,no,no,yes,yes,Systematic Review,69,Pembrolizumab,,,,no,,yes,,,,,,,,,,
158,,10.1016/j.annonc.2023.09.100,2023,Annals of Oncology,Hepatocellular Carcinoma (HCC),Advanced,,no,no,no,no,yes,no,,,"atezolizumab, durvalumab, tremelimumab, camrelizumab, tislelizumab, pembrolizumab",,,,,,no,"First-line, Post-sorafenib progression","atezolizumab + bevacizumab, durvalumab + tremelimumab, camrelizumab + rivoceranib",,,,,,,,
159,MO63-2 Overall survival for esophageal cancer patients with pembrolizumab: Systematic review,10.1016/j.annonc.2023.09.313,2023,Annals of Oncology,Esophageal cancer,advanced,,no,no,no,no,yes,no,Systematic review,2384,Pembrolizumab,,,,,,eligible,second line,chemotherapy,,,,,,,,
160,Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup,10.1016/j.annonc.2023.10.619,2023,Annals of Oncology,squamous non-small cell lung cancer,IIIB/IIIC or IV,"['serplulimab plus carboplatin/nab-paclitaxel', 'placebo plus carboplatin/nab-paclitaxel']",yes,no,yes,yes,yes,yes,"randomised, double-blind, international phase 3 study",359,serplulimab,32.9,41.3,,PD-L1 expression level,,eligible,first-line,chemotherapy,no,Asian,"{'hypothyroidism': 9.6, 'rash': 7.5, 'immune-mediated lung disease': 6.3}",,,clinical trial,,
161,First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study,10.1016/j.annonc.2023.10.621,2023,Annals of Oncology,squamous non-small cell lung cancer,IIIB/IIIC or IV,"['HLX07 (800 mg) + serplulimab (300 mg) + chemotherapy (carboplatin and nab-paclitaxel)', 'HLX07 (1000 mg) + serplulimab (300 mg) + chemotherapy (carboplatin and nab-paclitaxel)']",yes,no,yes,yes,no,yes,"Randomized, multicentre phase 2 study",12,serplulimab (anti-PD-1 antibody),3.5,,,EGFR,,eligible,first-line,HLX07 (anti-EGFR antibody) + serplulimab + chemotherapy,no,,{'dermatitis acneiform (grade 3)': 0.083},,,clinical trial,,
162,"211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)",10.1016/j.annonc.2023.10.347,2023,Annals of Oncology,Urothelial Carcinoma,Locally advanced metastatic,"['Enfortumab vedotin + Pembrolizumab', 'Gemcitabine + Cisplatin or Carboplatin']",yes,no,yes,yes,yes,yes,"Randomized, open-label, phase 3",886,Pembrolizumab,17.2,,55.9,PD-L1 expression,,eligible,First-line,Enfortumab vedotin + Pembrolizumab,no,global,"{'maculopapular rash': 7.7, 'hyperglycemia': 5.0, 'neutropenia': 4.8, 'skin reactions': 15.5, 'peripheral neuropathy': 6.8, 'severe skin reactions': 11.8}",Safety profile was generally manageable with no new safety signals.,,Clinical Trial,,
164,MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER: DOSTARLIMAB PLUS CHEMOTHERAPY COMPARED WITH CHEMOTHERAPY ALONE IN THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL,10.1136/ijgc-2023-IGCS.80,2023,International Journal of Gynecological Cancer,Endometrial Cancer,Primary advanced or recurrent,"['Dostarlimab + Carboplatin-Paclitaxel', 'Placebo + Carboplatin-Paclitaxel']",yes,no,yes,no,yes,yes,Randomized 1:1,487,Dostarlimab,,38.2,12.4,no,,eligible,,Carboplatin-Paclitaxel,no,,,"63.5% of patients with irAEs in the dostarlimab arm were treated with steroids, immunosuppressants, and/or thyroid therapy. 73.6% of irAEs resolved (median 10.0 days). 3.7% of patients discontinued placebo due to irAEs. No irAE-related deaths.",,Clinical Trial,,
165,"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results",10.1200/JCO.23.00172,2023,Journal of Clinical Oncology,Melanoma,Advanced,"['Bempegaldesleukin plus Nivolumab', 'Nivolumab monotherapy']",yes,no,yes,no,yes,yes,"Randomized, open-label, phase III",783,"Bempegaldesleukin, Nivolumab",11.6,,,no,,eligible,First-line,Bempegaldesleukin + Nivolumab,no,,,,,Clinical Trial,,
166,Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study,10.1159/000529996,2023,Liver Cancer,Hepatocellular Carcinoma,Unresectable,"['atezolizumab + bevacizumab', 'sorafenib']",yes,no,no,no,yes,yes,Randomized Controlled Trial,501,Atezolizumab,15.6,,,Albumin-Bilirubin (ALBI) score,,eligible,First-line,Atezolizumab + Bevacizumab,no,,,,"ALBI grade 1, ALBI grade 2",Post-hoc analysis,,
167,A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer,10.1016/j.lungcan.2023.107353,2023,Lung Cancer,non-small cell lung cancer,IIIB or IV,"['TQB2450 plus placebo', 'TQB2450 plus anlotinib 10 mg', 'TQB2450 plus anlotinib 12 mg']",yes,no,no,no,no,yes,randomized double-blind trial,101,TQB2450 (anti-PD-L1 antibody),,,,PD-L1,,yes,second-line,TQB2450 + anlotinib,no,,,,"wild-type EGFR/ALK, PD-L1 >= 1%",Phase Ib,,
168,"1540P Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study",10.1016/j.annonc.2023.09.1452,2023,Annals of Oncology,oesophageal squamous cell carcinoma,locally advanced,,yes,no,yes,yes,no,no,Phase II clinical study,26,Tislelizumab,,,,no,,eligible,neoadjuvant,"nCRT (Paclitaxel albumin, cisplatin/carboplatin)",no,,"{'leukopenia_grade3': 4, 'neutropenia_grade3': 1}",,,clinical trial,,
169,"744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)",10.1016/j.annonc.2023.09.1923,2023,Annals of Oncology,Cervical cancer,Recurrent/Metastatic,"['Tislelizumab + Ociperlimab', 'Tislelizumab monotherapy']",yes,no,yes,yes,yes,yes,"Randomized, multicenter, open-label, Phase II",138,"Tislelizumab, Ociperlimab",7.4,67.0,13.0,PD-L1,,eligible,Second-line or later,Tislelizumab + Ociperlimab,no,,"{'anemia': 2.0, 'rash': 1.0}",,PD-L1+,Clinical Trial,,no
173,"LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)",10.1016/j.annonc.2023.10.106,2023,Annals of Oncology,Urothelial Carcinoma,Locally advanced metastatic,"['Enfortumab vedotin + Pembrolizumab', 'Gemcitabine + Cisplatin or Carboplatin']",yes,no,yes,yes,yes,yes,Randomized controlled trial,886,Pembrolizumab,17.2,,55.9,PD-L1,,eligible,First-line,Enfortumab vedotin + Pembrolizumab,no,,"{'maculopapular rash': 7.7, 'hyperglycemia': 5.0, 'neutropenia': 4.8, 'skin reactions': 15.5, 'peripheral neuropathy': 6.8, 'severe skin reactions': 11.8}",The safety profile was generally manageable with no new safety signals.,regardless of PD-L1 expression,Clinical Trial,,
174,2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt),10.1016/j.annonc.2023.09.1008,2023,Annals of Oncology,Urothelial Cancer,Advanced or Metastatic,"['erdafitinib', 'pembrolizumab']",yes,no,yes,yes,yes,yes,"Randomized, open-label phase 3",351,Pembrolizumab,33.2,,,yes,,eligible,1 prior tx,,naive to anti–PD-(L)1,,"{'hyperphosphatemia_any_grade': 73, 'stomatitis_any_grade': 45, 'diarrhea_any_grade': 45, 'dry_mouth_any_grade': 35, 'pruritus_any_grade': 12, 'asthenia_any_grade': 10, 'hypothyroidism_any_grade': 10, 'fatigue_any_grade': 10}",Toxicities were manageable with dose modifications. 15% of pts discontinued erda and 5% discontinued pembro due to TRAEs.,FGFR3/2alt,Clinical Trial,0-2,
175,"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study",10.1016/S0140-6736(23)00961-3,2023,The Lancet,Hepatocellular Carcinoma,Unresectable or metastatic,"['camrelizumab + rivoceranib', 'sorafenib']",yes,no,yes,no,yes,yes,"Randomized, open-label, international phase 3 trial",543,camrelizumab,14.5,,,no,,eligible,First-line,camrelizumab + rivoceranib,no,International (13 countries and regions),"{'hypertension_grade3plus': 38, 'palmar-plantar erythrodysaesthesia syndrome_grade3plus': 12, 'increased aspartate aminotransferase_grade3plus': 17, 'increased alanine aminotransferase_grade3plus': 13}",,,Clinical Trial,,
176,Checkpoint Inhibitors in Combination with Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial,10.1001/jamaoncol.2023.2132,2023,JAMA Oncology,"melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma",advanced solid tumors,"['anti-PD-1/PD-1 ligand 1 ICIs alone', 'anti-PD-1/PD-1 ligand 1 ICIs combined with stereotactic body radiotherapy']",yes,no,yes,no,yes,yes,randomized phase 2 trial,96,anti-PD-1/PD-1 ligand 1 ICIs,12.5,78.5,18,no,,eligible,at least 1 previous line of systemic treatment,ICIs + stereotactic body radiotherapy,no,Belgium,,,,clinical trial,,
177,,10.1016/S0140-6736(23)01384-3,2023,The Lancet,NSCLC,"IA-IB, IIA, IIB","['SABR alone', 'SABR with nivolumab']",yes,no,yes,yes,no,yes,"Randomized, open-label, phase 2 trial",156,Nivolumab,33,,0.15,no,,eligible,treatment-naive or recurrent,SABR + Nivolumab,no,"TX, USA",{'pneumonitis_grade3plus': 0},,,Clinical Trial,,
178,,10.1016/S0140-6736(23)00769-9,2023,The Lancet,Merkel cell carcinoma,"any stage, completely resected","['nivolumab', 'observation']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 2 trial",179,nivolumab,24.3,,42,no,,eligible,adjuvant,,no,Germany and Netherlands,,,,clinical trial,0-1,
179,Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial,10.1016/j.jtcvs.2023.01.012,2023,Journal of Thoracic and Cardiovascular Surgery,non-small cell lung cancer,II-IIIA,"['atezolizumab', 'best supportive care']",yes,yes,yes,no,no,no,randomized phase III,871,atezolizumab,,,,PD-L1,,eligible,adjuvant,platinum-based chemotherapy,no,,,,PD-L1 tumor cell >= 1%,,,
180,Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial,10.1038/s41591-023-02498-y,2023,Nature Medicine,Melanoma,Metastatic,"['Ipilimumab + Nivolumab', 'Ipilimumab']",yes,no,yes,no,yes,yes,Randomized Phase 2,92,"Ipilimumab, Nivolumab",,,0.57,CD8 T cell infiltrate,,yes,Front-line anti-PD-1 or anti-PD-L1 refractory,Ipilimumab + Nivolumab,yes,,,,,Clinical Trial,,
181,Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial,10.1016/j.ejca.2023.112941,2023,European Journal of Cancer,melanoma,advanced,"['vemurafenib + cobimetinib', 'atezolizumab']",yes,no,yes,no,yes,yes,multicenter phase 2 randomized trial,185,atezolizumab,,,64,BRAFV600 mutation,,yes,previously untreated,no,no,,,,BRAFV600-mutated,clinical trial,,
185,Enfortumab Vedotin with or Without Pembrolizumab in Cisplatin-Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer,10.1200/JCO.22.02887,2023,Journal of Clinical Oncology,Urothelial Cancer,Locally advanced or metastatic,"['Enfortumab Vedotin + Pembrolizumab', 'Enfortumab Vedotin monotherapy']",yes,no,yes,yes,no,no,"Phase Ib/II, randomized",149,Pembrolizumab,,,,no,,eligible,First-line,Enfortumab Vedotin + Pembrolizumab,no,,"{'maculopapular rash grade 3+': 17.1, 'fatigue grade 3+': 9.2, 'neutropenia grade 3+': 9.2, 'skin reactions any grade': 67.1, 'peripheral neuropathy any grade': 60.5}","Adverse events for EV + Pembro were manageable, with no new safety signals observed.",,Clinical Trial,,no
186,IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study,10.1159/000528272,2023,Liver Cancer,Hepatocellular Carcinoma,BCLC Stage B Unresectable,"['Atezolizumab + Bevacizumab', 'Sorafenib']",yes,no,no,no,yes,yes,Randomized controlled trial,74,Atezolizumab,19.7,,,no,,yes,First-line,Atezolizumab + Bevacizumab,no,,,,,Phase III,,
187,"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study",10.1016/S0140-6736(23)00774-2,2023,The Lancet,non-small-cell lung cancer,IIIB or IV,"['atezolizumab monotherapy', 'single-agent chemotherapy (vinorelbine or gemcitabine)']",yes,no,yes,no,yes,no,randomised controlled study,453,atezolizumab,,,,no,,eligible,first-line,monotherapy,no,"Asia, Europe, North America, South America",,,,clinical trial,0-3,yes
188,"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial",10.1038/s41591-023-02465-7,2023,Nature Medicine,gastric or gastroesophageal junction adenocarcinoma,locally advanced unresectable or metastatic,"['zolbetuximab plus CAPOX', 'placebo plus CAPOX']",no,no,no,no,yes,yes,"randomized, double-blind, phase 3",507,zolbetuximab,,,,"CLDN18.2, HER2",,yes,first-line,CAPOX (capecitabine and oxaliplatin),no,global,,,"CLDN18.2-positive, HER2-negative",clinical trial,,
189,Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1,10.1016/j.jtho.2023.04.021,2023,Journal of Thoracic Oncology,NSCLC,IV,"['nivolumab plus ipilimumab', 'nivolumab', 'nivolumab plus chemotherapy', 'chemotherapy']",yes,no,no,no,yes,yes,Randomized Controlled Trial,1739,"Nivolumab, Ipilimumab",61.3,,,PD-L1,,yes,First-line,"nivolumab plus ipilimumab, nivolumab plus chemotherapy",no,,,,,,,
190,"IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications",10.1016/j.annonc.2023.05.009,2023,Annals of Oncology,non-small-cell lung cancer,locally advanced or metastatic,"['atezolizumab SC', 'atezolizumab IV']",yes,no,no,no,no,yes,"randomised phase III, open-label, multicentre, noninferiority study",371,atezolizumab,,,,no,,yes,previously treated,,,,,,,clinical trial,,
191,"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial",10.1016/S1470-2045(23)00276-0,2023,The Lancet Oncology,non-clear-cell renal cell carcinoma,IV,[],yes,no,yes,no,no,no,"single-arm, phase 2",158,pembrolizumab,14.9,,51.0,no,,yes,first-line,pembrolizumab plus lenvatinib,no,"Australia, Canada, France, Hungary, Ireland, Italy, Poland, South Korea, Russia, Spain, Türkiye, Ukraine, the UK, and the USA","{'hypertension': 23.0, 'proteinuria': 4.0, 'stomatitis': 4.0}",,,clinical trial,,
192,"Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer",10.1200/JCO.22.01994,2023,Journal of Clinical Oncology,Head and Neck Squamous Cell Carcinoma (HNSCC),Recurrent/Metastatic,"['Ficlatuzumab monotherapy', 'Ficlatuzumab with Cetuximab']",no,no,no,no,no,yes,"Randomized, noncomparative phase II",58,no,,,,yes,,eligible,,Ficlatuzumab + Cetuximab,anti-PD-1 mAb,,,,"HPV status, cMet overexpression",Clinical Trial,,
193,Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer,10.1093/oncolo/oyad097,2023,Oncologist,advanced cancer,advanced,,yes,yes,yes,no,no,no,retrospective,238,Immune checkpoint inhibitor,,0.39,0.13,no,,eligible,,,,,,,,,,
194,"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial",10.1016/S0140-6736(23)00922-4,2023,The Lancet,renal cell carcinoma,locally advanced or metastatic,"['atezolizumab plus cabozantinib', 'cabozantinib monotherapy']",yes,no,no,no,yes,yes,"multicentre, randomised, open-label, phase 3 trial",522,atezolizumab,15.2,,,no,,eligible,after progression with previous immune checkpoint inhibitor treatment,atezolizumab + cabozantinib,yes,"Asia, Europe, North America, South America",,,,clinical trial,,
195,"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results",10.1038/s41591-023-02385-6,2023,Nature Medicine,non-small cell lung cancer,advanced,"['pembrolizumab + lenvatinib', 'pembrolizumab + quavonlimab', 'pembrolizumab + favezelimab']",yes,no,no,no,yes,yes,"phase 2, adaptively randomized",,pembrolizumab,,,,yes,,eligible,first-line,pembrolizumab + lenvatinib; pembrolizumab + quavonlimab; pembrolizumab + favezelimab,no,,,,T-cell-inflamed gene expression profile (TcellinfGEP) and tumor mutational burden (TMB),clinical trial,,
196,,10.1016/j.jhepr.2023.100755,2023,JHEP Reports,Hepatocellular carcinoma (HCC),,,no,no,no,no,no,no,Retrospective analysis of phase 2 and 3 RCTs,51,,,,,,,eligible,,,,,,,,,,
197,"IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial",,2023,Journal of Clinical Oncology,Malignant Pleural Mesothelioma,Unresectable,"['Cisplatin/Pemetrexed (CP)', 'Cisplatin/Pemetrexed (CP) + Pembrolizumab (pembro)']",yes,no,yes,yes,yes,yes,"Randomized, Open-label, Phase III",440,Pembrolizumab,,,0.19,PD-L1,,eligible,First-line,Chemotherapy + Immunotherapy,no,"Canada, Italy, France","{'fatigue_grade3plus': 0.05, 'diarrhea_grade3plus': 0.02, 'pneumonitis_grade3plus': 0.02}",16% of pts discontinued pembro per protocol for related AEs (most commonly diarrhea and pneumonitis).,,Clinical Trial,0-1,
198,,,2023,Journal of Clinical Oncology,Soft Tissue Sarcoma,Metastatic,"['Cabozantinib + Nivolumab + Ipilimumab', 'Cabozantinib alone']",yes,no,yes,yes,no,yes,Randomized Phase II,105,"Nivolumab, Ipilimumab",,,,yes,,eligible,1-2 lines of prior therapy,Cabozantinib + Nivolumab + Ipilimumab,no,,,,,,0-1,
199,"A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial)",10.1200/jco.2023.41.16_suppl.9533,2023,Journal of Clinical Oncology,Uveal melanoma,Metastatic,"['IHP followed by combination immunotherapy (four cycles IPI3/NIVO1 q3w)', 'one neoadjuvant cycle of IPI3/NIVO1 prior to IHP followed by three cycles IPI3/NIVO1 q3w']",yes,no,yes,no,no,no,"Phase I, randomized, controlled, multicentre",18,"Ipilimumab, Nivolumab",,,,no,,eligible,First-line,Ipilimumab + Nivolumab + Isolated Hepatic Perfusion (Melphalan),no,,,,,Clinical Trial,,
201,Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results,10.1200/jco.2023.41.16_suppl.9125,2023,Journal of Clinical Oncology,NSCLC,metastatic,"['Pembrolizumab monotherapy', 'Pembrolizumab plus Vorinostat']",yes,no,yes,yes,yes,yes,"randomized, open-label, 1:1",86,Pembrolizumab,,,,PD-L1,,eligible,first-line,Pembrolizumab + Vorinostat,no,,"{'Arm A grade >=3 irAEs': 3, 'Arm A hepatitis grade 3': 1, 'Arm A pneumonitis grade 3': 1, 'Arm A rash grade 3': 1, 'Arm B grade >=3 irAEs': 3, 'Arm B pneumonitis grade 3': 2, 'Arm B myopericarditis grade 4': 1}",Vorinostat dose reduction or interruption occurred frequently due to grade 2-3 fatigue or nausea.,PD-L1 expression >= 1%,Phase II,0/1,
202,,10.1200/jco.2023.41.16_suppl.e14605,2023,Journal of Clinical Oncology,,,"['Standard interval (SI) dosing', 'Extended interval (EI) dosing']",yes,yes,yes,no,yes,no,Retrospective study,458,"pembrolizumab, nivolumab",,32,,no,,eligible,,,,United States of America,,,,,,
203,"Neoadjuvant tislelizumab, a PD-1 mAb plus nab-paclitaxel (nab-P) followed by tislelizumab plus epirubicin/cyclophosphamide (EC) for triple-negative breast cancers (TNBC): Interim analysis of clinical response in a phase 2 TREND trial",10.1200/jco.2023.41.16_suppl.e14623,2023,Journal of Clinical Oncology,Triple-negative breast cancer,Not specified,[],yes,no,yes,no,no,no,Single-arm phase 2 clinical study,43,Tislelizumab,,69.8,7.0,PD-L1 CPS,,yes,Neoadjuvant,"nab-paclitaxel, epirubicin, cyclophosphamide",no,,{},,,Clinical Trial,,
207,Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC,10.1016/j.jtho.2023.02.009,2023,Journal of Thoracic Oncology,NSCLC,III,"['durvalumab', 'placebo']",yes,no,no,no,yes,yes,Randomized controlled trial,35,durvalumab,42.7,,,EGFRm,,eligible,consolidation,chemoradiotherapy,no,,,,EGFRm,post hoc exploratory analysis,,
208,Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651,10.1200/JCO.22.00332,2023,Journal of Clinical Oncology,Squamous Cell Carcinoma of the Head and Neck,Recurrent/Metastatic,"['nivolumab plus ipilimumab', 'EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil six cycles, then cetuximab maintenance)']",yes,no,yes,no,yes,yes,Randomized controlled trial,947,"Nivolumab, Ipilimumab",,,28.2,PD-L1 CPS,,eligible,First-line,Nivolumab + Ipilimumab,no,,,,"PD-L1 CPS 1, PD-L1 CPS 20",Clinical Trial,,
209,"Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials",10.1001/jamaoncol.2022.7711,2023,JAMA Oncology,Non-Small Cell Lung Cancer,IV,"['atezolizumab with carboplatin plus nab-paclitaxel', 'chemotherapy alone', 'atezolizumab with carboplatin or cisplatin plus pemetrexed', 'atezolizumab plus bevacizumab plus carboplatin and paclitaxel', 'atezolizumab plus carboplatin and paclitaxel', 'bevacizumab plus carboplatin and paclitaxel']",yes,yes,yes,no,yes,no,"Phase 3, multicenter, open-label, randomized clinical trials (pooled post hoc analysis)",2503,Atezolizumab,,,,no,,eligible,first-line,chemoimmunotherapy,no,,,,,RCT,,
210,"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)",10.1007/s10388-022-00970-1,2023,Esophagus,esophageal squamous cell carcinoma,advanced,"['nivolumab + ipilimumab', 'nivolumab + chemotherapy', 'chemotherapy']",yes,no,yes,no,yes,yes,"open-label, phase 3 trial",394,"nivolumab, ipilimumab",,,,PD-L1,,yes,first-line,"nivolumab + ipilimumab, nivolumab + chemotherapy",no,Japan,,,PD-L1 expression ≥ 1%,clinical trial,,
211,Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy,10.1007/s12072-022-10478-6,2023,Hepatology International,Hepatocellular Carcinoma,,"['PA-PD-1 group', 'non-PD-1 group']",no,no,no,no,yes,yes,prospective observational study,94,anti-PD-1 antibody,,,,,,eligible,adjuvant,,no,,,,,,,
212,Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer,10.1007/s40262-023-01210-0,2023,Clinical Pharmacokinetics,Differentiated Thyroid Cancer,,"['cabozantinib 60 mg/day', 'placebo']",yes,no,yes,no,no,yes,Phase 3,115,cabozantinib,,,,no,,eligible,prior VEGFR-targeted therapy,,,,,The cabozantinib dose should be reduced to manage adverse events as indicated.,,Pharmacokinetics and Exposure-Response Analysis,,
213,Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder,10.4143/crt.2022.343,2023,Cancer Research and Treatment,Urothelial Carcinoma of the Bladder,cT2-T4a N0 MIBC,[],yes,no,no,no,no,yes,Prospective Phase II Trial,51,Nivolumab,24,,,PD-L1,,eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC),Neoadjuvant,Nivolumab + Gemcitabine/Cisplatin,no,,{},,,Clinical Trial,,
214,Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial,10.1093/oncolo/oyac243,2023,Oncologist,Renal Cell Carcinoma,Advanced,,yes,no,yes,no,yes,yes,"Phase Ib, open-label, multicenter",55,Avelumab,55.7,98.2,61.8,no,,eligible,First-line,Avelumab plus Axitinib,no,,,,,Clinical Trial,,
215,Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial,10.1200/JCO.22.00972,2023,Journal of Clinical Oncology,Hepatocellular Carcinoma,Advanced,"['nivolumab plus cabozantinib', 'nivolumab plus cabozantinib plus ipilimumab']",yes,no,yes,no,yes,yes,"multicohort, open-label, phase I/II",71,"Nivolumab, Ipilimumab",32,,,no,,eligible,"treatment-naive, sorafenib-intolerant, or progressed on sorafenib",nivolumab + cabozantinib; nivolumab + cabozantinib + ipilimumab,no,,,,,Clinical Trial,,
216,"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial",10.1016/S0140-6736(22)02574-0,2023,The Lancet,Renal Cell Carcinoma,"Localized, high risk of relapse","['Nivolumab plus Ipilimumab', 'Placebo']",yes,no,yes,no,yes,yes,"Double-blind, randomized, phase 3 trial",816,"Nivolumab, Ipilimumab",37,,0.38,no,,yes,Adjuvant,Nivolumab + Ipilimumab,no,Multinational (20 countries),,,,Clinical Trial,,
217,Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy,10.1136/jitc-2022-006629,2023,Journal for ImmunoTherapy of Cancer,Melanoma,III,"['Adjuvant RT', 'No Adjuvant RT']",no,no,no,no,yes,yes,Retrospective,71,anti-PD-1 (±ipilimumab),,,,BRAF V600E mutant,,eligible,Adjuvant,Immunotherapy + Radiotherapy,,,,,,Observational Study,,
218,Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor,10.1055/s-0043-1769609,2023,Thrombosis and Haemostasis,"Melanoma, Non-small cell lung cancer",,"['Nivolumab and Ipilimumab', 'Pembrolizumab', 'Nivolumab']",yes,yes,no,no,no,no,Retrospective,374,"Nivolumab, Ipilimumab, Pembrolizumab",15.2,,,no,,eligible,,Nivolumab and Ipilimumab,,,{'VTE': 13.4},,,Observational,,
219,Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study,10.1002/cam4.5483,2023,Cancer Medicine,Renal Cell Carcinoma,Advanced,"['lenvatinib plus pembrolizumab', 'sunitinib']",yes,no,yes,no,yes,yes,Phase 3,73,pembrolizumab,,,95.2,no,,eligible,First-line,lenvatinib plus pembrolizumab,no,Japan,,,,Clinical Trial,,
220,Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer,10.1111/cas.15650,2023,Cancer Science,colorectal cancer,metastatic,"['pembrolizumab', 'chemotherapy with or without bevacizumab or cetuximab']",yes,no,yes,no,yes,yes,"Phase 3, post hoc analysis",48,pembrolizumab,45.3,,9,MSI-H/dMMR,,eligible,first-line,,no,"Asia (Japan, Korea, Singapore, Taiwan)",,,MSI-H/dMMR,clinical trial,,
221,"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial",10.1016/j.annonc.2022.12.007,2023,Annals of Oncology,Nasopharyngeal carcinoma,Recurrent or metastatic,"['Pembrolizumab', 'Chemotherapy (capecitabine, gemcitabine, or docetaxel)']",yes,no,yes,yes,yes,no,"Randomized, open-label, phase III",233,Pembrolizumab,45.1,,10.3,PD-L1,,eligible,Second-line or later,no,no,Global,{'pneumonitis': 0.9},,PD-L1-positive,Interventional,,
223,"PD11-11 Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial",10.1158/1538-7445.SABCS22-PD11-11,2023,Cancer Research,Triple Negative Breast Cancer,Metastatic,"['Chemotherapy alone (PLD + cyclophosphamide)', 'Chemotherapy (PLD + cyclophosphamide) + Atezolizumab']",yes,no,yes,yes,yes,yes,Randomized Phase IIb,68,Atezolizumab,,,,PD-L1,,yes,Maximum one previous line of chemotherapy in the metastatic setting,Atezolizumab + Pegylated liposomal doxorubicin (PLD) + Cyclophosphamide,no,,"{'hypothyroidism': 10.0, 'pneumonitis': 10.0, 'hyperthyroidism': 5.0, 'rash': 7.5}",,PD-L1 positive; PD-L1 negative,Clinical Trial,,
224,,10.1158/1538-7445.SABCS22-GS5-03,2023,Cancer Research,Breast cancer,"Early-stage, high-risk","['Cemiplimab + REGN3767 + Paclitaxel + Doxorubicin/Cyclophosphamide', 'Paclitaxel + Doxorubicin/Cyclophosphamide']",yes,no,yes,yes,no,no,"Multicenter, phase 2, response-adaptive randomization",73,"Cemiplimab, REGN3767",,,,yes,,eligible,Neoadjuvant,Cemiplimab + REGN3767 + chemotherapy,no,,"{'hypothyroidism': 30.8, 'adrenal insufficiency': 19.2, 'hyperthyroidism': 14.1, 'pneumonitis': 1.3, 'hepatitis': 3.8, 'colitis_grade3': 3.8, 'rash': 62.8, 'rash_grade3': 9, 'pulmonary embolism': 2.6}",,"HER2-negative, HR+, HR-, MammaPrint, ImPrint signature",Clinical Trial,,
225,Durvalumab with or Without Tremelimumab in Combination with Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study,10.1200/JCO.22.00975,2023,Journal of Clinical Oncology,Non-small-cell lung cancer,Metastatic,"['Tremelimumab + Durvalumab + Chemotherapy', 'Durvalumab + Chemotherapy', 'Chemotherapy']",yes,no,yes,no,yes,yes,Randomized controlled trial,1013,"Durvalumab, Tremelimumab",,,,EGFR/ALK wild-type,,yes,First-line,Chemotherapy,no,,,,EGFR/ALK wild-type,Clinical Trial,,
226,"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis",10.1002/ijc.34296,2023,International Journal of Cancer,"gastric, gastroesophageal junction, esophageal adenocarcinoma",advanced/metastatic,"['nivolumab plus chemotherapy', 'chemotherapy alone']",yes,no,no,no,yes,yes,randomized controlled trial,208,nivolumab,,,,HER2,,yes,first-line,"nivolumab + XELOX (capecitabine and oxaliplatin) or FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil)",no,China,,,HER2-negative,subgroup analysis,,
229,Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?,10.1016/j.ejso.2022.10.018,2023,European Journal of Surgical Oncology,Rectal Cancer,Locally Advanced,,yes,no,no,no,no,no,Systematic Review,,,,,,dMMR/MSI-H,,eligible,Neoadjuvant,,,,,,,,,
230,"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial",10.1038/s41591-022-02179-2,2023,Nature Medicine,esophageal squamous cell carcinoma (ESCC),advanced,"['serplulimab plus chemotherapy', 'placebo plus chemotherapy']",yes,no,yes,no,yes,yes,"randomized, double-blind phase 3 trial",551,serplulimab (anti-PD-1 antibody),,,,PD-L1,,eligible,first-line,chemotherapy (cisplatin and 5-fluorouracil),no,,,,PD-L1 combined positive score of ≥1,clinical trial,,
231,Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study,10.1016/j.ygyno.2022.11.028,2023,Gynecologic Oncology,Endometrial cancer,Recurrent,"['Durvalumab', 'Durvalumab plus tremelimumab']",yes,no,no,no,no,yes,"Randomized, open-label, phase 2",82,"Durvalumab, Tremelimumab",,,,MMR status,,eligible,,Durvalumab + Tremelimumab,,,,,"MMR-deficient, MMR-proficient",Clinical Trial,,
232,Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915),10.1200/JCO.22.00533,2023,Journal of Clinical Oncology,Melanoma,IIIB-D or IV,"['nivolumab plus ipilimumab', 'nivolumab alone']",yes,no,yes,no,no,yes,"Randomized, double-blind, phase III",1833,"Nivolumab, Ipilimumab",23.7,,,PD-L1,,yes,Adjuvant,Nivolumab + Ipilimumab,no,,,,,,,
233,"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma",10.1200/JCO.22.00343,2023,Journal of Clinical Oncology,Melanoma,Stage IIIB-IVM1c,"['T-VEC plus pembrolizumab', 'placebo plus pembrolizumab']",yes,no,yes,no,yes,yes,"Randomized, double-blind, placebo-controlled, global phase III trial",692,Pembrolizumab,,,20.7,no,,eligible,,Talimogene laherparepvec (T-VEC) + Pembrolizumab,naïve to anti-programmed cell death protein-1,international,,,,Clinical Trial,,
234,"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial",10.1200/JCO.21.02961,2023,Journal of Clinical Oncology,Melanoma,Metastatic,"['Arm A: encorafenib + binimetinib -> ipilimumab + nivolumab', 'Arm B: ipilimumab + nivolumab -> encorafenib + binimetinib', 'Arm C: encorafenib + binimetinib (8 weeks) -> ipilimumab + nivolumab -> encorafenib + binimetinib']",yes,no,no,no,yes,yes,"Randomized, three-arm, noncomparative phase II trial",209,"Ipilimumab, Nivolumab",32.2,,,yes,,eligible,Untreated,"Ipilimumab + Nivolumab, Encorafenib + Binimetinib",no,Multinational (9 countries),{},,BRAFV600-mutant,Clinical Trial,,
235,Opdualag for Metastatic Melanoma,,2023,Medical Letter on Drugs and Therapeutics,Melanoma,Metastatic,,yes,no,yes,yes,no,yes,,,nivolumab and relatlimab,,,,LAG-3,,eligible,,nivolumab and relatlimab,,,"{'fatigue': 30, 'musculoskeletal pain': 29, 'rash': 28, 'diarrhea': 22, 'pruritus': 21, 'arthralgia': 19, 'hypothyroidism': 19, 'vitiligo': 19, 'headache': 17, 'nausea': 16, 'colitis': 4.7, 'hepatitis': 3.2, 'pneumonitis': 2.2, 'hypophysitis': 1.4, 'myocarditis': 0.4}","Management of irAEs with Opdualag is similar to other immune checkpoint inhibitors, involving corticosteroids and/or hormone replacement.",LAG-3 positive,,,
236,Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial,10.1016/j.eururo.2022.09.025,2023,European Urology,Urothelial Carcinoma,Advanced,"['Niraparib + Best Supportive Care', 'Best Supportive Care alone']",yes,no,yes,yes,no,yes,"Randomized, multicenter, open-label phase 2 trial",58,Niraparib,,,,no,,yes,First-line maintenance,Niraparib + Best Supportive Care,no,,"{'anemia': 50, 'anemia_G3': 11, 'thrombocytopenia': 37, 'thrombocytopenia_G3-4': 16, 'neutropenia': 21, 'neutropenia_G3': 5, 'fatigue': 32, 'fatigue_G3': 16, 'constipation': 32, 'constipation_G3': 3, 'mucositis': 13, 'mucositis_G3': 3, 'nausea': 13, 'nausea_G3': 3}",,,Clinical Trial,0 or 1,no
237,Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma,10.1016/j.ijrobp.2022.09.052,2023,International Journal of Radiation Oncology Biology Physics,Hepatocellular Carcinoma,Advanced/Unresectable,"['SBRT + Nivolumab', 'SBRT + Nivolumab + Ipilimumab']",yes,no,yes,yes,yes,yes,Phase 1 Randomized Trial,14,"Nivolumab, Ipilimumab",42.7,,61.6,no,,yes,,SBRT,no,,{'hepatotoxicity_grade3plus': 30.8},acceptable safety,,Clinical Trial,,
238,"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial",10.1016/S2213-2600(22)00309-5,2023,The Lancet Respiratory Medicine,Small-cell lung cancer,Relapsed,"['Lurbinectedin + Doxorubicin', ""Physician's choice (Topotecan or CAV)""]",no,no,no,no,yes,no,"Phase 3, open-label, randomized",613,,24.1,,,no,,yes,Second-line,Lurbinectedin + Doxorubicin,no,"North America, South America, Europe, Middle East",,,,Clinical Trial,,
239,"Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)",10.3390/ijms24021096,2023,International Journal of Molecular Sciences,Renal Cell Carcinoma,Metastatic,[],yes,no,yes,yes,no,yes,Observational,32,Pembrolizumab,,,,no,,eligible,First-line,Pembrolizumab-axitinib,no,Italy,"{'G3 hepatitis': 5, 'G3 hypophisitis': 1, 'G3 diarrhea': 1, 'G3 pancreatitis': 1, 'G3 asthenia': 1}",11 patients (34.3%) interrupted the full treatment due to irAEs.,,Observational Study,,
240,NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC,10.1016/j.jtho.2022.09.223,2023,Journal of Thoracic Oncology,NSCLC,Metastatic,"['durvalumab plus tremelimumab', 'chemotherapy']",yes,no,yes,no,yes,yes,"Phase 3, open-label, randomized",823,"durvalumab, tremelimumab",,,,"bTMB, PD-L1",,eligible,first-line,durvalumab plus tremelimumab,no,,,,EGFR and ALK wild-type,clinical trial,,
243,"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)",10.1200/JCO.22.00205,2023,Journal of Clinical Oncology,Urothelial Carcinoma,Metastatic,"['durvalumab plus olaparib', 'durvalumab plus placebo']",yes,no,yes,no,yes,yes,"Randomized, multicenter, double-blind, phase II trial",154,durvalumab,,,18,yes,,eligible,untreated,durvalumab + olaparib,no,,,,HRRm,Clinical Trial,,
244,,10.1056/NEJMoa2211437,2023,New England Journal of Medicine,Melanoma,IIIB-IVC,"['Neoadjuvant-adjuvant pembrolizumab', 'Adjuvant-only pembrolizumab']",yes,no,yes,no,no,yes,Phase 2 trial,313,Pembrolizumab,14.7,,,no,,eligible,neoadjuvant/adjuvant,,no,,,,,clinical trial,,
245,,10.1056/NEJMoa2212851,2023,New England Journal of Medicine,Renal-Cell Carcinoma,Advanced,"['Cabozantinib + Nivolumab + Ipilimumab', 'Placebo + Nivolumab + Ipilimumab']",yes,no,yes,no,yes,yes,"Phase 3, double-blind, randomized controlled trial",855,"Nivolumab, Ipilimumab",,,,no,,eligible,First-line,Cabozantinib + Nivolumab + Ipilimumab,no,,,,,Clinical Trial,,
246,Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer,10.1056/NEJMoa2215530,2023,New England Journal of Medicine,Non-small-cell lung cancer (NSCLC),IIIA or IIIB,"['neoadjuvant nivolumab plus platinum-based chemotherapy followed by surgery and adjuvant nivolumab', 'chemotherapy alone followed by surgery']",yes,no,yes,no,yes,yes,"open-label, phase 2, randomized controlled trial",86,Nivolumab,,,19,no,,yes,perioperative,Chemotherapy,no,,,,,Clinical Trial,,
248,Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG),10.1200/CCI.22.00165,2023,JCO Clinical Cancer Informatics,squamous non-small-cell lung cancer,IV,"['nivolumab', 'nivolumab plus ipilimumab']",yes,yes,yes,yes,no,no,randomized phase III trial,,"nivolumab, ipilimumab",,,,no,,eligible,,nivolumab + ipilimumab,,,"{'musculoskeletal_grade3plus': 0.056, 'skin_grade3plus': 0.056, 'vascular_grade3plus': 0.056, 'cardiac_grade3plus': 0.04}",,,clinical trial,,
251,Nivolumab (NIVO) + relatlimab (RELA) versus (vs) NIVO in patients (pts) with previously untreated metastatic or unresectable melanoma: safety outcomes in RELATIVITY-047,10.1111/pcmr.13073,2023,Pigment Cell and Melanoma Research,Melanoma,Metastatic or unresectable,"['NIVO + RELA', 'NIVO']",yes,yes,yes,yes,yes,yes,Phase 2/3 randomized controlled trial,714,"Nivolumab, Relatlimab",19.3,,,no,,yes,First-line,Nivolumab + Relatlimab,no,,,Median time to onset and resolution for non-endocrine and endocrine IMAEs were reported.,,Clinical Trial,,
252,,10.1200/jco.2023.41.6_suppl.181,2023,Journal of Clinical Oncology,Prostate Cancer,mCRPC,,yes,no,yes,yes,no,yes,Phase I/II,12,Pembrolizumab,6,,,PSA,,eligible,,Pembrolizumab + ARSI + 225Ac-J591,no,,"{'CRS': 58, 'rash': 16.5, 'hypothyroidism': 16.5}",CRS managed supportively by pausing ARSI.,,Clinical Trial,,
253,Post-neoadjuvant therapy in triple-negative breast cancer,,2023,Libri Oncologici,Triple-negative breast cancer,Stage II or III,"['Capecitabine plus standard therapy', 'Standard therapy alone', 'Olaparib', 'Placebo', 'Chemotherapy and pembrolizumab', 'Chemotherapy and placebo']",yes,no,yes,no,yes,yes,Phase 3 clinical trial,2746,Pembrolizumab,,,78,yes,,eligible,Adjuvant; Neoadjuvant,Chemotherapy and pembrolizumab,no,,,,BRCA1 or BRCA2 germline mutation,Clinical Trial,,
254,FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease,10.1158/1078-0432.CCR-22-0617,2022,Clinical cancer research : an official journal of the American Association for Cancer Research,Esophageal/Gastroesophageal Junction Cancer,,"['nivolumab', 'placebo']",yes,no,no,no,yes,yes,double-blind,,nivolumab,,,,no,,eligible,adjuvant,,no,,,,,,,
255,Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial,10.1186/s12885-022-09488-2,2022,BMC Cancer,Gastric Cancer,Advanced,"['Nivolumab', 'Placebo']",no,no,no,no,yes,yes,"Phase 3, subset analysis",45,Nivolumab,,,,yes,,eligible,>=3rd-line,,no,Asan Medical Center,,,"PD-L1 expression, blood NLR, serum Na, MSI status, tumor EBV infection, TMB",Retrospective,,
256,Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety,10.1016/j.jfma.2022.09.005,2022,Journal of the Formosan Medical Association,Hepatocellular Carcinoma,Advanced,[],yes,no,no,no,yes,yes,,40,Atezolizumab,,,,no,,eligible,First-line,Bevacizumab + Atezolizumab,no,Taiwan,"{'proteinuria': 50, 'hypertension': 37.5}",,,,,
257,,10.1038/s41591-022-02126-1,2022,Nature Medicine,metastatic triple-negative breast cancer (mTNBC),metastatic,"['atezolizumab + chemotherapy', 'placebo + chemotherapy']",yes,no,no,no,no,yes,"randomized, double-blind, placebo-controlled phase 2b",68,atezolizumab,,,,PD-L1,,eligible,,pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide,,,,,,clinical trial,,
258,Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial,10.1016/j.ejca.2022.09.020,2022,European Journal of Cancer,renal cell carcinoma,advanced,,yes,no,yes,yes,yes,yes,phase III,50,"nivolumab, ipilimumab",39.1,,84.0,no,,eligible,first-line,nivolumab + ipilimumab + cabozantinib,no,,{'hepatic immune-mediated AEs_grade3plus': 40.0},,,,,
260,IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours,10.1016/j.iotech.2022.100300,2022,Immuno-Oncology and Technology,advanced solid tumours,advanced,"['IPH5201 monotherapy', 'IPH5201 + Durvalumab']",yes,no,yes,no,yes,yes,"multicentre, non-randomised, open-label, phase 1",57,"IPH5201, Durvalumab",,66.7,10.5,CD39,,yes,median of 3 prior therapies,IPH5201 + Durvalumab,,,,,,clinical trial,,
261,"54P Oncolytic virus combined PD-1 antibody toripalimab in advanced lung cancer with liver metastases: An early stage, single arm, study (TROJAN 2201)",10.1016/j.iotech.2022.100159,2022,Immuno-Oncology and Technology,lung cancer,advanced,[],yes,no,yes,no,no,yes,single arm,10,toripalimab,,90,,no,,yes,refractory to previous several lines of standard treatment,recombinant human adenovirus 5 + toripalimab,yes,,{'fever': 90},,,early stage,,
262,,10.1016/j.iotech.2022.100258,2022,Immuno-Oncology and Technology,NSCLC,oligometastatic brain metastases,"['SBRT + anlotinib + toripalimab', 'SBRT + anlotinib']",yes,no,yes,yes,yes,yes,"Prospective, open-label, phase 1b",10,toripalimab,4.9,70,20,no,,yes,untreated,"SBRT, anlotinib",no,,"{'hypertension': 30, 'hypothyroidism': 10, 'elevated myocardial enzymes': 10, 'hand-foot syndrome': 20}","Dose reduction, suspension of therapy",,Clinical Trial,<=1,no
265,Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma,10.1136/jitc-2022-005684,2022,Journal for ImmunoTherapy of Cancer,Melanoma,IIIB/IIIC/IV,,yes,no,yes,no,yes,yes,Phase II clinical trial,56,"Nivolumab, Ipilimumab",63.9,,,yes,,yes,Adjuvant,Nivolumab + Ipilimumab,no,,,,"CD3+CD4+CD38+CD127-GARP- T cells, CD39 expression in CD8+ T cells, phosphorylated STAT2 and STAT5",Interventional,,
267,INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients,10.1016/j.ijrobp.2022.07.475,2022,International Journal of Radiation Oncology Biology Physics,Muscle Invasive Bladder Cancer,T2-T4aN0M0,"['TMT alone (control)', 'TMT + atezolizumab']",yes,no,yes,yes,no,no,Randomized Phase III,213,Atezolizumab,,,,PD-L1,,eligible,,Chemoradiotherapy,no,,"{'diarrhea_grade3': 2, 'cystitis_grade3': 2, 'pancreatitis_grade3plus': 1, 'rash_grade3plus': 1, 'acute_kidney_injury_grade3plus': 2, 'gastritis_grade3plus': 1, 'transaminitis_grade3plus': 1, 'dyspnea_grade3plus': 1}",,,Clinical Trial,0-1,no
268,"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial",10.1016/S1470-2045(22)00559-9,2022,The Lancet Oncology,Melanoma,IIB or IIC,"['Pembrolizumab', 'Placebo']",yes,no,yes,yes,no,yes,"Multicentre, double-blind, placebo-controlled, crossover or rechallenge, randomised, phase 3 trial",976,Pembrolizumab,27.4,,,no,,eligible,Adjuvant,no,no,Multicentre (16 countries),"{'hypertension_grade3plus': 3, 'diarrhoea_grade3plus': 2, 'rash_grade3plus': 1, 'autoimmune hepatitis_grade3plus': 1, 'increased lipase_grade3plus': 1}",,,Clinical Trial,0-1,no
269,,10.1016/j.annonc.2022.10.182,2022,Annals of Oncology,Urothelial Cancer,Metastatic,"['cis-ineligible', 'platinum-ineligible']",yes,no,yes,yes,yes,yes,Retrospective,39,"Atezolizumab, Pembrolizumab",14.4,,2.6,no,,eligible,1L,no,no,Spain,{'nephritis_grade3plus': 2.6},,,Observational Study,ECOG PS 2,
270,Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib + pembrolizumab (CLEAR study),10.1111/ajco.13869,2022,Asia-Pacific Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['lenvatinib + pembrolizumab', 'lenvatinib + everolimus', 'sunitinib']",yes,no,yes,yes,yes,yes,Randomized controlled trial,1069,Pembrolizumab,,,,no,,eligible,First-line,Lenvatinib + Pembrolizumab,no,,"{'decreased appetite': 14.6, 'diarrhoea': 20.0, 'fatigue': 4.4, 'hypertension': 3.0, 'hypothyroidism': 14.3, 'musculoskeletal pain': 6.4, 'nausea': 14.4, 'rash': 11.4, 'stomatitis': 6.6}",Clinicians play a critical role in prompt identification and AR-directed management; such management may potentially reduce treatment interruption(s) and/or lenvatinib dose reduction.,,Clinical Trial,,
271,,,2022,Swiss Medical Weekly,Small Cell Lung Cancer (SCLC),Extensive Disease (ED-SCLC),[],yes,no,no,no,yes,yes,Retrospective analysis,200,"atezolizumab, durvalumab",,25.0,,no,,eligible,First-line,Chemoimmunotherapy,no,Switzerland,,,,Real-world evidence,25.3% had PS ≥2,no
272,Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial,10.1016/j.annonc.2022.07.002,2022,Annals of Oncology,mucosal melanoma,resected,"['toripalimab', 'high-dose interferon-α2b (HDI)']",yes,no,yes,no,yes,yes,randomized controlled trial,145,toripalimab,26.3,,27.4,no,,yes,adjuvant,,no,,,,,Phase II,,
273,"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer",10.1016/j.esmoop.2022.100559,2022,ESMO Open,colorectal cancer,metastatic,"['fluoropyrimidine (FP)/bevacizumab', 'FP/bevacizumab + atezolizumab']",no,no,no,no,yes,yes,"randomized, signal-seeking trial",445,atezolizumab,20.3,,,BRAF wild-type,,eligible,first-line maintenance,FOLFOX + bevacizumab induction followed by FP/bevacizumab +/- atezolizumab maintenance,no,,,,BRAFwt,clinical trial,,
275,"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial",10.1016/S0140-6736(22)01654-3,2022,The Lancet,Melanoma,IV,"['nivolumab plus ipilimumab', 'nivolumab monotherapy', 'placebo']",yes,no,yes,no,yes,yes,"randomized, double-blind, placebo-controlled, three-arm, phase 2 trial",175,"Nivolumab, Ipilimumab",49.2,,71.0,no,,yes,Adjuvant,Nivolumab + Ipilimumab,no,Germany,,,,Clinical Trial,,
276,"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial",10.1016/S0140-6736(22)01658-0,2022,The Lancet,renal cell carcinoma,locoregional,"['atezolizumab', 'placebo']",yes,no,yes,no,no,yes,"randomised, double-blind, multicentre, phase 3 trial",778,atezolizumab,44.7,,,PD-L1 status,,eligible,adjuvant,,no,"North America (excluding Mexico), rest of the world",,,,clinical trial,,
277,Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients with Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial,10.1001/jamaoncol.2022.3511,2022,JAMA Oncology,Renal Cell Carcinoma,Metastatic,"['Telaglenastat + Cabozantinib', 'Placebo + Cabozantinib']",no,no,no,no,no,yes,"Randomized, placebo-controlled, double-blind, pivotal trial",444,,,,,,,yes,1 to 2 prior lines of therapy,Telaglenastat + Cabozantinib,yes,"US, Europe, Australia, New Zealand",,,,Clinical Trial,,
278,MOLECULAR PREDICTORS OF IMMUNOTHERAPY EFFICACY IN LUNG SQUAMOUS-CELL CARCINOMA (LSCC): RESULTS FROM THE RANDOMIZED PROSPECTIVE SQUINT TRIAL,10.1177/03008916221114500,2022,Tumori,Lung Squamous Cell Carcinoma (LSCC),advanced/metastatic,"['Nivolumab + Ipilimumab (NI)', 'Nivolumab + platinum-based chemotherapy (N-CT)']",no,no,no,no,yes,yes,"randomized, prospective, phase II",91,"Nivolumab, Ipilimumab",18,,,yes,,eligible,,"Nivolumab + Ipilimumab, Nivolumab + platinum-based chemotherapy",,,,,PD-L1,clinical trial,,
279,"CLINICAL OUTCOME OF PATIENTS WITH NON-CLEAR METASTATIC RENAL CELL CARCINOMA TREATED WITH PEMBROLIZUMAB-AXITINIB COMBINATION. NEMESIA (NON CLEAR METASTATIC RENAL CELL CARCINOMA PEMBROLIZUMABAXITINIB) STUDY, A SUBGROUP ANALYSIS OF I-RARE OBSERVATIONAL STUDY (MEETURO 23A)",10.1177/03008916221114500,2022,Tumori,Renal Cell Carcinoma,Metastatic,,yes,no,yes,yes,no,yes,Retrospective observational study,25,Pembrolizumab,,,,no,,eligible,First-line,Pembrolizumab-Axitinib,no,Italy,"{'hepatitis_grade3': 4, 'hypophysitis_grade3': 1, 'pneumonia_grade2': 1, 'pancreatitis_grade3': 1}",7/25 (28%) patients interrupted the full treatment due to irAEs.,,Observational,,
280,"LONG TERM FOLLOW-UP OF A PHASE I STUDY COMBINATIONS OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOGACRIN RESEARCH GROUP (E4412: ARMS A-I)",,2022,HemaSphere,Hodgkin Lymphoma,Relapsed/Refractory,"['Brentuximab Vedotin (BV) + Ipilimumab (I)', 'Brentuximab Vedotin (BV) + Nivolumab (N)', 'Brentuximab Vedotin (BV) + Nivolumab (N) + Ipilimumab (I)']",yes,yes,yes,yes,yes,yes,"Phase 1/2, 3+3 dose escalation, expansion cohorts",64,"Ipilimumab, Nivolumab",35.76,,,no,,yes,,"Brentuximab Vedotin + Ipilimumab, Brentuximab Vedotin + Nivolumab, Brentuximab Vedotin + Nivolumab + Ipilimumab",,,"{'rash_grade3plus_BVI': 0.22, 'rash_grade3plus_other': 0.07, 'any_grade3plus_BVI': 0.43, 'any_grade3plus_BVN': 0.16, 'any_grade3plus_triplet': 0.55, 'pneumonitis_death_BVN': 1, 'dyspnea_death_BVNI': 1}",,,Clinical Trial,,no
281,,10.1097/MD.0000000000030690,2022,Medicine (United States),Bladder Cancer,,"['long-term conventional nursing plus atezolizumab (LTCN-ATZ)', 'long-term extended nursing services plus atezolizumab (LTENS-ATZ)']",no,no,no,no,yes,no,Randomized Controlled Trial,126,Atezolizumab,36,,,no,,eligible,,Atezolizumab + Nursing Services,,,,,,,,
282,Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade,10.1158/1078-0432.CCR-22-0404,2022,Clinical Cancer Research,Melanoma,,"['ipilimumab', 'nivolumab', 'ipilimumab plus nivolumab']",yes,yes,yes,no,no,yes,Retrospective analysis of clinical trial data,950,"Nivolumab, Ipilimumab",,,,yes,,yes,Adjuvant,Ipilimumab plus Nivolumab,no,,,,Baseline serum autoantibody signatures,,,
283,"Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: The non-randomised, open-label, phase IIIb/IV CheckMate 920 trial",10.1136/bmjopen-2021-058396,2022,BMJ Open,Renal Cell Carcinoma,Advanced,['Nivolumab plus Ipilimumab alternating with Nivolumab monotherapy'],yes,no,yes,yes,yes,yes,"Non-randomised, open-label, phase IIIb/IV",106,"Nivolumab, Ipilimumab",28.5,,,no,,eligible,First-line,Nivolumab + Ipilimumab,no,USA,"{'diarrhoea/colitis_grade3/4': 7.5, 'rash_grade3/4': 6.6}",,,Clinical Trial,,
284,Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis,10.1097/MD.0000000000029390,2022,Medicine (United States),Melanoma,,"['nivolumab', 'nivolumab plus ipilimumab', 'chemotherapy']",yes,no,no,no,yes,yes,network meta-analysis,,Nivolumab,,,,no,,yes,,nivolumab plus ipilimumab,,,,,,clinical trial,,
285,"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial",10.1016/S1470-2045(22)00382-5,2022,The Lancet Oncology,non-small-cell lung cancer,locally advanced or metastatic,"['sintilimab plus IBI305 plus pemetrexed and cisplatin', 'sintilimab plus pemetrexed and cisplatin', 'pemetrexed and cisplatin (chemotherapy alone)']",yes,no,yes,no,no,yes,"randomised, double-blind, multicentre, phase 3 trial",444,"sintilimab, IBI305",9.8,,,EGFR mutation,,yes,,sintilimab + IBI305 + chemotherapy,no,China,,,EGFR-mutated,clinical trial,0 or 1,no
286,"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial",10.1016/S1470-2045(22)00487-9,2022,The Lancet Oncology,Renal Cell Carcinoma,,"['Pembrolizumab', 'Placebo']",yes,no,yes,no,no,yes,"Randomized, double-blind, placebo-controlled, phase 3 trial",994,Pembrolizumab,30.1,,,no,,eligible,Adjuvant,Monotherapy,no,"North America, South America, Europe, Asia, Australia",,,,Clinical Trial,0 or 1,no
287,EP10.01-006 Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients,10.1016/j.jtho.2022.07.883,2022,Journal of Thoracic Oncology,NSCLC,advanced,"['pembrolizumab-cisplatin based combinations', 'pembrolizumab-carboplatin based combinations', 'pemetrexed-cisplatin based combinations', 'pemetrexed-carboplatin based combinations']",yes,yes,no,yes,no,no,retrospective,845,pembrolizumab,,,,no,,eligible,,platinum-based chemotherapy,,"Americas, Europe, Asia",,,,observational,,yes
289,MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC,10.1016/j.jtho.2022.07.108,2022,Journal of Thoracic Oncology,NSCLC,III,"['Nivolumab alone', 'Nivolumab + Ipilimumab']",yes,no,yes,yes,yes,yes,Randomized Phase II,105,"Nivolumab, Ipilimumab",24.3,76.3,45.9,no,,eligible,consolidation,Nivolumab + Ipilimumab,no,,"{'pneumonitis_any_grade': 25.8, 'pneumonitis_grade3plus': 12.4, 'fatigue_any_grade': 31.45, 'rash_any_grade': 16.2, 'dyspnea_any_grade': 17.2, 'hypothyroidism_any_grade': 14.35, 'diarrhea_any_grade': 19.6, 'pruritus_any_grade': 17.7, 'arthralgia_any_grade': 11.8, 'nausea_any_grade': 11.8}",,,clinical trial,,no
291,,10.1016/j.annonc.2022.07.1634,2022,Annals of Oncology,Small Cell Lung Cancer (SCLC),Extensive Disease (ED-SCLC),,yes,no,no,no,yes,yes,Retrospective analysis,200,"Atezolizumab, Durvalumab",,25.0,,no,,eligible,First-line,Chemo-immunotherapy,no,Switzerland,,,,Real-world evidence,yes,no
292,1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial,10.1016/j.annonc.2022.07.1174,2022,Annals of Oncology,Lung squamous-cell carcinoma (LSCC),advanced/metastatic,"['nivolumab plus investigator-choice platinum-based chemotherapy (N-CT)', 'nivolumab and ipilimumab (NI)']",no,no,no,no,yes,yes,"randomized, prospective, phase II trial",91,"nivolumab, ipilimumab",18,,,"PD-L1, MSI, TMB, SNV, CNV, gene fusions, splice variants",,eligible,,nivolumab + platinum-based chemotherapy; nivolumab + ipilimumab,,,,,,clinical trial,,
293,LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743,10.1016/j.annonc.2022.08.077,2022,Annals of Oncology,Malignant Pleural Mesothelioma,unresectable,"['Nivolumab + Ipilimumab', 'Chemotherapy']",yes,no,yes,yes,yes,yes,"Randomized, phase 3",,"Nivolumab, Ipilimumab",47.5,,,yes,,eligible,First-line,Nivolumab + Ipilimumab,no,,"{'hepatitis_grade3plus': 0.05, 'diarrhea/colitis_grade3plus': 0.04, 'rash_grade3plus': 0.03}",,"soluble mesothelin (sMESO) levels, TP53, BAP1, SETD2, NF2, LATS2 mutations",Clinical Trial,,
294,LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator's choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09),10.1016/j.annonc.2022.08.073,2022,Annals of Oncology,Renal Cell Carcinoma,Advanced/metastatic,"['Bempegaldesleukin + Nivolumab', 'Sunitinib', 'Cabozantinib']",yes,no,yes,yes,yes,no,"Randomized, Phase III",623,"Bempegaldesleukin, Nivolumab",15.5,,26.8,no,,yes,First-line,Bempegaldesleukin + Nivolumab,no,,"{'pyrexia': 32.6, 'pruritus': 31.3, 'nausea': 24.2, 'eosinophilia': 23.9, 'hypothyroidism': 22.9, 'rash': 22.9, 'arthralgia': 20.0}",,,Clinical Trial,,
295,"1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)",10.1016/j.annonc.2022.07.1565,2022,Annals of Oncology,Renal Cell Carcinoma,Metastatic,,yes,yes,yes,yes,no,yes,Retrospective observational study,25,Pembrolizumab,,,,no,,eligible,First-line,Pembrolizumab-axitinib,no,Italy,"{'G3 hepatitis': 4, 'G3 hypophisitis': 1, 'G2 pneumonia': 1, 'G3 pancreatitis': 1}",7/25 (28%) patients interrupted the full treatment due to irAEs.,,Observational,,
296,"LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial",10.1016/j.annonc.2022.08.072,2022,Annals of Oncology,Renal Cell Carcinoma,"cT2, cT3-4, cN1, cM1","['perioperative nivolumab', 'surgery alone']",yes,no,yes,yes,yes,yes,Phase III randomized open label trial,819,Nivolumab,,,20,no,,eligible,perioperative,,no,,"{'kidney injury': 1, 'rash': 2, 'elevated lipase': 4}",,,Clinical Trial,,
297,CLINICAL OUTCOME OF NIVOLUMAB COMBINATION THERAPY AS 1ST LINE TREATMENT FOR ESOPHAGEAL CANCER IN A JAPANESE HOSPITAL (CHECKMATE 648),10.1093/dote/doac051.152,2022,Diseases of the Esophagus,Esophageal squamous cell carcinoma (ESCC),Advanced/recurrent,"['Nivolumab + Ipilimumab', 'Nivolumab + 5FU/CDDP', '5FU/CDDP']",yes,no,yes,yes,yes,no,Post-hoc exploratory subgroup analysis of a global phase 3 trial,34,"Nivolumab, Ipilimumab",19.5,,,no,,eligible,First-line,"Nivolumab + Ipilimumab, Nivolumab + Chemotherapy",no,Japan,"{'pruritus_grade3plus': 2, 'rash_grade3plus': 2, 'neutropenia_grade3plus': 5, 'leukopenia_grade3plus': 3, 'anorexia_grade3plus': 3}",,,Clinical Trial,,
298,,10.1159/000526456,2022,Oncology Research and Treatment,Small Cell Lung Cancer (SCLC),Extensive-Disease (ED-SCLC),[],yes,no,no,no,yes,yes,Retrospective Analysis,200,"Atezolizumab, Durvalumab",,25.0,,no,,eligible,First-line,Chemo-immunotherapy,no,Switzerland,,,,Real-world evidence,ECOG PS ≥2 included,
299,,10.1016/S1470-2045(22)00369-2,2022,The Lancet Oncology,Pancreatic Cancer,Advanced,"['niraparib plus nivolumab', 'niraparib plus ipilimumab']",yes,no,yes,no,no,yes,"Randomized, Phase 1b/2",91,"Nivolumab, Ipilimumab",23,,,no,,eligible,,"Niraparib + Nivolumab, Niraparib + Ipilimumab",no,,,,,,,
300,"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial",10.1016/S1470-2045(22)00326-6,2022,The Lancet Oncology,Hepatocellular Carcinoma,Advanced,"['cabozantinib plus atezolizumab', 'sorafenib', 'single-agent cabozantinib']",yes,no,yes,yes,yes,yes,"Randomized, open-label, phase 3",837,Atezolizumab,13.3,,,no,,eligible,First-line,Cabozantinib plus atezolizumab,no,Multicenter (32 countries),"{'alanine aminotransferase increase_grade3plus': 9.0, 'hypertension_grade3plus': 9.0, 'aspartate aminotransferase increase_grade3plus': 9.0, 'palmar-plantar erythrodysaesthesia_grade3plus': 8.0}",,,Clinical Trial,0 or 1,
301,Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024),10.1016/S0090-8258(22)01242-2,2022,Gynecologic Oncology,Cervical cancer,"Locally advanced, node-positive","['Atezolizumab before and concurrent with CRT (Arm A)', 'Atezolizumab concurrent with CRT (Arm B)']",yes,no,yes,yes,no,yes,Randomized phase I/Ib trial,36,Atezolizumab,20,,0.08,yes,,eligible,,Atezolizumab + Chemoradiation (CRT),no,,{'colitis': 0.03},,"TCRB repertoires, tumor-associated T cell clones",Clinical Trial,0,no
302,A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma,10.1158/1078-0432.CCR-21-4115,2022,Clinical Cancer Research,Renal Cell Carcinoma,Advanced or Metastatic,"['MEDI0680 + Durvalumab', 'Nivolumab monotherapy']",yes,no,no,no,yes,yes,Randomized Phase II,63,"MEDI0680, Durvalumab, Nivolumab",,,,yes,,eligible,at least one prior line of antiangiogenic therapy,MEDI0680 + Durvalumab,no,,,,"ctDNA, tumor mutational burden, tumor-infiltrated immune cell profiles",Clinical Trial,,
303,"Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial",10.3802/jgo.2022.33.e45,2022,Journal of Gynecologic Oncology,Ovarian Cancer,,"['olaparib + cediranib', 'olaparib + durvalumab', 'durvalumab + PLD/topotecan/weekly paclitaxel (PD-L1 expression)', 'durvalumab + tremelimumab + PLD/topotecan/weekly paclitaxel (no PD-L1 expression)', 'durvalumab + tremelimumab + weekly paclitaxel']",yes,no,yes,no,no,no,"Phase 2, open-label, uncontrolled, umbrella trial",70,"durvalumab, tremelimumab",,,,yes,,yes,heavily pre-treated (at least 2 prior lines of CT),yes,no,,,,"HRD, PD-L1",Interventional,0/1,no
304,"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial",10.1016/S1470-2045(22)00290-X,2022,The Lancet Oncology,renal cell carcinoma,advanced or metastatic,"['nivolumab plus cabozantinib', 'sunitinib']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 3",651,nivolumab,32.9,,,PD-L1,,yes,first-line,nivolumab + cabozantinib,no,multi-country (18 countries),,,,clinical trial,,no
305,Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study),10.1111/ajco.13827,2022,Asia-Pacific Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['lenvatinib + pembrolizumab', 'lenvatinib + everolimus', 'sunitinib']",yes,no,yes,yes,yes,yes,Randomized controlled trial,355,Pembrolizumab,,,,no,,eligible,First-line,Lenvatinib + Pembrolizumab,no,,"{'decreased appetite': 14.6, 'diarrhea': 20.0, 'fatigue': 4.4, 'hypertension': 3.0, 'hypothyroidism': 14.3, 'musculoskeletal pain': 6.4, 'nausea': 14.4, 'rash': 11.4, 'stomatitis': 6.6}",Judicious use of lenvatinib dose modifications (interruption/reduction) and pembrolizumab interruption were undertaken to manage ARs. Rash and diarrhea most frequently led to discontinuation.,,Clinical Trial,,
306,"Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course",10.3389/fonc.2022.906251,2022,Frontiers in Oncology,,,,yes,no,no,no,no,no,Review,,,,,,no,,eligible,,,,,,,,,,
307,First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study,10.1038/s41416-022-01737-2,2022,British Journal of Cancer,colorectal cancer,metastatic,"['trifluridine/tipiracil + bevacizumab (TT-B)', 'capecitabine + bevacizumab (C-B)']",no,no,no,no,yes,no,"open-label, non-comparative phase II trial",153,,,,,no,,eligible,first-line,trifluridine/tipiracil + bevacizumab,no,,,,,clinical trial,,
308,Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial,10.1038/s41591-022-01829-9,2022,Nature Medicine,Pancreatic Ductal Adenocarcinoma (PDAC),Metastatic,"['nivolumab/chemotherapy', 'sotigalimab/chemotherapy', 'sotigalimab/nivolumab/chemotherapy']",yes,no,no,no,yes,yes,Randomized Phase 2,105,"nivolumab, sotigalimab",,,,yes,,eligible,First-line,Chemotherapy (gemcitabine/nab-paclitaxel),no,,,,"Immune signatures, tumor microenvironment, circulating T cells, CD4 T cell infiltration, antigen-presenting cells",Clinical Trial,,
309,"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study",10.1016/S1470-2045(22)00226-1,2022,The Lancet Oncology,non-small-cell lung cancer,recurrent or metastatic,"['tiragolumab plus atezolizumab', 'placebo plus atezolizumab']",yes,no,yes,no,no,yes,"randomised, double-blind, placebo-controlled, phase 2",135,"tiragolumab, atezolizumab",5.9,,,PD-L1,,eligible,first-line,yes,no,"Europe, Asia, USA",,,PD-L1-positive (≥1%),clinical trial,0 or 1,no
310,O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials,10.1016/j.annonc.2022.04.448,2022,Annals of Oncology,metastatic colorectal cancer,,"['cetuximab + irinotecan', 'cetuximab + avelumab']",yes,no,yes,yes,yes,yes,Phase II prospective trials (pooled analysis),46,"cetuximab, avelumab",,,,RAS WT liquid biopsy,,yes,third-line,"cetuximab + irinotecan, cetuximab + avelumab",,,"{'Skin rash (CAVE)': 87.9, 'Skin rash (CRICKET)': 30.8, 'Non-haematological toxicity (CAVE)': 87.9, 'Non-haematological toxicity (CRICKET)': 46.2, 'Haematological toxicity (CRICKET)': 15.4, 'Haematological toxicity (CAVE)': 0}",,RAS WT,Clinical Trial,0,no
311,"Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non- Hodgkin lymphoma (r/r B-NHL)",10.1200/JCO.2022.40.17_suppl.LBA7564,2022,Journal of Clinical Oncology,B-cell non-Hodgkin lymphoma,relapsed/refractory,"['nivolumab', 'nivolumab plus varlilumab']",yes,no,yes,no,yes,yes,randomized phase II,53,"nivolumab, varlilumab",,,33.3,no,,eligible,,nivolumab + varlilumab,CAR-T cell therapy,,,,,clinical trial,,
312,Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor,10.1158/1538-7445.AM2022-CT557,2022,Cancer Research,Melanoma,III-IV,"['Qmab + pembro', 'Qmab monotherapy']",yes,no,yes,yes,yes,yes,"Randomized, open-label, multiarm phase 1/2 study",151,"Quavonlimab, Pembrolizumab",7.7,,,"BRAF-mutant tumors, LDH",,yes,,Quavonlimab + Pembrolizumab,PD-1/PD-L1 inhibitor,,"{'pruritus': 26, 'fatigue': 14, 'diarrhea': 14, 'rash': 13}",5% of pts discontinued because of TRAEs.,,Clinical Trial,,no
313,Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) in patients (pts) with cervical cancer naive to PD-1/PD-L1 inhibitors,10.1158/1538-7445.AM2022-CT508,2022,Cancer Research,Cervical cancer,Locally advanced or metastatic,"['Vibostolimab 200 mg + Pembrolizumab 200 mg', 'Vibostolimab 700 mg + Pembrolizumab 200 mg']",yes,no,yes,yes,no,yes,Randomized controlled trial,80,"Vibostolimab, Pembrolizumab",12,,,PD-L1,,eligible,Failed prior standard-of-care chemotherapy or early progression on definitive chemoradiation,Vibostolimab + Pembrolizumab,no,,"{'rash': 22, 'increased lipase': 17, 'pruritus': 17, 'pyrexia': 21, 'fatigue': 15}",,PD-L1-positive tumors,Phase 1,1,no
315,Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081,10.1200/JCO.2022.40.16_suppl.8509,2022,Journal of Clinical Oncology,non-small cell lung cancer,IIIA/IIIB,"['Nivolumab alone', 'Nivolumab + Ipilimumab']",yes,no,yes,yes,yes,yes,Randomized Phase II,105,"Nivolumab, Ipilimumab",24.3,,,no,,eligible,consolidation,Nivolumab + Ipilimumab,no,,"{'pneumonitis_grade2plus_armA': 22.2, 'pneumonitis_grade2plus_armB': 29.4, 'pneumonitis_grade3plus_armA': 9.3, 'pneumonitis_grade3plus_armB': 15.7, 'fatigue_armA': 31.5, 'fatigue_armB': 31.4, 'rash_armA': 16.7, 'rash_armB': 15.7, 'dyspnea_armA': 14.8, 'dyspnea_armB': 19.6, 'hypothyroidism_armA': 13.0, 'hypothyroidism_armB': 15.7, 'diarrhea_armB': 19.6, 'pruritus_armB': 17.7, 'arthralgia_armB': 11.8, 'nausea_armB': 11.8}",,,clinical trial,,
319,A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC),10.1200/JCO.2022.40.16_suppl.4021,2022,Journal of Clinical Oncology,Pancreatic Cancer,Advanced,"['Niraparib + Nivolumab', 'Niraparib + Ipilimumab']",yes,no,yes,yes,yes,yes,Randomized Phase Ib/II,91,"Nivolumab, Ipilimumab",23,,,yes,,eligible,Maintenance,Niraparib + Nivolumab; Niraparib + Ipilimumab,no,,"{'Thrombocytopenia (nira/nivo)': 0.28, 'Arthralgia (nira/nivo)': 0.25, 'Nausea (nira/nivo)': 0.23, 'Fatigue (nira/nivo)': 0.23, 'Thrombocytopenia (nira/ipi)': 0.45, 'Anemia (nira/ipi)': 0.43, 'Fatigue (nira/ipi)': 0.43, 'Nausea (nira/ipi)': 0.41, 'AST increase (nira/ipi)': 0.36, 'Rash (nira/ipi)': 0.34, 'ALT increase (nira/ipi)': 0.29}",,"DDR deficiencies, BRCA, PALB2",Clinical Trial,,
320,,10.1200/JCO.2022.40.16_suppl.e16011,2022,Journal of Clinical Oncology,Esophageal squamous cell carcinoma (ESCC),IIB-IVA,,yes,no,yes,no,no,no,Prospective clinical trial,27,Pembrolizumab,,,,yes,,eligible,Neoadjuvant,Pembrolizumab + chemotherapy (docetaxel + cisplatin or carboplatin),no,China,"{'leucopenia_grade3plus': 33.3, 'decreased_neutrophil_count_grade3plus': 51.9, 'dermatitis_grade3plus': 3.7}",,,Clinical Trial,,
321,The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory study,10.1200/JCO.2022.40.16_suppl.e15603,2022,Journal of Clinical Oncology,Rectal Cancer,T1-3aN0-1M0,[],yes,no,yes,no,no,no,"Single-arm, phase II trial",23,Sintilimab,,,0.174,"MSI-H/dMMR, MSS/pMMR",,eligible,Neoadjuvant,Chemoradiotherapy (50 Gy) + Sintilimab + Capecitabine/CAPOX,no,,,,MSS/pMMR,Interventional,,
324,"Recombinant human adenovirus 5 injection plus toripalimab therapy in patients with advanced and refractory melanoma: A single arm, single-center, prospective study.",10.1200/JCO.2022.40.16_suppl.e21503,2022,Journal of Clinical Oncology,Melanoma,Advanced,,yes,no,no,yes,no,yes,"Single-arm, single-center, prospective study",10,Toripalimab,,,,yes,,yes,Second line and above,Recombinant human adenovirus 5 injection + Toripalimab,yes,,{'fever': 80},,"IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ, peripheral blood neutrophils, lymphocytes, NLR",Clinical Trial,,no
325,Comparing overall survival of patients with metastatic uveal melanoma by sequence of Tebentafusp versus combination immune checkpoint inhibitors.,10.1200/JCO.2022.40.16_suppl.e21505,2022,Journal of Clinical Oncology,Uveal melanoma,Metastatic,"['Tebentafusp followed by combination ICI', 'Combination ICI followed by Tebentafusp']",no,no,no,no,yes,no,Retrospective chart review,6,"Tebentafusp, Ipilimumab, Nivolumab, Pembrolizumab",,,,yes,,eligible,"First-line, Second-line",Ipilimumab plus Nivolumab,,,,,"Glycoprotein 100 (Gp-100), Lactate dehydrogenase (LDH)",Observational,,
328,Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study.,10.1200/JCO.2022.40.16_suppl.e21578,2022,Journal of Clinical Oncology,Melanoma,III,"['Immunotherapy (IO)', 'Targeted therapy (TT)']",yes,no,no,yes,yes,yes,Retrospective analysis,104,"Nivolumab, Pembrolizumab",21,,,no,,eligible,Adjuvant,,no,,"{'hypothyroidism': 0.14, 'diarrhea/colitis': 0.1, 'pruritic rash': 0.09}",,,Observational,,
330,Health-related quality of life in patients with resectable undifferentiated pleomorphic sarcoma treated with neoadjuvant checkpoint blockade in a single institution randomized phase II clinical trial,10.1200/JCO.2022.40.16_suppl.11544,2022,Journal of Clinical Oncology,undifferentiated pleomorphic sarcoma,resectable,"['nivolumab + radiotherapy', 'ipilimumab + nivolumab + radiotherapy']",no,no,no,no,no,no,"randomized, phase II, non-comparative trial",10,"nivolumab, ipilimumab",,,,no,,eligible,neoadjuvant,radiotherapy,no,,,,,clinical trial,,yes
331,Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): A phase 2 non-randomized clinical trial,10.1136/jitc-2022-004822,2022,Journal for ImmunoTherapy of Cancer,Cancer of unknown primary (CUP),advanced,,yes,no,yes,yes,yes,yes,"Phase 2 basket trial, non-randomized",29,pembrolizumab,27.3,76.0,16.0,yes,,eligible,second line or later,,no,,{'acute kidney injury': 4.0},One patient had grade 3 immune-related acute kidney injury requiring treatment discontinuation.,"PD-L1, TILs",clinical trial,0/1,no
332,First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743,10.1016/j.annonc.2022.01.074,2022,Annals of Oncology,Malignant Pleural Mesothelioma,Unresectable,"['Nivolumab plus Ipilimumab', 'Platinum plus Pemetrexed Chemotherapy']",yes,no,no,no,yes,yes,Randomized Controlled Trial,,"Nivolumab, Ipilimumab",43.1,,,yes,,eligible,First-line,Nivolumab + Ipilimumab,no,,,"Patients who discontinued nivolumab plus ipilimumab due to TRAEs had a median OS of 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation.",four-gene inflammatory expression signature score,Clinical Trial,<=1,no
333,"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study",10.1016/S1470-2045(22)00197-8,2022,The Lancet Oncology,colorectal cancer,metastatic,"['pembrolizumab', 'chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab/cetuximab)']",yes,no,yes,yes,yes,yes,"randomized, open-label, phase 3",307,pembrolizumab,44.5,,22.0,microsatellite instability-high or mismatch repair-deficient,,eligible,first-line,,no,multinational (23 countries),"{'increased alanine aminotransferase': 2.0, 'colitis': 2.0, 'diarrhoea': 2.0, 'fatigue': 2.0}",,MSI-H/dMMR,clinical trial,0 or 1,no
334,"Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial",10.1016/S1470-2045(22)00128-0,2022,The Lancet Oncology,Renal Cell Carcinoma,Metastatic,"['Nivolumab', 'Nivolumab-Ipilimumab', 'VEGFR-TKI (Sunitinib or Pazopanib)']",yes,no,yes,yes,no,no,"Randomized, Open-label, Non-comparative, Phase 2",202,"Nivolumab, Ipilimumab",18,,,yes,,yes,First-line,Nivolumab + Ipilimumab,no,France,"{'hepatic failure grade 3-4': 0.03, 'lipase increase grade 3-4': 0.03, 'hepatobiliary disorders grade 3-4': 0.06, 'hypertension grade 3-4': 0.15}",,"ccrcc1, ccrcc2, ccrcc3, ccrcc4 gene expression classifier",Clinical Trial,0-2,no
335,"98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase",10.1016/j.annonc.2022.03.114,2022,Annals of Oncology,Breast Cancer,Early stage,,yes,no,yes,yes,no,no,"Open-label, single arm, safety run-in",6,"Durvalumab, Oleclumab",12,,0.167,no,,yes,Neo-adjuvant,"Paclitaxel, Doxorubicin, Cyclophosphamide, Durvalumab, Oleclumab, SBRT",no,"France, Belgium","{'pericarditis_grade3': 0.167, 'ALT/AST_increase_grade1-2': 0.5, 'rash_grade1': 0.333, 'conjunctivitis_grade1': 0.167, 'hands_eczema_grade1': 0.167, 'hyperthyroidism_grade1': 0.167, 'diarrhea_grade1': 0.167, 'lipase_increase_grade1': 0.167, 'radiation_dermatitis_grade2-3': 0, 'pneumonitis_grade2-3': 0}",One grade 3 AE (pericarditis) resolved with corticosteroids.,,Clinical Trial,<=1,
337,"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial",10.1016/S0140-6736(22)00562-1,2022,The Lancet,Melanoma,IIB or IIC,"['Pembrolizumab', 'Placebo']",yes,no,yes,no,no,yes,"Randomized, double-blind, placebo-controlled, phase 3",976,Pembrolizumab,20.9,,16.0,no,,yes,Adjuvant,no,no,"Multinational (Australia, Belgium, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, UK, USA)",,,,Clinical Trial,,
338,A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes,10.1182/bloodadvances.2021005487,2022,Blood Advances,Myelodysplastic Syndromes,Higher-risk,"['Azacitidine + Durvalumab', 'Azacitidine monotherapy']",yes,no,yes,no,yes,no,Randomized Phase 2,84,Durvalumab,15.25,71.1,,yes,,eligible,First-line,Azacitidine,no,,,,"TP53 mutations, PD-L1 (CD274) expression",Clinical Trial,,
339,A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML,10.1182/bloodadvances.2021006138,2022,Blood Advances,Acute Myeloid Leukemia (AML),,"['azacitidine with durvalumab', 'azacitidine alone']",yes,no,no,no,yes,no,Randomized Phase 2,129,durvalumab,,,,yes,,yes,first-line,azacitidine,no,,,,"DNA methylation, mutational status, and PD-L1 expression",Clinical Trial,,
340,Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial,10.1038/s41591-022-01694-6,2022,Nature Medicine,renal cell carcinoma,metastatic,"['nivolumab + ipilimumab + CBM588', 'nivolumab + ipilimumab']",yes,no,no,no,no,yes,randomized phase 1 trial,30,"nivolumab, ipilimumab",,,,gut microbiome,,yes,treatment-naive,nivolumab + ipilimumab,no,,,,,,,
342,Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma,10.1016/j.jhep.2021.11.030,2022,Journal of Hepatology,Hepatocellular Carcinoma,Unresectable,"['Atezolizumab plus bevacizumab', 'Sorafenib']",yes,no,yes,no,yes,yes,"Open-label, phase III",501,Atezolizumab,15.6,,,no,,eligible,First-line,Atezolizumab plus bevacizumab,no,,,,,Clinical Trial,,
343,Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101,10.1016/j.esmoop.2022.100450,2022,ESMO Open,renal cell carcinoma,advanced,"['avelumab plus axitinib', 'sunitinib']",yes,yes,yes,no,yes,yes,Phase III,886,avelumab,,,,no,,yes,first-line,avelumab plus axitinib,no,,,,,clinical trial,,
344,"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer",10.1200/JCO.22.00227,2022,Journal of Clinical Oncology,Non-small-cell lung cancer,III,"['durvalumab alone', 'durvalumab plus oleclumab', 'durvalumab plus monalizumab']",yes,no,yes,no,no,yes,Randomized controlled trial,189,"Durvalumab, Oleclumab, Monalizumab",11.5,,,no,,yes,consolidation therapy,durvalumab + oleclumab; durvalumab + monalizumab,no,,,,,Phase II,0/1,
345,"A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer",,2022,clinicaltrials.gov,Non-small cell lung cancer,IIIB/IIIC or IV,"['anti-PD-1/PD-L1 treatment + UV1 vaccination', 'anti-PD-1/PD-L1 treatment alone']",yes,no,no,no,no,yes,"Randomized, Open-label, Multicenter",,Pembrolizumab,,,,,,yes,First line,UV1 vaccination,no,,,,,Phase II,,
346,"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer",10.1136/jitc-2021-004233,2022,Journal for ImmunoTherapy of Cancer,Endometrial cancer,"Advanced, recurrent, or metastatic","['Nivolumab with cabozantinib (Arm A)', 'Nivolumab alone (Arm B)', 'Nivolumab with cabozantinib (Arm C - immunotherapy-pretreated patients)']",yes,no,no,no,no,yes,Randomized Phase II,54,Nivolumab,,,,yes,,eligible,,Cabozantinib,yes,,,,CD103+CD69+ I δT cells,Clinical Trial,,
347,CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC,10.1016/j.jtho.2021.10.023,2022,Journal of Thoracic Oncology,NSCLC,IV,"['durvalumab + tremelimumab + platinum-doublet chemotherapy', 'durvalumab + tremelimumab']",yes,no,yes,no,yes,yes,Randomized clinical trial,301,"durvalumab, tremelimumab",,,,yes,,eligible,first-line,chemotherapy,no,"Canada, Australia",,,"programmed death-ligand 1 expression, blood-based tumor mutation burden",clinical trial,,
348,Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma,10.1158/2159-8290.CD-21-1141,2022,Cancer Discovery,Melanoma,High-risk resected,"['Pembrolizumab', 'IFNα-2b', 'Ipilimumab']",yes,no,yes,no,yes,yes,Randomized phase III trial,1301,Pembrolizumab,47.5,,,no,,yes,Adjuvant,,,,,,,Clinical Trial,,
349,"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial",10.1016/S2468-1253(21)00427-1,2022,The Lancet Gastroenterology and Hepatology,Hepatocellular carcinoma,resectable,"['nivolumab monotherapy', 'nivolumab plus ipilimumab']",yes,no,yes,yes,no,yes,"randomised, open-label, phase 2 trial",27,"nivolumab, ipilimumab",,,,no,,yes,perioperative,nivolumab + ipilimumab,no,,"{'increased alanine aminotransferase (nivolumab)': 23, 'increased aspartate aminotransferase (nivolumab)': 23, 'increased alanine aminotransferase (nivolumab + ipilimumab)': 50, 'increased aspartate aminotransferase (nivolumab + ipilimumab)': 50}",,,clinical trial,,no
350,,10.1016/j.ejca.2021.12.028,2022,European Journal of Cancer,colorectal cancer,advanced,,no,no,no,no,yes,yes,"single-arm, phase II trial",21,cetuximab,,,,BRAF V600E mutation,,eligible,,vemurafenib and cetuximab plus FOLFIRI,,,,,BRAF V600E-mutated,,,
351,"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial",10.1016/S1470-2045(22)00066-3,2022,The Lancet Oncology,Pancreatic cancer,Locally recurrent after surgery,"['SBRT + pembrolizumab + trametinib', 'SBRT + gemcitabine']",yes,no,yes,no,yes,no,Randomized controlled phase 2 trial,170,Pembrolizumab,13.1,,,"PD-L1, KRAS",,yes,Postoperative,SBRT + pembrolizumab + trametinib,no,China,,,mutant KRAS and positive immunohistochemical staining of PD-L1,Interventional,0 or 1,no
352,Assessment of Capecitabine and Bevacizumab with or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial,10.1001/jamanetworkopen.2021.49040,2022,JAMA Network Open,Colorectal Cancer,Metastatic,"['Capecitabine + Bevacizumab + Atezolizumab', 'Capecitabine + Bevacizumab + Placebo']",yes,no,yes,no,yes,yes,Randomized Clinical Trial,133,Atezolizumab,20.9,,,yes,,eligible,Refractory,Capecitabine + Bevacizumab,no,,,,microsatellite-stable (MSS),Phase 2,,
353,Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer,10.1056/NEJMoa2112651,2022,New England Journal of Medicine,Triple-Negative Breast Cancer,Stage II or III,"['pembrolizumab-chemotherapy group', 'placebo-chemotherapy group']",yes,no,no,no,no,yes,Randomized controlled trial,1174,Pembrolizumab,39.1,,,no,,eligible,Neoadjuvant and adjuvant,"Chemotherapy (paclitaxel, carboplatin, doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide)",no,,,,,Clinical Trial,,
354,"Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial",10.1007/s12185-021-03241-4,2022,International Journal of Hematology,Diffuse large B-cell lymphoma (DLBCL),High-risk,,yes,no,no,no,no,yes,"Phase 2, open-label trial",46,Durvalumab,,,,yes,,eligible,First-line,R-CHOP or R2-CHOP,no,,,,,Clinical Trial,,
355,Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis,10.1007/s10147-021-02067-8,2022,International Journal of Clinical Oncology,Urothelial Carcinoma,Advanced,"['Avelumab + BSC', 'BSC alone']",yes,no,yes,no,yes,yes,Randomized controlled trial,73,Avelumab,,,13.9,no,,eligible,First-line maintenance,Avelumab + BSC,no,Japan,,,,Subgroup analysis,,
356,"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial",10.1016/j.jtho.2021.09.010,2022,Journal of Thoracic Oncology,NSCLC,IV or recurrent,"['nivolumab plus ipilimumab', 'nivolumab', 'chemotherapy', 'nivolumab plus chemotherapy']",yes,no,no,yes,yes,no,"Randomized, Open-Label, Phase 3",,"nivolumab, ipilimumab",54.8,,,PD-L1,,eligible,first-line,"nivolumab plus ipilimumab, nivolumab plus chemotherapy",no,,,"Immune-mediated AEs (except endocrine events) occurred within 6 months from start of treatment and resolved within 3 months after, mainly with systemic corticosteroids.","PD-L1 >=1%, PD-L1 <1%",clinical trial,,
358,"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial",10.1016/S1470-2045(21)00630-6,2022,The Lancet Oncology,non-small-cell lung cancer,III,"['sugemalimab', 'placebo']",yes,no,yes,yes,no,yes,"randomised, double-blind, placebo-controlled, phase 3 trial",381,sugemalimab,14.3,,0.09,no,,eligible,consolidation therapy,no,no,China,"{'pneumonitis': 0.03, 'immune-mediated pneumonitis': 0.03}",,,clinical trial,0 or 1,
360,"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial",10.1016/S1470-2045(21)00692-6,2022,The Lancet Oncology,Gastric or gastro-oesophageal junction cancer,Advanced or recurrent,"['Nivolumab plus chemotherapy', 'Placebo plus chemotherapy']",yes,no,yes,no,yes,yes,"Randomized, multicentre, double-blind, placebo-controlled, phase 2–3 trial",724,Nivolumab,26.6,,,"PD-L1 expression, HER2-negative",,eligible,First-line,Chemotherapy (oxaliplatin-based),no,"Japan, South Korea, Taiwan",,,HER2-negative,Clinical Trial,0 or 1,no
361,FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma,10.1158/1078-0432.CCR-21-1466,2022,Clinical Cancer Research,Malignant Pleural Mesothelioma,Unresectable,"['nivolumab and ipilimumab', 'chemotherapy (cisplatin or carboplatin plus pemetrexed)']",no,no,no,no,yes,no,open-label trial,605,"Nivolumab, Ipilimumab",,,,no,,eligible,first-line,Nivolumab + Ipilimumab,no,"Multinational (US, Australia, Switzerland, Canada, Brazil)",,,,Clinical Trial,,
362,First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients,10.1016/j.esmoop.2022.100394,2022,ESMO Open,NSCLC,IV/recurrent,"['nivolumab plus ipilimumab', 'nivolumab monotherapy', 'chemotherapy', 'nivolumab plus chemotherapy']",yes,no,yes,no,yes,yes,Randomized controlled trial,162,"Nivolumab, Ipilimumab",,,40,PD-L1,,yes,First-line,Nivolumab + Ipilimumab,no,"Japan, South Korea, Taiwan",,,PD-L1 expression ≥1% or <1%,,,
363,,10.1200/JCO.2022.40.4-suppl.012,2022,Journal of Clinical Oncology,colorectal cancer,metastatic,,yes,no,yes,yes,yes,yes,"single-arm, single-institution, phase I/II clinical trial",26,nivolumab,,,18,"BRAFV600E, MSS",,yes,treatment-refractory,"encorafenib, cetuximab, nivolumab",no,,"{'colitis_grade3': 1, 'maculopapular_rash_grade3': 1, 'leukocytosis_grade3': 1, 'elevated_amylase/lipase_grade3': 1, 'myositis_grade4': 1, 'myocarditis_grade4': 1}",,"BRAFV600E positive, MSS",clinical trial,,
364,Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results,10.1200/jco.2022.40.4_suppl.135,2022,Journal of Clinical Oncology,colorectal cancer,advanced,,yes,no,yes,no,yes,yes,"Phase II, multi-cohort, multi-center trial",36,durvalumab,,,16.6,yes,,eligible,2 or more lines of therapy,cabozantinib + durvalumab,no,,,,"pMMR/MSS, RAS wild type, HER2 amplification, KRAS G12V, ARID1A, IDH1, MET amplification, ATM",clinical trial,1,
365,A pilot study of paclitaxel plus pembrolizumab in patients with metastatic HER2-negative breast cancer (PePPy),10.1158/1538-7445.SABCS21-P2-14-03,2022,Cancer Research,Breast Cancer,Metastatic,"['Paclitaxel followed by paclitaxel and pembrolizumab (phased schedule)', 'Paclitaxel and pembrolizumab concurrently (concurrent schedule)']",yes,no,yes,yes,yes,yes,Randomized controlled trial,40,Pembrolizumab,10.1,28.0,5.0,yes,,yes,0-3 prior lines of chemotherapy for MBC,Paclitaxel + Pembrolizumab,no,,"{'hypothyroidism': 15.0, 'AST/ALT increased': 5.0, 'lipase increased': 5.0}",,"PD-L1, TILs",Pilot study,,no
366,A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer,10.1158/1538-7445.SABCS21-P2-14-18,2022,Cancer Research,Triple-negative breast cancer,Metastatic,"['Carboplatin + Nivolumab', 'Carboplatin alone']",yes,no,yes,no,yes,yes,Randomized Phase II,78,Nivolumab,23.5,67.6,29.7,PD-L1,,yes,0-1 prior lines of chemotherapy in the metastatic setting,Carboplatin,no,,,,PD-L1+,Interventional,,
367,The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer,10.1158/1538-7445.SABCS21-PD10-01,2022,Cancer Research,Triple Negative Breast Cancer,Stage I-III,,yes,no,yes,yes,no,no,Phase II,50,Pembrolizumab,12,,,PD-L1,,yes,Pre-operative,Pembrolizumab + Radiation Therapy + Neoadjuvant Chemotherapy,no,,"{'fatigue': 76, 'nausea': 66, 'maculopapular rash': 32, 'diarrhea': 38, 'colitis': 2, 'hypothyroidism': 8, 'peripheral neuropathy': 40, 'hyponatremia_grade3': 1, 'colitis_grade3': 1, 'adrenal insufficiency_grade3': 1, 'pneumonitis_grade3': 1}",,,Clinical Trial,,
368,"Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)",10.1158/1538-7445.SABCS21-PD10-04,2022,Cancer Research,Breast Cancer,,"['atezo + ipat + fulv', 'fulv', 'atezo + ipat', 'capecitabine']",yes,no,yes,yes,yes,yes,"Phase Ib/II, open-label, randomized",94,Atezolizumab,7.6,,,yes,,eligible,2L/3L,Atezolizumab + Ipatasertib + Fulvestrant; Atezolizumab + Ipatasertib,no,,"{'rash_any_grade': 73, 'diarrhea_any_grade': 53.8, 'nausea_any_grade': 42.3, 'fatigue_any_grade': 26.9, 'vomiting_any_grade': 23.1, 'decreased_appetite_any_grade': 19.2, 'headache_any_grade': 15.4, 'pyrexia_any_grade': 11.5, 'hyperglycemia_any_grade': 11.5, 'AST_increase_any_grade': 11.5, 'rash_grade3plus': 38.4, 'diarrhea_grade3plus': 7.7, 'AST_increase_grade3plus': 7.7, 'encephalitis_grade5': 1, 'rash_TNBC_any_grade': 55.2, 'diarrhea_TNBC_any_grade': 48.3, 'nausea_TNBC_any_grade': 37.9, 'pyrexia_TNBC_any_grade': 31.0, 'fatigue_TNBC_any_grade': 24.1, 'rash_TNBC_grade3plus': 24.1, 'fatigue_TNBC_grade3plus': 3.4, 'pyrexia_TNBC_grade3plus': 3.4}",Tx-related AEs leading to tx withdrawal: 7.7% (atezo+ipat+fulv) and 0% (fulv) in HR+ BC; 6.9% (atezo+ipat) and 4.2% (capecitabine) in TNBC.,"PI3K pathway status, PD-L1, CD8-panCK expression",,,
369,,10.1136/jitc-2021-003853,2022,Journal for ImmunoTherapy of Cancer,Melanoma,Advanced,"['ipilimumab', 'ipilimumab + nivolumab']",yes,no,yes,no,no,yes,Randomized multicenter phase II trial,19,"Ipilimumab, Nivolumab",,,53.0,yes,,yes,,ipilimumab + nivolumab,PD-1 blockade,,,,"circulating CD4+ T cells, NRAS mutations",,,
370,First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study,10.1200/JCO.21.01015,2022,Journal of Clinical Oncology,Colorectal Cancer,Metastatic,[],yes,no,yes,no,yes,yes,Phase II,45,"Nivolumab, Ipilimumab",29.0,,22.0,yes,,yes,First-line,Nivolumab + Ipilimumab,no,,,,"MSI-H/dMMR, BRAF, KRAS",,,no
371,Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma,10.1056/NEJMoa2109970,2022,New England Journal of Medicine,Melanoma,Advanced,"['Relatlimab and Nivolumab', 'Nivolumab']",yes,no,yes,no,no,yes,"Phase 2-3, global, double-blind, randomized trial",,"Relatlimab, Nivolumab",,,18.9,no,,eligible,First-line,Relatlimab + Nivolumab,no,,,,,Clinical Trial,,
372,Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis,10.1080/14737167.2021.1937130,2022,Expert Review of Pharmacoeconomics and Outcomes Research,Renal Cell Carcinoma,Advanced,"['pembrolizumab-lenvatinib', 'pembrolizumab-axitinib', 'nivolumab-cabozantinib', 'nivolumab-ipilimumab', 'sunitinib']",yes,no,no,no,yes,yes,Number Needed to Treat (NNT) and Number Needed to Harm (NNH) analysis of existing phase III trials,,"pembrolizumab, nivolumab, ipilimumab",,,,no,,eligible,,"pembrolizumab + lenvatinib, pembrolizumab + axitinib, nivolumab + cabozantinib, nivolumab + ipilimumab",,,,,,Meta-analysis,,
373,,10.1007/s10147-021-02014-7,2022,International Journal of Clinical Oncology,Renal Cell Carcinoma,Metastatic,"['Pembrolizumab plus axitinib', 'Sunitinib']",yes,no,yes,no,yes,yes,"Randomized, Phase III, Open-label",94,Pembrolizumab,29.5,,,no,,eligible,First-line,Pembrolizumab + Axitinib,no,Japan,,,,Clinical Trial,,
374,Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial,10.1016/j.annonc.2021.09.011,2022,Annals of Oncology,small-cell lung cancer,limited-disease,"['consolidation combination immunotherapy (nivolumab + ipilimumab)', 'observation']",yes,no,yes,no,yes,yes,randomized phase II trial,153,"nivolumab, ipilimumab",35,,62,no,,yes,consolidation,nivolumab + ipilimumab,no,,,,,clinical trial,0/1,
375,,10.1016/S2468-1253(21)00348-4,2022,The Lancet Gastroenterology and Hepatology,Colorectal Cancer,Locally Advanced,"['Toripalimab plus celecoxib', 'Toripalimab monotherapy']",yes,no,yes,yes,no,no,"Randomized, Phase 2",34,Toripalimab,14.9,59,3,yes,,eligible,Neoadjuvant,Celecoxib,no,China,"{'increased aspartate aminotransferase levels': 3, 'increased alanine aminotransferase levels': 3}",,Mismatch repair-deficient or microsatellite instability-high,Clinical Trial,0-1,no
376,A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors,10.1158/1078-0432.CCR-21-0878,2022,Clinical Cancer Research,Gastrointestinal Stromal Tumors (GIST),Advanced/metastatic,"['Nivolumab monotherapy', 'Nivolumab + Ipilimumab']",yes,no,yes,no,no,yes,"Randomized Phase II, noncomparative, parallel group, unblinded",36,"Nivolumab, Ipilimumab",,,,KIT/PDGFRa mutations,,eligible,refractory to at least imatinib (median 3 prior lines),Nivolumab + Ipilimumab,no,,,,,Clinical Trial,,
377,The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma,10.1155/2022/2700166,2022,Journal of Oncology,Renal Cell Carcinoma,Advanced,"['axitinib', 'axitinib combined with tislelizumab']",yes,no,no,no,yes,no,Randomized controlled trial,49,tislelizumab,,,,yes,,yes,,axitinib + tislelizumab,no,,,,"TNF-β1, VEGF, TIMP-1, MMP-2",,,
378,First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States,10.1177/17562848221140662,2022,Therapeutic Advances in Gastroenterology,hepatocellular carcinoma,advanced,"['atezolizumab combined with bevacizumab', 'sintilimab combined with bevacizumab', 'lenvatinib (LEVA)', 'sorafenib (SORA)', 'donafenib']",no,no,no,no,no,no,network meta-analysis and cost-effectiveness study,1712,"atezolizumab, sintilimab",,,,no,,yes,first-line,"atezolizumab + bevacizumab, sintilimab + bevacizumab",no,"China, United States",,,,NMA,,
379,Phase 3 Randomized Trial Comparing Tebentafusp with Investigator's Choice in First Line Metastatic Uveal Melanoma,10.1111/pcmr.13018,2022,Pigment Cell and Melanoma Research,Uveal Melanoma,Metastatic,"['Tebentafusp', ""Investigator's Choice (pembrolizumab, ipilimumab, or dacarbazine)""]",yes,no,no,yes,yes,yes,"Randomized, open-label, Phase 3",378,Tebentafusp,,,,HLA-A*02:01,,eligible,First line,Monotherapy,no,,,Generally manageable with standard interventions,HLA-A*02:01+,Clinical Trial,,
380,Avelumab first-line (1L) maintenance + best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis,10.1200/JCO.2022.40.6_suppl.486,2022,Journal of Clinical Oncology,Urothelial Carcinoma,Locally advanced or metastatic,"['Avelumab 1L maintenance + BSC', 'BSC alone']",yes,no,yes,no,yes,yes,Randomized controlled trial,147,Avelumab,,,,PD-L1,,eligible,First-line maintenance,Avelumab + BSC,no,"Asia (Japan, South Korea, Taiwan, Hong Kong, India)",,,PD-L1+,Phase 3,,
381,The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer,10.1038/s41586-021-04161-3,2021,Nature,Gastric or gastro-oesophageal junction adenocarcinoma,Unresectable or metastatic,"['Pembrolizumab plus trastuzumab and chemotherapy', 'Placebo plus trastuzumab and chemotherapy']",no,no,no,no,no,no,"Randomized, double-blind, placebo-controlled phase III",,Pembrolizumab,,,,HER2,,eligible,First-line,Pembrolizumab + Trastuzumab + Chemotherapy,no,,,,HER2-positive,Clinical Trial,,
383,,10.1038/s41392-021-00658-5,2021,Signal Transduction and Targeted Therapy,,,,no,no,no,no,no,no,,,,,,,,,no,,,,,,,,,,
384,Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma,10.1038/s41467-021-26415-4,2021,Nature Communications,Renal cell carcinoma,Metastatic,"['Tremelimumab with cryoablation', 'Tremelimumab without cryoablation']",yes,no,yes,yes,no,yes,Pilot study,29,Tremelimumab,,,55,no,,eligible,,Cryoablation,no,,"{'diarrhea/colitis': 6, 'hepatitis': 3, 'pneumonitis': 1, 'glomerulonephritis': 1}",Toxicity led to treatment discontinuation in 5 patients in each arm.,,Clinical Trial,,no
385,,10.1016/j.annonc.2021.10.133,2021,Annals of Oncology,non-small cell lung cancer (NSCLC),oligometastatic,"['SBRT + anlotinib + toripalimab', 'SBRT + anlotinib']",yes,no,no,no,yes,yes,"prospective, single-center, open-label, phase Ib study",10,toripalimab,,,,"driver mutation-negative (EGFR, ALK, ROS1)",,eligible,induction therapy,"SBRT, anlotinib, toripalimab",no,,,,driver mutation-negative,interventional,≤ 1,no
386,"Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer",10.1158/1078-0432.CCR-21-0822,2021,Clinical Cancer Research,Nasopharyngeal Cancer,Recurrent/Metastatic,"['Spartalizumab', 'Chemotherapy']",yes,no,no,no,yes,yes,"Phase II, Randomized",122,Spartalizumab (anti-PD-1 antibody),,,,yes,,eligible,platinum-refractory,,no,,,,"IFNg, LAG-3, and TIM-3 gene expression",,,
387,,10.1172/JCI152670,2021,Journal of Clinical Investigation,Biliary tract cancer,"Unresectable, metastatic","['Atezolizumab monotherapy', 'Atezolizumab + Cobimetinib']",yes,no,no,no,no,yes,"Randomized, open-label, phase II",77,Atezolizumab,,,,yes,,eligible,1-2 lines of prior therapy in metastatic setting,Cobimetinib,no,,,,"PD-L1, LAG3, BTLA, VISTA",Clinical Trial,<=1,no
388,"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)",10.1200/JCO.21.00334,2021,Journal of Clinical Oncology,Ovarian Cancer,,"['Nivolumab', 'Gemcitabine or Pegylated Liposomal Doxorubicin']",yes,no,no,no,yes,yes,"Phase III, multicenter, randomized, open-label",316,Nivolumab,,,,no,,yes,,,,Japan,,,,Clinical Trial,0-1,
389,Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome,10.1111/bjh.17689,2021,British Journal of Haematology,Myelodysplastic Syndrome,Intermediate-1 or higher-risk,,yes,no,no,no,yes,no,Phase II trial,37,Pembrolizumab,12.8,43,,"PD-1, PD-L1",,eligible,Previously untreated; HMA-failure,Azacitidine + Pembrolizumab,no,,,corticosteroids,,,,
390,Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC),10.1016/j.cllc.2021.05.009,2021,Clinical Lung Cancer,NSCLC,III,"['durvalumab', 'placebo']",yes,no,yes,no,yes,yes,randomized controlled trial,713,durvalumab,,,,no,,yes,consolidation,no,no,,,,,clinical trial,,yes
391,"Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma",10.1016/j.ejca.2021.09.023,2021,European Journal of Cancer,Melanoma,III,"['Pembrolizumab', 'Placebo']",yes,no,yes,no,no,yes,"Phase III, double-blind, randomized",1019,Pembrolizumab,,37,7,no,,eligible,Adjuvant,,,,,,,Clinical Trial,,
392,,10.1016/S1470-2045(21)00471-X,2021,The Lancet Oncology,Malignant Mesothelioma,,"['nivolumab', 'placebo']",yes,no,yes,yes,yes,yes,"multicentre, placebo-controlled, double-blind, parallel group, randomised, phase 3 trial",332,nivolumab,11.6,,,no,,eligible,second-line,no,no,UK,"{'diarrhoea_grade3plus': 3, 'infusion-related reaction_grade3plus': 3}",,,clinical trial,0 or 1,
393,EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: Pembrolizumab crossover and rechallenge following recurrence,10.1111/ajco.13716,2021,Asia-Pacific Journal of Clinical Oncology,Melanoma,III,"['Pembrolizumab', 'Placebo']",yes,no,yes,no,no,yes,"Phase 3, randomized, placebo-controlled",1019,Pembrolizumab,41,29.0,6.0,no,,eligible,Adjuvant,no,no,,,,,Clinical Trial,0-2,no
395,Safety and efficacy of intratumoral ipilimumab with iv nivolumab in metastatic melanoma. the nivipit trial,10.1136/jitc-2021-SITC2021.277,2021,Journal for ImmunoTherapy of Cancer,Melanoma,Metastatic,"['IV Nivo (1mg/kg) + IV Ipi (3mg/kg)', 'IV Nivo (1mg/kg) + IT Ipi (0.3mg/kg)']",yes,yes,yes,no,no,no,Randomized multicenter Phase 1b,61,"Nivolumab, Ipilimumab",,,30,yes,,yes,Previously untreated,Nivolumab + Ipilimumab,no,,,,"CD25hi CD39hi activated Tregs, granzyme B",Clinical Trial,,
397,"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial",10.1016/S0140-6736(21)02098-5,2021,The Lancet,non-small-cell lung cancer,IB-IIIA,"['adjuvant atezolizumab', 'best supportive care']",yes,no,yes,no,no,yes,"randomised, multicentre, open-label, phase 3",1005,atezolizumab,32.2,,0.11,PD-L1,,eligible,adjuvant,adjuvant platinum-based chemotherapy,no,22 countries and regions,,,PD-L1 on 1% or more of tumour cells,clinical trial,,
398,Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma,10.1016/j.clgc.2021.03.019,2021,Clinical Genitourinary Cancer,Renal Cell Carcinoma,Advanced,"['axitinib monotherapy', 'axitinib + IO', 'other TKI']",yes,no,yes,no,no,no,Pooled analysis of randomized or single-arm studies,1955,IO (unspecified),,,,no,,yes,First-line,axitinib + IO,no,,,TTR of AEs after treatment interruption,,Clinical Trial,,no
399,A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma,10.1016/j.clgc.2021.04.007,2021,Clinical Genitourinary Cancer,Renal Cell Carcinoma,Advanced,"['pazopanib plus pembrolizumab', 'pazopanib monotherapy followed by pazopanib plus pembrolizumab', 'pazopanib monotherapy', 'pembrolizumab monotherapy']",yes,no,yes,no,no,yes,"open-label, two-part, multicenter study",42,Pembrolizumab,,,90,no,,eligible,treatment-naïve,Pazopanib + Pembrolizumab,no,,,,,Phase I/II,,
400,"Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC",10.1016/j.jtho.2021.05.001,2021,Journal of Thoracic Oncology,NSCLC,advanced,"['pembrolizumab', 'docetaxel']",no,no,no,no,yes,no,randomized,1034,pembrolizumab,67.4,,,"PD-L1 TPS, tumor mutational burden",,eligible,second-line or later,,no,,,,"PD-L1 TPS >=1%, PD-L1 TPS >=50%",clinical trial,,
401,,10.1038/s41591-021-01510-7,2021,Nature Medicine,Melanoma,IIIB-IVM1a,"['T-VEC plus surgery', 'surgery alone']",yes,no,no,no,yes,yes,"Randomized, open-label, phase 2 trial",150,Talimogene laherparepvec (T-VEC),,,,yes,,eligible,Neoadjuvant,T-VEC + surgery,no,,,,CD8+ density,Clinical Trial,,
402,"Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study",10.1016/j.lungcan.2021.08.006,2021,Lung Cancer,NSCLC,advanced,[],yes,no,no,no,yes,yes,"open-label, dose escalation and expansion study",,camrelizumab,,,,no,,eligible,second-line or later-line,anlotinib + camrelizumab,no,,{},,,Phase IB clinical trial,0 and 1,
403,"Interim results of hbv001, a phase 1 study evaluating the safety and tolerability of therapeutic vaccination with chadox1-hbv in healthy volunteers and patients with chronic hepatitis b infection",10.1002/hep.32188,2021,Hepatology,,,,yes,no,no,no,no,no,"open label, non-randomised, dose escalation phase I clinical trial",17,ChAdOx1-HBV,,,,yes,,eligible,,,,,,,HBV DNA suppressed on nucleos(t)ide therapy,Interventional,,
404,Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (study 309/keynote-775),10.1136/ijgc-2021-ESGO.120,2021,International Journal of Gynecological Cancer,Endometrial Cancer,advanced,"['lenvatinib + pembrolizumab', ""treatment of physician's choice (doxorubicin or paclitaxel)""]",yes,no,no,no,yes,yes,randomized controlled trial,827,pembrolizumab,,,,no,,eligible,prior platinum-based therapy,lenvatinib + pembrolizumab,no,,,Clinicians play a critical role in prompt identification and AR-directed management of patients with aEC; such management may potentially reduce treatment interruption(s) and/or lenvatinib dose reduction.,,Clinical Trial,,
405,Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival,10.1136/jitc-2021-002472,2021,Journal for ImmunoTherapy of Cancer,Esophageal cancer,Advanced,[],no,no,no,no,yes,yes,Phase 2 clinical trial,49,Pembrolizumab,,,,yes,,eligible,at least one prior line of therapy,no,no,,,,"PD-L1, TMB, CXCL10, IL2RA, IL6",Interventional,,
406,Overall survival benefit with tebentafusp in metastatic uveal melanoma,10.1056/NEJMoa2103485,2021,New England Journal of Medicine,Uveal melanoma,Metastatic,"['Tebentafusp', ""Investigator's choice (pembrolizumab, ipilimumab, or dacarbazine)""]",yes,no,no,yes,yes,yes,"Open-label, phase 3, randomized controlled trial",378,Tebentafusp,,,,yes,,eligible,Previously untreated,,no,,"{'rash': 83, 'pyrexia': 76, 'pruritus': 69}",Adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported.,HLAA*02:01-positive,Clinical Trial,,
407,"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study",10.1200/JCO.20.03555,2021,Journal of Clinical Oncology,Hepatocellular Carcinoma,Unresectable,"['T300 1 D (tremelimumab 300 mg + durvalumab 1500 mg)', 'Durvalumab monotherapy (1500 mg)', 'Tremelimumab monotherapy (750 mg)', 'T75 1 D (tremelimumab 75 mg + durvalumab 1500 mg)']",yes,no,yes,no,yes,no,Randomized Phase I/II,332,"Tremelimumab, Durvalumab",,,,yes,,eligible,"Second-line or later (progressed on, intolerant to, or refused sorafenib)",Tremelimumab + Durvalumab,no,,,,CD81 lymphocytes,Clinical Trial,,no
408,Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial,10.1038/s41591-021-01444-0,2021,Nature Medicine,Nasopharyngeal Carcinoma,Recurrent or metastatic,"['Toripalimab + Gemcitabine-cisplatin (GP)', 'Placebo + Gemcitabine-cisplatin (GP)']",yes,no,yes,no,yes,yes,"Randomized, double-blind, phase 3 trial",289,Toripalimab,,39.7,,PD-L1 expression,,eligible,First-line,Chemotherapy (Gemcitabine-cisplatin),no,,,,,Clinical Trial,,
409,"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer",10.1016/j.annonc.2021.06.004,2021,Annals of Oncology,nonsquamous non-small-cell lung cancer,IIIB/IV or recurrent,"['nivolumab + carboplatin + paclitaxel + bevacizumab', 'placebo + carboplatin + paclitaxel + bevacizumab']",yes,no,yes,no,no,yes,"randomized, double-blind phase III",550,nivolumab,13.7,,,PD-L1,,eligible,first-line,"carboplatin, paclitaxel, bevacizumab",no,"Japan, Korea, Taiwan",,,,clinical trial,,
410,"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial",10.1016/S1470-2045(21)00342-9,2021,The Lancet Oncology,Epithelial Ovarian Cancer,III-IV,"['Chemotherapy followed by avelumab maintenance', 'Chemotherapy plus avelumab followed by avelumab maintenance', 'Chemotherapy followed by observation (control)']",yes,no,yes,no,no,yes,"Randomized, open-label, phase 3",998,Avelumab,10.8,,,no,,eligible,First-line,Chemotherapy (carboplatin + paclitaxel) + Avelumab,no,Global (25 countries),,,,Clinical Trial,0 or 1,
411,Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases,10.1158/1078-0432.CCR-21-1046,2021,Clinical Cancer Research,Melanoma,,"['fotemustine', 'ipilimumab plus fotemustine', 'ipilimumab plus nivolumab']",yes,no,yes,no,yes,no,Phase III,80,"ipilimumab, nivolumab",48,,,BRAF,,eligible,,"ipilimumab plus fotemustine, ipilimumab plus nivolumab",no,,,,BRAF wild-type or mutant,,,
413,1500P Health-related quality of life in melanoma patients treated with neoadjuvant nivolumab and domatinostat: Preliminary results,10.1016/j.annonc.2021.08.828,2021,Annals of Oncology,Melanoma,III,"['nivolumab (NIVO)', 'NIVO+DOM (Domatinostat)']",yes,no,no,yes,no,no,Randomized controlled trial,20,Nivolumab,,,,yes,,yes,Neoadjuvant,Nivolumab + Domatinostat,no,,,,high interferon-gamma (IFN-γ) signature,Clinical Trial,,yes
414,Avelumab in relapsed/refractory classical hodgkin lymphoma: Phase 1b results from the JAVELIN hodgkins trial,10.1182/BLOODADVANCES.2021004511,2021,Blood Advances,Classical Hodgkin Lymphoma (cHL),,[],yes,no,yes,yes,no,no,"Phase 1b, multiple-dose, open-label, randomized, parallel-arm trial",31,Avelumab (anti–PD-L1),,,,PD-L1/PD-L2,,eligible,,,,,"{'infusion-related reaction': 30.0, 'nausea': 20.0, 'increased alanine aminotransferase': 16.7, 'rash': 16.7, 'fatigue': 13.3}",,9p24.1 chromosomal alteration,clinical trial,,
415,"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study",10.1016/S0140-6736(21)01234-4,2021,The Lancet,oesophageal cancer,advanced,"['pembrolizumab plus chemotherapy', 'placebo plus chemotherapy']",yes,no,yes,no,yes,yes,"randomised, placebo-controlled, double-blind, phase 3",749,pembrolizumab,22.6,,72.0,PD-L1 CPS,,eligible,first-line,chemotherapy (5-fluorouracil and cisplatin),no,multi-regional (26 countries),,,PD-L1 CPS >= 10,clinical trial,0-1,
416,Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival,10.1136/jitc-2021-003188,2021,Journal for ImmunoTherapy of Cancer,Melanoma,III/IV,"['Nivolumab', 'Ipilimumab']",yes,no,no,yes,no,yes,Phase III,905,Nivolumab,,67.7,,no,,eligible,Adjuvant,,,,"{'pruritus': 15.5, 'diarrhea': 15.3}",Most select TRAEs resolved within 6 months.,,Clinical Trial,,
417,Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC,10.1002/cnr2.1368,2021,Cancer Reports,NSCLC,,"['statin users', 'non-statin users']",no,no,no,no,yes,yes,observational study,162,,,,,,,eligible,first- and second-line,statin + immunotherapy,,,,,,,,
418,,10.1016/j.jtho.2021.03.009,2021,Journal of Thoracic Oncology,NSCLC,IIIB or IV or recurrent,"['avelumab', 'docetaxel']",yes,no,no,no,yes,no,Randomized controlled trial,792,avelumab,35.4,,,PD-L1,,eligible,second-line,no,no,,,,PD-L1+,clinical trial,,
419,"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis",10.1016/j.annonc.2021.05.355,2021,Annals of Oncology,triple-negative breast cancer,"unresectable, locally advanced, or metastatic","['atezolizumab plus nab-paclitaxel (A + nP)', 'placebo plus nab-paclitaxel (P + nP)']",yes,no,no,no,yes,yes,randomized controlled trial,902,atezolizumab,18.8,58.7,,PD-L1,,eligible,first-line,nab-paclitaxel,no,,,,PD-L1 IC-positive,clinical trial,,
420,,10.1016/S1470-2045(21)00286-2,2021,The Lancet Oncology,Pancreatic Cancer,Locally recurrent after surgical resection,"['SBRT + pembrolizumab + trametinib', 'SBRT + gemcitabine']",yes,no,yes,yes,yes,no,Randomized controlled phase 2 trial,170,Pembrolizumab,23.3,,,"PD-L1, KRAS",,eligible,Postoperative,SBRT + pembrolizumab + trametinib,no,China,"{'increased alanine aminotransferase or aspartate aminotransferase': 0.12, 'increased blood bilirubin': 0.05, 'neutropenia': 0.01, 'thrombocytopenia': 0.01}",,"mutant KRAS, positive PD-L1",Clinical Trial,0 or 1,no
421,"Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study",10.1200/JCO.20.03579,2021,Journal of Clinical Oncology,Non-small-cell lung cancer,Metastatic,"['Pembrolizumab-ipilimumab', 'Pembrolizumab-placebo']",yes,no,yes,no,yes,yes,"Randomized, double-blind, phase III",568,"Pembrolizumab, Ipilimumab",,,,PD-L1 TPS,,eligible,First-line,Pembrolizumab + Ipilimumab,no,,,,PD-L1 TPS >= 50%,Clinical Trial,,
422,Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50%,10.1200/JCO.21.00174,2021,Journal of Clinical Oncology,Non-Small-Cell Lung Cancer,Metastatic,"['Pembrolizumab', 'Platinum-based chemotherapy']",yes,no,no,no,yes,yes,Randomized controlled trial,305,Pembrolizumab,59.9,,,PD-L1,,eligible,First-line,,no,,,,PD-L1 TPS >= 50%,Clinical Trial,,
423,Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial,10.1016/j.ccell.2021.05.009,2021,Cancer Cell,Breast Cancer,II/III,"['Durvalumab/Olaparib/Paclitaxel (DOP)', 'Standard of Care (Paclitaxel)']",yes,no,yes,no,no,no,"Phase II, adaptive randomized",372,Durvalumab,,,12.3,yes,,yes,Neoadjuvant,Durvalumab + Olaparib + Paclitaxel,no,,,,"HER2-negative, HR-positive/HER2-negative, TNBC, MammaPrint ultra-high (MP2), MammaPrint (MP1)",Clinical Trial,,
424,"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial",10.1016/S0140-6736(21)00797-2,2021,The Lancet,"Gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma",Advanced or metastatic,"['nivolumab plus chemotherapy', 'nivolumab plus ipilimumab', 'chemotherapy alone']",yes,no,yes,no,yes,yes,"Randomised, open-label, phase 3 trial",1581,"Nivolumab, Ipilimumab",13.1,,,PD-L1 CPS,,eligible,First-line,"Nivolumab + chemotherapy (capecitabine and oxaliplatin or leucovorin, fluorouracil, and oxaliplatin)",no,Multicentre (29 countries),,,PD-L1 CPS >= 5,Clinical Trial,,
425,Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR),10.1002/onco.13777,2021,Oncologist,Renal Cell Carcinoma,Advanced or Metastatic,"['carotuximab + axitinib', 'axitinib monotherapy']",no,no,no,no,no,yes,Randomized Phase II,150,carotuximab,,,,yes,,eligible,second-line or later,carotuximab + axitinib,no,international,,,VEGF levels,clinical trial,0 vs 1,no
426,"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study",10.1016/S1470-2045(21)00216-3,2021,The Lancet Oncology,Ovarian cancer,,"['Avelumab', 'Avelumab plus PLD', 'PLD']",yes,no,yes,yes,yes,yes,"Randomized, Phase 3",566,Avelumab,18.4,,,no,,eligible,platinum-resistant or platinum-refractory,Avelumab + PLD,no,24 countries,"{'palmar-plantar erythrodysesthesia syndrome': 0.1, 'rash': 0.06, 'fatigue': 0.05, 'stomatitis': 0.05, 'anaemia': 0.03, 'neutropenia': 0.05, 'neutrophil count decreased': 0.05}",,,Clinical Trial,0 or 1,no
427,"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study",10.1016/S1470-2045(21)00252-7,2021,The Lancet Oncology,Hepatocellular carcinoma,Unresectable or metastatic,"['sintilimab plus IBI305', 'sorafenib']",yes,no,yes,yes,yes,yes,"Randomized, open-label, phase 2-3",595,Sintilimab,10,,29,no,,eligible,First-line,Sintilimab + IBI305 (bevacizumab biosimilar),no,China,"{'hypertension_grade3_4': 14, 'palmar-plantar erythrodysaesthesia syndrome_grade3_4': 0, 'abnormal liver function_death': 1, 'hepatic failure_death': 1, 'gastrointestinal haemorrhage_death': 1, 'interstitial lung disease_death': 1, 'hyperkalemia_death': 1, 'upper gastrointestinal haemorrhage_death': 1, 'intestinal volvulus_death': 1}",,,Clinical Trial,0 or 1,no
428,"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial",10.1016/S1470-2045(21)00152-2,2021,The Lancet Oncology,Urothelial Carcinoma,"Advanced, unresectable, or metastatic","['Pembrolizumab plus chemotherapy', 'Pembrolizumab monotherapy', 'Chemotherapy alone']",yes,no,yes,no,yes,yes,"Randomized, open-label, phase 3 trial",1010,Pembrolizumab,31.7,,,PD-L1 CPS,,eligible,First-line,Pembrolizumab + chemotherapy (gemcitabine + cisplatin/carboplatin),no,21 countries,,,PD-L1 combined positive score (CPS),Clinical Trial,up to 2,no
429,"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study",10.1159/000513486,2021,Liver Cancer,Hepatocellular Carcinoma,Unresectable,"['Atezolizumab plus Bevacizumab', 'Sorafenib']",yes,no,yes,no,yes,yes,"Randomized, Open-label, Phase 3",194,Atezolizumab,,,,no,,eligible,First-line,Atezolizumab + Bevacizumab,no,China,,,,Clinical Trial,,
430,,10.1158/1538-7445.AM2021-CT143,2021,Cancer Research,Melanoma,Metastatic,"['Pembrolizumab 200 mg IV', 'Pembrolizumab 285 mg SC (two different formulations)']",yes,no,yes,yes,no,no,"Open-label, phase 1, cross-over",31,Pembrolizumab,,,,,,eligible,,,,,"{'pruritus': 2, 'rash': 2}",,,Pharmacokinetics,,yes
431,Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma,10.1158/1538-7445.AM2021-CT002,2021,Cancer Research,metastatic uveal melanoma,metastatic,"['tebentafusp', ""investigator's choice (pembrolizumab, ipilimumab, or dacarbazine)""]",yes,no,no,yes,yes,yes,"randomized, open-label, Phase 3",378,tebentafusp,,,,HLA-A*02:01,,eligible,first line,monotherapy,no,,,generally manageable with standard interventions,HLA-A*02:01+,clinical trial,,
432,"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39)",10.1200/JCO.21.00306,2021,Journal of Clinical Oncology,Ovarian Cancer,III or IV,"['Atezolizumab + paclitaxel + carboplatin + bevacizumab', 'Placebo + paclitaxel + carboplatin + bevacizumab']",yes,no,yes,no,yes,yes,Randomized controlled trial,1301,Atezolizumab,,,,PD-L1,,yes,First-line,Chemotherapy + Bevacizumab,no,,,,PD-L1-positive,Interventional,,
434,"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study",10.1016/S2352-3026(21)00103-4,2021,The Lancet Haematology,Lymphoma,Relapsed or refractory,[],yes,no,yes,no,no,no,"Phase 1, dose-escalation, dose-expansion, multicentre trial",133,Camidanlumab tesirine,9.2,,,no,,eligible,,,,"USA, UK",,,,,0-2,
435,Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states,10.1111/liv.14795,2021,Liver International,Hepatocellular Carcinoma,Unresectable,"['Atezolizumab and bevacizumab combination', 'Sorafenib']",no,no,no,no,yes,yes,Markov model based on a phase III randomized trial (IMbrave150),,Atezolizumab,,,,no,,eligible,First-line,Atezolizumab and Bevacizumab,no,"China, USA",,,,Cost-effectiveness analysis,,
436,"Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial",10.1002/pros.24110,2021,Prostate,prostate cancer,metastatic castration-resistant,"['nivolumab + ipilimumab', 'nivolumab + ipilimumab + enzalutamide']",yes,no,yes,no,yes,yes,"Phase 2, nonrandomized",30,"nivolumab, ipilimumab",,,,yes,,eligible,,nivolumab + ipilimumab; nivolumab + ipilimumab + enzalutamide,no,,,,"AR-V7-positive, alkaline phosphatase, IL-7, IL-6, IL-17, sPD-L1",clinical trial,,
437,Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice,10.1016/j.ejca.2021.02.030,2021,European Journal of Cancer,Melanoma,Advanced,"['Prolgolimab 1 mg/kg every 2 weeks', 'Prolgolimab 3 mg/kg every 3 weeks']",yes,no,yes,no,yes,yes,Multicenter open-label parallel-arm phase II trial,126,Prolgolimab (anti-PD-1),25.7,,7.95,no,,eligible,no,no,no,,,,,Clinical Trial,0 or 1,
438,Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451,10.1200/JCO.20.02212,2021,Journal of Clinical Oncology,Small-Cell Lung Cancer,Extensive-Disease,"['nivolumab plus ipilimumab', 'nivolumab monotherapy', 'placebo']",yes,no,yes,no,yes,yes,double-blind phase III trial,834,"Nivolumab, Ipilimumab",8.9,,52.2,yes,,eligible,maintenance therapy following first-line chemotherapy,nivolumab plus ipilimumab,no,,,,tumor mutational burden,Clinical Trial,0-1,no
439,Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma,10.1056/NEJMoa2035716,2021,New England Journal of Medicine,renal cell carcinoma,advanced,"['lenvatinib plus pembrolizumab', 'lenvatinib plus everolimus', 'sunitinib']",no,no,no,no,yes,yes,"Phase 3 trial, randomized",1069,pembrolizumab,,,,no,,eligible,first-line,lenvatinib plus pembrolizumab; lenvatinib plus everolimus,no,,,,,clinical trial,,
441,63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID),10.1016/S1556-0864(21)01905-5,2021,Journal of Thoracic Oncology,non-small cell lung cancer (NSCLC),early-stage,"['SBRT alone (arm A)', 'SBRT followed by adjuvant durvalumab (arm B)']",yes,no,yes,yes,no,yes,Randomized multicentre open-label phase II study,47,durvalumab,,55,,no,,eligible,adjuvant,SBRT + durvalumab,no,,"{'skin reactions/rash': 45, 'pruritus': 27, 'thyroid disorders': 18, 'pneumonitis_grade3': 2, 'dyspnoea_grade3': 1, 'hepatitis_grade3': 3, 'increased lipase_grade4': 1}",,,clinical trial,,
442,"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study",10.1016/S1470-2045(21)00005-X,2021,The Lancet Oncology,classical Hodgkin lymphoma,relapsed or refractory,"['pembrolizumab', 'brentuximab vedotin']",yes,no,yes,yes,no,yes,"randomised, open-label, phase 3",304,pembrolizumab,25.7,,,no,,eligible,,no,,multicentre (20 countries and territories),"{'pneumonitis_grade3plus': 4.0, 'neutropenia_grade3plus': 2.0, 'decreased neutrophil count_grade3plus': 1.0, 'peripheral neuropathy_grade3plus': 1.0}",,,clinical trial,0 or 1,
443,"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial",10.1016/S1470-2045(20)30737-3,2021,The Lancet Oncology,squamous cell carcinoma of the head and neck,locally advanced,"['avelumab plus chemoradiotherapy', 'placebo plus chemoradiotherapy']",yes,no,yes,no,no,yes,"randomised, double-blind, placebo-controlled, multicentre, phase 3",697,avelumab,14.6,,,"PD-L1 status, human papillomavirus status",,yes,previously untreated,chemoradiotherapy (cisplatin + intensity-modulated radiotherapy),no,multicentre (22 countries),,,,clinical trial,0 or 1,no
444,"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial",10.1016/S1470-2045(21)00004-8,2021,The Lancet Oncology,Urothelial Carcinoma,Muscle-invasive,"['Atezolizumab', 'Observation']",yes,no,yes,no,no,yes,"Randomized, open-label, phase 3",809,Atezolizumab,21.9,,0.16,PD-L1 expression,,eligible,Adjuvant,,no,Multicenter (24 countries/regions),,,,Clinical Trial,"0, 1, or 2",
445,"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial",10.1016/S1470-2045(20)30754-3,2021,The Lancet Oncology,Breast Cancer,Metastatic,"['Pembrolizumab', 'Chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)']",yes,no,yes,no,yes,no,"Randomized, open-label, phase 3 trial",622,Pembrolizumab,31.4,,,PD-L1,,eligible,Second-line or third-line,no,no,Multinational (31 countries),,,"PD-L1 CPS ≥10, PD-L1 CPS ≥1",Interventional,0 or 1,no
446,Fda approval summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma,10.1158/1078-0432.CCR-20-3407,2021,Clinical Cancer Research,Hepatocellular Carcinoma,Advanced unresectable or metastatic,"['Atezolizumab plus bevacizumab', 'Sorafenib']",yes,no,no,no,yes,yes,Randomized controlled trial,,Atezolizumab,,,,no,,eligible,First-line,Atezolizumab + Bevacizumab,no,,,,,,,
447,Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer,10.1056/NEJMoa2032125,2021,New England Journal of Medicine,Esophageal or gastroesophageal junction cancer,II or III,"['Nivolumab', 'Placebo']",yes,no,yes,no,no,yes,"Randomized, double-blind, placebo-controlled phase 3 trial",794,Nivolumab,24.4,,0.13,no,,eligible,Adjuvant,,no,global,,,,Clinical Trial,,
448,Enfortumab vedotin in previously treated advanced urothelial carcinoma,10.1056/NEJMoa2035807,2021,New England Journal of Medicine,Urothelial Carcinoma,Locally advanced or metastatic,"['Enfortumab vedotin', 'Investigator-chosen chemotherapy (docetaxel, paclitaxel, or vinflunine)']",no,no,no,no,yes,yes,"Phase 3, randomized, open-label",608,Enfortumab vedotin,11.1,,,no,,yes,Previously treated (after platinum-containing chemotherapy and PD-1/PD-L1 inhibitor),,yes,global,,,,Clinical Trial,,
449,Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma,10.1056/NEJMoa2026982,2021,New England Journal of Medicine,Renal-Cell Carcinoma,Advanced,"['Nivolumab plus Cabozantinib', 'Sunitinib']",yes,no,yes,no,yes,yes,"Phase 3, randomized, open-label trial",651,Nivolumab,18.1,75.3,,no,,eligible,First-line,Nivolumab + Cabozantinib,no,,,,,Clinical Trial,,yes
450,Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study,10.1016/j.annonc.2020.12.004,2021,Annals of Oncology,Melanoma,Advanced,"['cobimetinib plus atezolizumab', 'pembrolizumab']",yes,no,yes,yes,no,yes,"Randomized, open-label, phase III",446,"atezolizumab, pembrolizumab",7.1,,,"BRAFV600 wild-type, tumor mutational burden",,eligible,Previously untreated,cobimetinib plus atezolizumab,no,International,"{'increased blood creatine phosphokinase': 10, 'diarrhea': 7.7, 'rash': 6.8, 'hypertension': 6.4, 'dermatitis acneiform': 5}",,BRAFV600 wild-type,Clinical Trial,,no
452,OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints,10.1016/j.jtho.2021.01.300,2021,Journal of Thoracic Oncology,NSCLC,IIIB/IV,[],yes,no,yes,yes,yes,yes,Phase I,22,sintilimab,15.8,,4.5,PD-L1,,eligible,first-line,sintilimab + anlotinib,no,,"{'hypothyroidism': 50, 'pneumonitis': 13.6, 'myositis': 4.5, 'adrenal insufficiency': 4.5}",Five patients required dose reduction of anlotinib and one patient had treatment discontinuation due to grade 3 rash.,,clinical trial,,
453,P03.01 A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm,10.1016/j.jtho.2021.01.374,2021,Journal of Thoracic Oncology,NSCLC,I,"['Pembrolizumab', 'Observation']",yes,no,no,no,yes,yes,Randomized Phase II,368,Pembrolizumab,,,,PD-L1 TPS,,eligible,adjuvant,no,no,United States,,,,clinical trial,,
454,"Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer",10.1200/JCO.20.01605,2021,Journal of Clinical Oncology,non-small-cell lung cancer,advanced,"['nivolumab', 'docetaxel']",yes,no,yes,no,yes,yes,"randomized, phase III trials",854,nivolumab,64.2,25.8,3.2,no,,eligible,second-line,no,no,,,,,clinical trial,1,no
455,nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+),10.3389/fonc.2020.569715,2020,Frontiers in Oncology,Non-small cell lung cancer,Advanced,[],yes,no,no,no,yes,yes,"Single-arm, open-label",79,Durvalumab,,,,no,,eligible,Second-line,nab-paclitaxel + durvalumab,yes,,,,,Clinical Trial,,
456,Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma,10.1038/s41591-020-01211-7,2021,Nature Medicine,Melanoma,III,,no,no,no,no,no,yes,"Phase 1b, Phase 2",95,"Ipilimumab, Nivolumab",48,,,yes,,eligible,Neoadjuvant,Ipilimumab + Nivolumab,no,,,,"TMB, IFN-γ score",,,
457,"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial",10.1016/S1470-2045(20)30641-0,2021,The Lancet Oncology,non-small-cell lung cancer,IV or recurrent,"['nivolumab plus ipilimumab with two cycles of chemotherapy', 'chemotherapy alone']",yes,no,yes,yes,yes,no,"randomised, open-label, phase 3 trial",719,"nivolumab, ipilimumab",13.2,,,PD-L1 expression,,eligible,first-line,chemotherapy,no,19 countries,"{'neutropenia_grade3plus': 7, 'anaemia_grade3plus': 6, 'diarrhoea_grade3plus': 4, 'increased lipase_grade3plus': 6, 'asthenia_grade3plus': 1, 'acute kidney failure_death': 1, 'diarrhoea_death': 1, 'hepatotoxicity_death': 1, 'hepatitis_death': 1, 'pneumonitis_death': 1, 'sepsis with acute renal insufficiency_death': 1, 'thrombocytopenia_death': 1}",,,clinical trial,0–1,no
458,Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101,10.1200/jco.2021.39.6_suppl.301,2021,Journal of Clinical Oncology,renal cell carcinoma,advanced,"['Avelumab + Axitinib', 'Sunitinib']",yes,yes,yes,no,yes,yes,Randomized Controlled Trial,853,Avelumab,19.3,,,no,,yes,first-line,Avelumab + Axitinib,no,,,,,,,
459,,10.1200/jco.2021.39.6_suppl.436,2021,Journal of Clinical Oncology,Urothelial Carcinoma,Advanced,"['eganelisib in combination with nivolumab', 'placebo with nivolumab']",yes,no,yes,yes,yes,yes,"Phase II, multicenter, randomized, active-control",49,Nivolumab,,,,"PD-L1, mMDSC",,eligible,post platinum-based chemotherapy,eganelisib + nivolumab,no,,"{'pyrexia_any_grade': 33, 'decreased appetite_any_grade': 30, 'pruritis_any_grade': 24, 'rash_any_grade': 24, 'asthenia_any_grade': 21, 'transaminase elevation_any_grade': 21, 'hepatotoxicity_grade3plus': 15, 'transaminase elevation_grade3plus': 12, 'rash_grade3plus': 9}","Eganelisib dose was reduced from 40 to 30 mg, resulting in a reduction of hepatic AEs.","PD-L1-, high baseline mMDSC levels",Clinical Trial,,
461,Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218),10.1097/CMR.0000000000000708,2021,Melanoma Research,Melanoma,III/IV,[],yes,no,yes,no,yes,no,Expanded Access Program,754,"Nivolumab, Ipilimumab",17.8,96,53,BRAF,,eligible,,Nivolumab + Ipilimumab,no,North America,,,,,0/1,
462,"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial",10.1016/S0140-6736(20)32714-8,2021,The Lancet,Malignant Pleural Mesothelioma,Unresectable,"['Nivolumab plus ipilimumab', 'Platinum plus pemetrexed chemotherapy']",yes,no,yes,yes,yes,no,"Randomized, open-label, phase 3",605,"Nivolumab, Ipilimumab",29.7,,30.0,no,,eligible,First-line,Nivolumab + Ipilimumab,no,Multicentre (21 countries),"{'pneumonitis': 1.0, 'encephalitis': 1.0, 'heart failure': 1.0}",,,Clinical Trial,0 or 1,
463,"Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)",10.1007/s10388-020-00794-x,2021,Esophagus,esophageal squamous cell carcinoma,advanced,"['nivolumab', 'chemotherapy']",yes,no,no,no,yes,no,"randomized, open-label, phase 3",274,nivolumab,,,,no,,eligible,second-line,,,Japan,,,,subgroup analysis,,
464,A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,10.1016/j.ijrobp.2020.08.018,2021,International Journal of Radiation Oncology Biology Physics,Adenoid Cystic Carcinoma,Metastatic,"['Pembrolizumab alone', 'Pembrolizumab with radiation therapy (pembroRT)']",yes,no,yes,yes,yes,yes,Randomized Phase 2,20,Pembrolizumab,,,,yes,,eligible,,Radiation therapy,no,,{'liver enzyme elevation': 0.05},,"PD-L1 expression, CD8 infiltrating T-cells, MYB/NFIB translocation",Clinical Trial,,
465,Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma,10.1158/1078-0432.CCR-20-2063,2021,Clinical Cancer Research,Renal Cell Carcinoma,Advanced,"['Nivolumab + Ipilimumab', 'Sunitinib']",yes,no,no,no,yes,yes,"Phase III, Post hoc analysis",139,"Nivolumab, Ipilimumab",42,,,no,,eligible,First-line,Nivolumab + Ipilimumab,no,,{},,,Clinical Trial,,
466,,10.1155/2021/2338800,2021,Journal of Healthcare Engineering,Non-small-cell lung cancer,Advanced,"['Anlotinib capsules combined with PD-1 inhibitor (camrelizumab)', 'Anlotinib capsules']",yes,no,no,no,no,no,Randomized controlled trial,88,Camrelizumab,,,,yes,,eligible,Third-line,Anlotinib capsules + Camrelizumab,,,,,Serum tumor markers,,,
467,,10.1200/jco.2021.39.3_suppl.306,2021,Journal of Clinical Oncology,Hepatocellular Carcinoma,BCLC stage B or C,,yes,no,yes,yes,yes,yes,"open-label, multicenter phase Ib/II study",31,Penpulimab (Anti-PD-1),11.9,90.3,16.1,,,eligible,first-line,Penpulimab + Anlotinib,no,,"{'increased AST': 38.7, 'increased ALT': 35.5, 'increased blood bilirubin': 22.6, 'asthenia': 22.6, 'decreased platelet count': 19.4, 'rash': 16.1}",,,Clinical Trial,0/1,
468,Nivolumab (NIVO) plus ipilimumab(IPI) combination therapy inpatients (Pts) with advanced hepatocellular carcinoma (aHCC):Long-term results from Check Mate 040,10.1200/JCO.2021.39.3_suppl.269,2021,Journal of Clinical Oncology,hepatocellular carcinoma,advanced,"['NIVO 1 mg/kg + IPI 3 mg/kg Q3W (4 doses) followed by NIVO 240 mg Q2W', 'NIVO 3 mg/kg + IPI 1 mg/kg Q3W (4 doses) followed by NIVO 240 mg Q2W', 'NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W']",yes,no,no,yes,yes,no,randomized,148,"Nivolumab, Ipilimumab",44,,,yes,,eligible,second-line,Nivolumab + Ipilimumab,no,,,Most IMAEs were reversible and resolved when treated using established algorithms.,"programmed death ligand 1 expression, alpha-fetoprotein level, hepatitis B or C virus (HBV or HCV) etiology",,,
469,,10.1200/JCO.2021.39.3_suppl.215,2021,Journal of Clinical Oncology,Esophageal squamous cell carcinoma (ESCC),advanced,,yes,no,yes,yes,yes,yes,"single-arm, open-label, phase II study",36,Camrelizumab,5.0,72.2,30.6,no,,eligible,second-line,Camrelizumab plus apatinib,no,China,"{'elevated aspartate aminotransferase': 30.6, 'elevated alanine aminotransferase': 30.6, 'hypertension': 25.0, 'neutrophil': 25.0, 'thrombocytopenia': 25.0, 'leukopenia': 22.2, 'anemia': 11.1, 'proteinuria': 11.1, 'hematochezia': 8.3, 'reactive cutaneous capillary endothelial proliferation': 5.6, 'pruritus': 5.6, 'esophageal fistula': 5.6, 'fatigue': 2.8, 'hypothyroidism': 2.8}",,,clinical trial,0-1,
470,,,2021,Libri Oncologici,Bladder Cancer,Advanced,,yes,no,yes,no,yes,yes,,,"Nivolumab, Atezolizumab, Pembrolizumab, Avelumab, Enfortumab vedotin, Sacituzumab govitecan",49,,,"PD-L1, ctDNA",,eligible,"First-line, Second-line, Adjuvant, Neoadjuvant",Chemotherapy + Nivolumab,,,,,,,,
471,"Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325- MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of highrisk stage III melanoma",10.1200/JCO.2021.39.15_suppl.9500,2021,Journal of Clinical Oncology,Melanoma,III,"['Pembrolizumab', 'Placebo']",yes,yes,yes,no,no,yes,"Phase 3, double-blind, randomized, placebo-controlled",1019,Pembrolizumab,41,37,7,no,,eligible,Adjuvant,no,no,,,,,Clinical Trial,0-2,
472,Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511,10.1200/JCO.2021.39.15_suppl.9516,2021,Journal of Clinical Oncology,Melanoma,III/IV,"['NIVO 3 mg/kg + IPI 1 mg/kg', 'NIVO 1 mg/kg + IPI 3 mg/kg']",yes,no,yes,yes,yes,yes,Randomized controlled trial,358,"Nivolumab, Ipilimumab",44.15,,,no,,yes,First-line,Nivolumab + Ipilimumab,no,,"{'Diarrhea (NIVO3+IPI1)': 27, 'Fatigue (NIVO3+IPI1)': 26, 'Pruritus (NIVO3+IPI1)': 26, 'Diarrhea (NIVO1+IPI3)': 31, 'Pruritus (NIVO1+IPI3)': 29, 'Rash (NIVO1+IPI3)': 27, 'Grade 3-5 TRAE (NIVO3+IPI1)': 33.9, 'Grade 3-5 TRAE (NIVO1+IPI3)': 48.3}",TRAEs led to tx discontinuation in 26% (NIVO3+IPI1) and 39% (NIVO1+IPI3) of pts.,,Clinical Trial,,no
473,,10.1200/JCO.2021.39.15_suppl.e16113,2021,Journal of Clinical Oncology,Hepatocellular Carcinoma (HCC),BCLC stage C (advanced),"['ICIs plus proton therapy', 'ICIs plus photon therapy']",yes,no,yes,yes,yes,yes,Retrospective review,52,Immune checkpoint inhibitors (ICIs),10.7,,,no,,eligible,,ICIs + proton therapy; ICIs + photon therapy,,Taiwan,"{'grade 3 dermatitis': 1, 'grade 3 hepatitis': 1, 'grade 5 pneumonitis': 1}",Most adverse events were manageable.,,Observational Study,,
476,A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153,10.1200/jco.2021.39.15_suppl.tps8583,2021,Journal of Clinical Oncology,non-small cell lung cancer (NSCLC),I,"['Pembrolizumab', 'observation alone']",yes,no,no,no,yes,yes,randomized phase II multicenter trial,368,Pembrolizumab,,,,PD-L1,,eligible,adjuvant,,no,United States,,,,interventional,,
478,Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma,10.1056/nejmoa2106391,2021,New England Journal of Medicine,Renal-cell carcinoma,,"['pembrolizumab', 'placebo']",yes,no,yes,no,yes,yes,"double-blind, phase 3 trial",994,pembrolizumab,24.1,,32.4,no,,eligible,adjuvant,,no,,,,,clinical trial,,
479,Top ten news (except COVID) in 2020 oncology,,2021,Libri Oncologici,"Breast cancer, Ovarian cancer, Hepatocellular carcinoma, Non-small cell lung cancer, Colorectal cancer, Urothelial carcinoma","Metastatic, Advanced, Resected stage IB-IIIA","['Olaparib vs placebo', 'Atezolizumab + bevacizumab vs sorafenib', 'Osimertinib vs placebo', 'Lorlatinib vs crizotinib', 'Nivolumab + ipilimumab + chemotherapy vs chemotherapy', 'Tiragolumab + atezolizumab vs atezolizumab', 'Pembrolizumab vs chemotherapy +/- biologic therapy', 'Avelumab + best supportive care vs best supportive care alone']",no,no,no,no,yes,yes,"Phase III, Randomized study",501,"Atezolizumab, Nivolumab, Ipilimumab, Tiragolumab, Pembrolizumab, Avelumab",,,,"HER2, EGFR mutation, ALK, MSI-H, PD-L1",,eligible,"Adjuvant, First-line, Maintenance","Atezolizumab + bevacizumab, Nivolumab + ipilimumab + chemotherapy, Tiragolumab + atezolizumab, Pembrolizumab +/- biologic therapy, Avelumab + best supportive care",no,,,,,Clinical Trial,,
480,"KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma",10.1136/jitc-2020-001806,2020,Journal for ImmunoTherapy of Cancer,Melanoma,Advanced,"['Pembrolizumab + Dabrafenib + Trametinib', 'Placebo + Dabrafenib + Trametinib']",yes,no,yes,no,yes,yes,"Randomized, double-blind, phase 2",120,Pembrolizumab,36.6,,,BRAF V600E/K mutation,,eligible,Previously untreated,"Dabrafenib, Trametinib",no,Multi-country (7 countries),,,BRAF V600E/K-mutated,Clinical Trial,,
481,Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study,10.1136/jitc-2020-001302,2020,Journal for ImmunoTherapy of Cancer,Small Cell Lung Cancer,,"['durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without stereotactic body radiation therapy (SBRT))', 'immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T']",yes,no,yes,no,yes,yes,Randomized Phase II,18,"Durvalumab, Tremelimumab",,,,yes,,yes,salvage therapy,Durvalumab + Tremelimumab +/- SBRT,no,,,,CD8+ICOS+ T cells,,,
482,Systemic Therapy for Advanced Hepatocellula Carcinoma: ASCO Guideline,10.1200/JCO.20.02672,2020,Journal of Clinical Oncology,Hepatocellular Carcinoma,Advanced,,yes,no,no,no,yes,no,Guideline,,"Atezolizumab, Bevacizumab, Pembrolizumab, Nivolumab, Ipilimumab",,,,yes,,eligible,"First-line, Second-line, Third-line","Atezolizumab + Bevacizumab, Nivolumab + Ipilimumab",,,,,alpha-fetoprotein,Clinical Practice Guideline,0-1,
485,"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial",10.1016/S1470-2045(20)30541-6,2020,The Lancet Oncology,Urothelial Carcinoma,Locally advanced or metastatic,"['durvalumab monotherapy', 'durvalumab plus tremelimumab', 'standard-of-care chemotherapy (gemcitabine plus cisplatin or gemcitabine plus carboplatin)']",yes,no,yes,yes,yes,no,"Randomized, open-label, multicentre, phase 3 trial",1032,"Durvalumab, Tremelimumab",41.2,,,PD-L1,,eligible,First-line,Durvalumab + Tremelimumab,no,Multicentre (23 countries),"{'increased lipase (grade 3 or 4)': 0.02, 'neutropenia (grade 3 or 4)': 0.21, 'acute hepatic failure (death)': 0.01, 'hepatitis (death)': 0.01, 'septic shock (death)': 0.01, 'pneumonitis (death)': 0.01, 'acute kidney injury (death)': 0.003}",,High PD-L1 expression,Clinical Trial,0 or 1,no
486,Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH),10.1016/j.ejca.2020.09.008,2020,European Journal of Cancer,squamous-cell carcinoma of the head and neck,locally advanced,"['IMRT with cisplatin', 'IMRT with weekly cetuximab', 'IMRT with cetuximab and avelumab followed by avelumab']",yes,no,yes,no,no,no,randomized phase III trial,82,Avelumab,,,,no,,eligible,,Avelumab + Cetuximab + Radiotherapy,no,,,,,clinical trial,,
487,A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial,10.1016/j.annonc.2020.09.009,2020,Annals of Oncology,Malignant pleural mesothelioma,advanced,"['pembrolizumab', 'single-agent chemotherapy (gemcitabine or vinorelbine)']",yes,no,yes,no,yes,yes,randomized phase III,144,pembrolizumab,11.8,,,PD-L1,,eligible,relapsed after/on previous platinum-based chemotherapy,,no,Europe,,,PD-L1 status,clinical trial,0-1,no
488,"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial",10.1016/S1470-2045(20)30436-8,2020,The Lancet Oncology,renal cell carcinoma,advanced,"['pembrolizumab plus axitinib', 'sunitinib monotherapy']",yes,no,yes,no,yes,yes,"randomised, open-label, phase 3",861,pembrolizumab,30.6,,,no,,eligible,first-line,pembrolizumab plus axitinib,no,,,,,clinical trial,,
489,84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial,10.1016/j.annonc.2020.10.571,2020,Annals of Oncology,Breast Cancer,Early Stage,"['Arm 1: q1w paclitaxel x 12 → q2w doxorubicin/cyclophosphamide x 4, with 3x8Gy RT to the tumor at week 5', 'Arm 2: equal arm 1 + durvalumab (anti-PD-L1) x 5 q4w', 'Arm 3: equal arm 2 + oleclumab x 5 q2w → 2 doses q4w']",yes,no,yes,yes,no,no,"Multicentre, open-label, phase II trial with a safety run-in",132,"durvalumab, oleclumab",,,,PD-L1,,eligible,Neo-adjuvant,Chemotherapy + Radiation Therapy + Immunotherapy,no,,,,"ER-positive/HER2-negative, MammaPrint genomic high risk",Clinical Trial,<=1,no
490,Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma,10.2217/imt-2020-0034,2020,Immunotherapy,renal cell carcinoma,advanced,"['pembrolizumab plus axitinib', 'sunitinib']",no,no,no,no,no,no,Markov model,,pembrolizumab,,,,no,,eligible,first-line,pembrolizumab plus axitinib,no,US,,,,cost-effectiveness analysis,,
491,,10.1200/JCO.20.00995,2020,Journal of Clinical Oncology,Melanoma,III/IV,"['Nivolumab', 'Dacarbazine']",yes,no,no,no,yes,yes,"Multicenter, double-blind, phase III",418,Nivolumab,32,,,BRAF wild-type,,eligible,First-line,,no,,,,BRAF wild-type,,,
492,European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma,10.1136/esmoopen-2020-000798,2020,ESMO Open,renal cell carcinoma,advanced,"['nivolumab + ipilimumab', 'sunitinib']",no,no,no,no,yes,no,"randomised, open-label, phase III",1096,"nivolumab, ipilimumab",,,,no,,eligible,first-line,nivolumab + ipilimumab,no,,,,,,,
493,Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma,10.1182/blood-2020-135845,2020,Blood,Multiple Myeloma,Relapsed/Refractory,"['Cobimetinib (Arm A)', 'Cobimetinib + Venetoclax (Arm B)', 'Cobimetinib + Venetoclax + Atezolizumab (Arm C)']",yes,no,yes,no,yes,no,Phase Ib/II,49,Atezolizumab,13.4,,,yes,,yes,3-5 prior therapies,Cobimetinib + Venetoclax + Atezolizumab,no,,,,"t(11;14) positive, RAS mutations, PD-L1 expression, BCL2/BCL2L1 (BCL-XL) high",Clinical Trial,0-1,no
494,"Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial",10.1634/theoncologist.2020-0519,2020,Oncologist,Non-small cell lung carcinoma,Advanced,"['Apatinib combined with docetaxel or pemetrexed', 'Docetaxel or pemetrexed']",no,no,no,no,yes,yes,"Randomized, controlled, multicenter clinical trial",37,,,,,no,,eligible,Second-line,Apatinib + Chemotherapy,no,,,,,Clinical Trial,,
495,A Phase II Trial of Adjuvant Cetuximab and Radiation Therapy in Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck,10.1016/j.ijrobp.2020.07.285,2020,International Journal of Radiation Oncology Biology Physics,Cutaneous Squamous Cell Carcinoma of the Head and Neck,Locally Advanced,,yes,no,yes,yes,yes,yes,Single-institutional phase II trial,24,Cetuximab,42,,0.167,EGFR,,eligible,Adjuvant,Cetuximab + Radiation Therapy,no,,{'skin toxicity': 0.167},Cetuximab was well tolerated with a low rate of adverse effects.,,Clinical Trial,,
496,Incidence and Risk of Colitis with Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer,10.1097/CJI.0000000000000339,2020,Journal of Immunotherapy,solid tumors,,"['PD-1 inhibitors', 'PD-L1 inhibitors']",yes,yes,yes,yes,no,no,meta-analysis,,"nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab",,,,no,,yes,,monotherapy,,,"{'colitis_any_grade_PD1': 1.49, 'colitis_any_grade_PDL1': 0.83, 'colitis_grade3-4_PD1': 0.85, 'colitis_grade3-4_PDL1': 0.34}",,,,,
497,Phase 3 LEAP-006 Safety Run-In (Part 1): 1L Pembrolizumab + Chemotherapy With Lenvatinib for Metastatic NSCLC,10.1111/ajco.13498,2020,Asia-Pacific Journal of Clinical Oncology,NSCLC,metastatic,['lenvatinib 8 mg/d + pembrolizumab 200 mg + pemetrexed 500 mg/m2 + carboplatin AUC 5 or cisplatin 75 mg/m2 Q3W'],yes,no,yes,no,no,yes,"Phase 3, open-label safety run-in",13,Pembrolizumab,7.5,,,no,,eligible,first-line,lenvatinib + pembrolizumab + platinum-based chemotherapy,no,,,,,clinical trial,,
498,,10.1182/blood-2020-135845,2020,Blood,Multiple Myeloma,Relapsed/Refractory,"['Cobimetinib (C)', 'Cobimetinib (C) + Venetoclax (V)', 'Cobimetinib (C) + Venetoclax (V) + Atezolizumab (A)']",no,no,yes,no,yes,no,Phase Ib/II,49,Atezolizumab,13.4,,,yes,,eligible,3-5 prior therapies,Cobimetinib + Venetoclax + Atezolizumab,no,,,,"t(11;14) positive, RAS mutations, PD-L1 expression, BCL2/BCL2L1 (BCL-XL) high",Clinical Trial,0-1,
500,Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: One institutional experience in taiwan since 2016,10.1136/jitc-2020-SITC2020.0474,2020,Journal for ImmunoTherapy of Cancer,Esophageal squamous cell carcinoma,Advanced,,yes,no,yes,yes,no,no,Retrospective,15,"Nivolumab, Pembrolizumab",,,,,,eligible,"1st line, 2nd line","Afatinib + Anti-PD1, Afatinib + Pembrolizumab, Afatinib + Nivolumab",,Taiwan,"{'pneumonitis_grade3plus': 1, 'hepatitis_grade2': 1}",,,Observational,,
1,A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer,10.1002/cncr.33067,2020,Cancer,Urothelial cancer,Metastatic,"['Pembrolizumab', 'Pembrolizumab plus acalabrutinib']",yes,no,yes,no,yes,yes,Randomized Phase 2,75,Pembrolizumab,,,,yes,,eligible,Platinum-resistant,Pembrolizumab + Acalabrutinib,no,,,,"MDSCs, CD8+ T cells",Clinical Trial,,
2,"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial",10.1016/S0140-6736(20)31953-X,2020,The Lancet,triple-negative breast cancer,II–III,"['atezolizumab plus chemotherapy', 'placebo plus chemotherapy']",yes,no,yes,no,no,no,"randomized, double-blind, phase 3",333,atezolizumab,20.6,,,PD-L1,,eligible,neoadjuvant,"nab-paclitaxel, doxorubicin, cyclophosphamide",no,multi-country (13 countries),,,PD-L1-positive,clinical trial,,
3,Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial,10.1016/j.euo.2019.06.004,2020,European Urology Oncology,Renal Cell Carcinoma,Advanced,"['Temsirolimus', 'Pazopanib']",no,no,no,no,no,no,Randomized Phase II,,no,,,,no,,no,First-line,,,,,,,,,
4,"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies",10.1007/s10637-020-00904-7,2020,Investigational New Drugs,Solid Tumors,"Advanced, incurable","['Sequential (SEQ) tremelimumab 75 mg IV followed by durvalumab 1500 mg IV q4wks', 'Concurrent (CON) durvalumab and tremelimumab over 1h']",yes,no,yes,no,no,no,"Phase Ib, randomized",14,"Durvalumab, Tremelimumab",,,,no,,eligible,,Durvalumab + Tremelimumab,,Canada,"{'fatigue': 0.43, 'rash': 0.43, 'pruritus': 0.43, 'nausea': 0.14}",Drug related adverse events (AEs) were mainly low grade and manageable. One patient in each cohort discontinued treatment due to toxicity.,,Clinical Trial,,
5,Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141),10.1002/hed.26331,2020,Head and Neck,squamous cell carcinoma of the head and neck (SCCHN),recurrent or metastatic,"['nivolumab', ""investigator's choice of therapy (IC)""]",yes,no,no,yes,yes,no,randomized phase III clinical trial,34,nivolumab,24,,,no,,eligible,,,,Asia,,,,clinical trial,,
6,"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407",10.1016/j.jtho.2020.06.015,2020,Journal of Thoracic Oncology,NSCLC,Metastatic,"['pembrolizumab plus chemotherapy', 'placebo plus chemotherapy']",yes,no,yes,no,yes,yes,"Randomized, Placebo-Controlled Trial",559,Pembrolizumab,14.3,,,no,,eligible,First-line,Chemotherapy (carboplatin and paclitaxel/nab-paclitaxel),no,,,,,Clinical Trial,,
7,"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial",10.1016/S1470-2045(20)30465-4,2020,The Lancet Oncology,HER2-positive advanced breast cancer,advanced,"['trastuzumab emtansine (3.6 mg/kg) + atezolizumab (1200 mg)', 'trastuzumab emtansine + placebo']",yes,no,yes,yes,no,yes,"randomised, double-blind, placebo-controlled, phase 2",202,atezolizumab,8.5,,,PD-L1,,yes,previously treated,trastuzumab emtansine,no,"Asia, Australia, North America, western Europe","{'thrombocytopenia_grade3plus': 0.13, 'increased aspartate aminotransferase_grade3plus': 0.08, 'anaemia_grade3plus': 0.05, 'neutropenia_grade3plus': 0.05, 'increased alanine aminotransferase_grade3plus': 0.05}",,PD-L1 status,clinical trial,0 or 1,no
8,"Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study",10.1158/1078-0432.CCR-20-1170,2020,Clinical Cancer Research,Head and Neck Squamous Cell Carcinoma,Recurrent or Metastatic,[],yes,no,yes,no,yes,yes,Phase 1b,36,"Talimogene laherparepvec, Pembrolizumab",5.8,,,no,,eligible,,Talimogene laherparepvec + Pembrolizumab,no,,,,,,,
9,Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial,10.1001/jamaoncol.2020.2955,2020,JAMA Oncology,Oral Cavity Squamous Cell Carcinoma,"T2 or greater T stage, node-positive","['nivolumab', 'nivolumab + ipilimumab']",yes,no,yes,no,yes,yes,randomized phase 2 clinical trial,29,"nivolumab, ipilimumab",14.2,,,yes,,eligible,neoadjuvant,nivolumab + ipilimumab,no,not specified,,,Multiplex immunofluorescence was used to evaluate primary tumor immune markers.,interventional,,no
10,"Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial",10.1001/jamaoncol.2020.3370,2020,JAMA Oncology,Gastric/Gastroesophageal Junction (G/GEJ) cancer,Advanced,"['pembrolizumab', 'pembrolizumab plus chemotherapy', 'chemotherapy plus placebo']",yes,no,yes,no,yes,yes,"Randomized, controlled, partially blinded interventional trial",763,Pembrolizumab,29.4,,,PD-L1 CPS,,eligible,First-line,Pembrolizumab plus chemotherapy (cisplatin + fluorouracil or capecitabine),no,29 countries,,,"PD-L1 CPS of 1 or greater, PD-L1 CPS of 10 or greater",Clinical Trial,,
11,"Updated results from the randomized phase 2 trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The caracas study",10.1177/0300891620953388,2020,Tumori,squamous cell anal carcinoma,locally advanced or metastatic,"['avelumab', 'avelumab plus cetuximab']",yes,no,no,no,yes,yes,randomized phase 2,60,avelumab,11,,,no,,eligible,second line or later,avelumab + cetuximab,no,,,,,clinical trial,,
12,"Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx",10.1159/000510995,2020,Oncology Research and Treatment,Non-Hodgkin lymphoma,first relapse or progression,['Nivolumab + (R)-GemOx'],yes,no,yes,yes,no,no,safety run-in cohort,16,Nivolumab,,,,no,,eligible,,(R)-GemOx,no,,"{'rash': 2, 'pneumonitis': 1, 'leptomeningeal vasculitis': 1}",,,clinical trial,,
13,"FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab (N+I) for treatment-refractory advanced renal cell carcinoma (aRCC)",10.1159/000510995,2020,Oncology Research and Treatment,Renal Cell Carcinoma,advanced,[],yes,no,yes,yes,no,yes,"randomized, open-label, phase 2",46,"Nivolumab, Ipilimumab",8.9,47.8,,no,,eligible,post-CPI progression,Nivolumab + Ipilimumab,anti-PD-(L)1,,"{'rash': 19.6, 'diarrhea': 17.4, 'alanine aminotransferase increased': 8.7}",,,clinical trial,,no
14,Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma,10.1056/NEJMoa2002788,2020,New England Journal of Medicine,Urothelial Carcinoma,Advanced or metastatic,"['Avelumab maintenance therapy + best supportive care', 'Best supportive care alone']",yes,no,yes,no,yes,yes,Phase 3 trial,700,Avelumab,,98,47.4,PD-L1,,eligible,First-line maintenance,Avelumab + best supportive care,no,,,,PD-L1 positive,Clinical Trial,,
15,Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study,10.1016/j.annonc.2020.08.1260,2020,Annals of Oncology,Melanoma,Advanced,"['Atezolizumab + Vemurafenib + Cobimetinib', 'Placebo + Vemurafenib + Cobimetinib']",yes,yes,yes,yes,no,yes,"Phase III, Randomized",514,Atezolizumab,18.9,,,BRAFV600 mutation,,yes,First-line,"Vemurafenib, Cobimetinib",no,,"{'rash': 81, 'elevated creatine phosphokinase': 53, 'pyrexia': 49, 'hepatitis': 53, 'diarrhea': 50}","Manageable, with resolution times similar to those with V+C; low to moderate risk of recurrence. Recurrent AESIs are generally mild to moderate in severity with no evidence of cumulative effect.",BRAFV600 mutation-positive,Clinical Trial,,no
16,"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)",10.1016/j.annonc.2020.08.946,2020,Annals of Oncology,Ovarian Cancer,"Advanced or recurrent, platinum-resistant","['Nivolumab', 'Gemcitabine or Pegylated Liposomal Doxorubicin (GEM/PLD)']",yes,no,yes,yes,yes,yes,"Randomized, open-label, phase III",316,Nivolumab,,,22.4,no,,yes,,,no,Japan,"{'diarrhea': 15.4, 'nausea': 12.2, 'pruritus': 12.2, 'rash': 12.2}",,,Clinical Trial,14.2% had ECOG PS score of 1,no
17,"EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)",10.1016/j.annonc.2020.08.1583,2020,Annals of Oncology,NSCLC,advanced,"['cemiplimab 350 mg Q3W', 'cemiplimab 350 mg Q3W + ipilimumab 50 mg Q6W', 'cemiplimab 1050 mg Q3W']",yes,no,yes,yes,no,no,"Phase II, randomized, open-label",28,"cemiplimab, ipilimumab",,,,PD-L1,,eligible,second-line,cemiplimab + ipilimumab,no,,{'increased alanine aminotransferase (Grade >=3)': 0.182},,PD-L1 expression <50%,clinical trial,,no
19,Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis,10.1159/000508901,2020,Liver Cancer,Hepatocellular Carcinoma,Advanced,,no,no,no,no,yes,yes,Retrospective analysis,92,,,,,,,eligible,First-line; Second-line or later,,yes,Korea,,,,Observational,,
20,KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer,10.1634/theoncologist.2020-0067,2020,Oncologist,non-small cell lung cancer,advanced,"['pembrolizumab 2 mg/kg', 'pembrolizumab 10 mg/kg', 'pembrolizumab 200 mg']",yes,no,yes,no,yes,yes,randomized phase I,44,pembrolizumab,7.9,12.0,,no,,eligible,prior treatment failure and/or ineligibility for standard therapy,,no,China,,,,clinical trial,,
22,Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study,10.1016/j.annonc.2020.04.478,2020,Annals of Oncology,non-small-cell lung cancer,III/IV,"['alectinib', 'crizotinib']",no,no,no,no,yes,yes,randomized,303,no,48.2,,,ALK-positive,,eligible,treatment-naive,,no,,,,,clinical trial,,
25,"Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previouslyuntreated patients with BRAFV600 mutation-positiveadvanced melanoma: Primary results from the phase 3IMspire150 trial",10.1158/1538-7445.AM2020-CT012,2020,Cancer Research,Melanoma,IIIc/IV,"['Atezolizumab + Cobimetinib + Vemurafenib', 'Placebo + Cobimetinib + Vemurafenib']",yes,no,yes,yes,no,yes,Randomized Controlled Trial,514,Atezolizumab,18.9,,,BRAFV600 mutation,,eligible,First-line,Atezolizumab + Cobimetinib + Vemurafenib,no,,"{'blood CPK increase': 51.3, 'diarrhea': 42.2, 'rash': 40.9, 'arthralgia': 39.1, 'pyrexia': 38.7, 'ALT increase': 33.9, 'lipase increase': 32.2, 'lipase increase grade 3/4': 20.4, 'blood CPK increase grade 3/4': 20.0, 'ALT increase grade 3/4': 13.0, 'maculopapular rash grade 3/4': 12.6}",Treatment was continued until disease progression or unacceptable toxicity. 12.6% of patients in the A + C + V group and 15.7% in the Pbo + C + V group stopped all treatment because of AEs.,BRAFV600 mutation-positive,Clinical Trial,,no
26,Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer,10.1158/1078-0432.CCR-19-3978,2020,Clinical Cancer Research,Pancreatic Cancer,Metastatic,"['Cy/GVAX followed by CRS-207 with nivolumab (Arm A)', 'Cy/GVAX followed by CRS-207 without nivolumab (Arm B)']",yes,no,yes,no,yes,yes,Randomized controlled trial,93,Nivolumab,,,,yes,,eligible,Second-line,Cyclophosphamide/GVAX Pancreas + Listeria-Mesothelin (CRS-207) +/- Nivolumab,no,,,manageable,"CD8+ T cells, CD68+ myeloid cells",Clinical Trial,,
27,FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma,10.1634/theoncologist.2020-0184,2020,Oncologist,Merkel cell carcinoma,recurrent locally advanced or metastatic,[],yes,no,no,no,no,no,"multicenter, nonrandomized, open-label trial",50,pembrolizumab,,,,no,,eligible,first-line,no,no,,,,,clinical trial,,
28,,10.1634/theoncologist.2020-0561,2020,Oncologist,Hodgkin Lymphoma,Relapsed/Refractory,[],yes,no,no,no,no,yes,,,Pembrolizumab,,,,no,,eligible,,,,,{},,,,,
29,"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study",10.1016/j.annonc.2020.04.001,2020,Annals of Oncology,head and neck squamous cell carcinoma,recurrent/metastatic,"['durvalumab', 'durvalumab plus tremelimumab', 'standard of care (cetuximab, a taxane, methotrexate, or a fluoropyrimidine)']",yes,no,yes,yes,yes,yes,"randomized, open-label phase III",736,"durvalumab, tremelimumab",,,,,,yes,,durvalumab plus tremelimumab,,,"{'hypothyroidism_durvalumab': 11.4, 'hypothyroidism_durvalumab_plus_tremelimumab': 12.2}",,,clinical trial,,
30,"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 Study",10.1200/JCO.20.00793,2020,Journal of Clinical Oncology,Small-cell lung cancer,Extensive-stage,"['Pembrolizumab plus etoposide and platinum (EP)', 'Placebo plus EP']",yes,no,yes,no,yes,yes,"Randomized, double-blind, phase III",453,Pembrolizumab,,,76.7,no,,eligible,First-line,Etoposide and platinum,no,,,,,Clinical Trial,,
31,"Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results",10.1158/1078-0432.CCR-19-3977,2020,Clinical Cancer Research,Oropharyngeal squamous cell carcinoma (OPC),II-IVA,"['durvalumab', 'durvalumab + tremelimumab']",yes,no,yes,no,no,no,Randomized controlled trial,28,"durvalumab, tremelimumab",15.79,,14,yes,,yes,Neoadjuvant,durvalumab + tremelimumab,no,,,,"CD8+ TIL density, PD-L1 expression, p16 status",Clinical Trial,,
32,Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial,10.1001/jamaoncol.2020.1024,2020,JAMA Oncology,Glioblastoma,Recurrent,"['Nivolumab', 'Bevacizumab']",yes,no,yes,no,yes,no,"Randomized, open-label, phase 3 clinical trial",369,Nivolumab,9.5,,18.1,MGMT promoter methylation status,,eligible,First recurrence,,no,Multinational,,,MGMT promoter methylated/unmethylated,Clinical Trial,,
33,"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial",10.1186/s12885-020-07055-1,2020,BMC Cancer,NSCLC,IV,"['SABR + L19-IL2', 'Standard of Care']",no,no,no,no,yes,yes,Randomized controlled open-label phase II trial,126,L19-IL2,,,,yes,,eligible,"1st, 2nd or 3rd line",SABR + L19-IL2,,6 countries,,,,Clinical Trial,,
34,"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial",10.1016/S0140-6736(20)30934-X,2020,The Lancet,Melanoma,IIIc-IV,"['atezolizumab, vemurafenib, and cobimetinib', 'atezolizumab placebo, vemurafenib, and cobimetinib']",yes,no,no,no,no,yes,"Randomized, double-blind, placebo-controlled, phase 3",514,Atezolizumab,18.9,,,BRAFV600 mutation,,eligible,First-line,"Vemurafenib, Cobimetinib",no,20 countries,,,BRAFV600 mutation-positive,Clinical Trial,,
35,Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer,10.1073/pnas.1922867117,2020,Proceedings of the National Academy of Sciences of the United States of America,bladder cancer,,"['atezolizumab monotherapy', 'chemotherapy']",yes,yes,no,yes,yes,no,randomized controlled trial,,atezolizumab (anti-PD-L1),,,,yes,,eligible,,no,,,,,"polygenic risk scores (PRSs) for vitiligo, psoriasis, and atopic dermatitis",,,
38,Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial,10.1001/jamaoncol.2020.0409,2020,JAMA Oncology,Non-Small Cell Lung Cancer,Advanced,"['pembrolizumab plus docetaxel', 'docetaxel alone']",yes,no,yes,yes,yes,yes,Randomized Clinical Trial,78,Pembrolizumab,,,,"EGFR/ALK alteration, PD-L1 status",,eligible,Second-line,Docetaxel,no,,"{'pneumonitis_grade1-2': 23, 'hypothyroidism_any_grade': 28}",No new safety signals were identified.,"EGFR/ALK alteration, PD-L1 status",Phase 2,,
39,Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial,10.1136/jitc-2020-000696,2020,Journal for ImmunoTherapy of Cancer,Triple-negative breast cancer,Advanced,"['Camrelizumab + apatinib (continuous dosing)', 'Camrelizumab + apatinib (intermittent dosing)']",yes,no,yes,no,no,yes,"Open-label, non-comparative, two-arm, phase II trial",40,Camrelizumab,,,26.7,yes,,eligible,Less than three lines of systemic therapy,Apatinib,no,,,,tumor-infiltrating lymphocytes (>10%),Clinical Trial,,
40,"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial",10.1016/S0140-6736(20)30417-7,2020,The Lancet,Melanoma,IV,"['nivolumab plus ipilimumab', 'nivolumab monotherapy', 'placebo']",yes,no,yes,no,no,yes,"Randomized, double-blind, placebo-controlled, phase 2 trial",167,"Nivolumab, Ipilimumab",28.4,,,no,,eligible,Adjuvant,Nivolumab + Ipilimumab,no,Germany,,,,Clinical Trial,,
41,Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma,10.1056/NEJMoa1915745,2020,New England Journal of Medicine,Hepatocellular Carcinoma,Unresectable,"['Atezolizumab plus Bevacizumab', 'Sorafenib']",yes,no,yes,no,yes,yes,"Phase 3, open-label, randomized",501,Atezolizumab,,,56.5,no,,eligible,First-line,Atezolizumab + Bevacizumab,no,Global,{'Hypertension_grade3plus': 15.2},,,Clinical Trial,,
42,COMBINED NIVOLUMAB PLUS IPILIMUMAB THERAPY CAUSE HIGHER GRADE AND EARLIER IMMUNE-RELATED ADVERSE EVENTS HEPATITIS OCCURRENCE THAN SINGLE AGENT THERAPY,10.1016/S0016-5085(20)33929-9,2020,Gastroenterology,"melanoma, renal cell carcinoma, lung cancer",,"['single agent group (Nivolumab, Pembrolizumab, Durvalumab, Tecentriq and Ipilimumab)', 'combined Nivolumab Plus Ipilimumab therapy']",yes,yes,yes,yes,yes,yes,retrospective medical record review study,273,"Nivolumab, Ipilimumab, Pembrolizumab, Durvalumab, Tecentriq",,,,no,,eligible,,Nivolumab + Ipilimumab,,,"{'hepatitis_any_grade_single_agent': 0.15, 'hepatitis_any_grade_combined_agent': 0.42, 'hepatitis_grade3plus_single_agent': 0.073, 'hepatitis_grade3plus_combined_agent': 0.28}",The study mentions the need to understand irAE management of combined therapy and that they keep contact with other department doctors to treat irAE hepatitis as soon as it occurs.,,Observational,,no
43,Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial,10.1001/jamaoncol.2019.6650,2020,JAMA Oncology,Breast Cancer,II/III,"['Pembrolizumab + NACT', 'NACT (control)']",yes,no,no,yes,no,yes,"Phase 2, open-label, multicenter, adaptively randomized platform trial",250,Pembrolizumab,33.6,,,yes,,eligible,Neoadjuvant,Pembrolizumab + Chemotherapy (taxane and anthracycline-based),no,,"{'thyroid abnormalities': 13, 'adrenal insufficiency': 8.7}",,"ERBB2-negative, HR-positive/ERBB2-negative, triple-negative",Clinical Trial,,
44,Durvalumab with or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial,10.1001/jamaoncol.2020.0237,2020,JAMA Oncology,Non-small cell lung cancer,Metastatic,"['durvalumab', 'durvalumab plus tremelimumab', 'platinum-based doublet chemotherapy']",yes,no,yes,no,yes,yes,Randomized Clinical Trial,1118,"Durvalumab, Tremelimumab",,,0.149,yes,,yes,First-line,durvalumab plus tremelimumab,no,Multinational (17 countries),,,"PD-L1 expression, blood tumor mutational burden (bTMB)",Phase 3,,
45,,10.1200/JCO.19.03091,2020,Journal of Clinical Oncology,Urothelial Cancer,Metastatic,"['Pembrolizumab', 'Placebo']",yes,no,yes,no,yes,yes,Randomized Double-Blind Phase II,108,Pembrolizumab,,,,PD-L1 CPS,,eligible,First-line,Chemotherapy followed by immunotherapy maintenance,no,,,,,Clinical Trial,,
46,"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial",10.1016/S1470-2045(20)30011-5,2020,The Lancet Oncology,Hepatocellular Carcinoma,Advanced,"['Camrelizumab 3 mg/kg IV every 2 weeks', 'Camrelizumab 3 mg/kg IV every 3 weeks']",yes,no,yes,no,yes,no,"Randomized, open-label, parallel-group, phase 2",217,Camrelizumab,12.5,,22.0,no,,yes,Previously treated,no,no,China,,,,Clinical Trial,0-1,
47,Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101,10.1111/cas.14294,2020,Cancer Science,Renal Cell Carcinoma,Advanced,"['Avelumab + Axitinib', 'Sunitinib']",yes,no,yes,yes,yes,yes,Randomized Controlled Trial,67,Avelumab,,,,PD-L1,,eligible,First-line,Avelumab + Axitinib,no,Japan,"{'hand-foot syndrome any grade': 64, 'hand-foot syndrome grade 3+': 9, 'hypertension any grade': 55, 'hypertension grade 3+': 30, 'hypothyroidism any grade': 55, 'hypothyroidism grade 3+': 0, 'dysgeusia any grade': 21, 'dysgeusia grade 3+': 0, 'platelet count decreased any grade': 3, 'platelet count decreased grade 3+': 0}",,PD-L1+,Subgroup analysis,,
48,Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma,10.1158/1078-0432.CCR-19-2443,2020,Clinical Cancer Research,"Gastric cancer, Gastroesophageal junction (GEJ) cancer",Advanced,"['durvalumab plus tremelimumab (arm A)', 'durvalumab (arm B)', 'tremelimumab monotherapy (arm C)', 'durvalumab plus tremelimumab (arm D)', 'durvalumab plus tremelimumab with IFNγ gene signature (arm E)']",yes,no,yes,no,yes,yes,"Randomized, multicenter, open-label, phase Ib/II",113,"Durvalumab, Tremelimumab",,,,yes,,eligible,"Second-line, Third-line",Durvalumab + Tremelimumab,no,,,No new safety signals were identified.,IFNγ gene signature,Clinical Trial,,no
49,"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial",10.1016/j.annonc.2019.10.021,2020,Annals of Oncology,small-cell lung cancer,extensive-stage,"['atezolizumab + carboplatin + etoposide', 'placebo + carboplatin + etoposide']",yes,no,yes,yes,yes,yes,randomized phase I/III trial,394,atezolizumab,,28,,no,,eligible,first-line,carboplatin + etoposide,no,,"{'rash': 11, 'hypothyroidism': 4}",interruption and withdrawal rates reported,,clinical trial,,yes
50,A Pilot Study of Radiation Therapy in Combination with Pembrolizumab in Patients with Metastatic Renal Cell Cancer,10.1097/COC.0000000000000636,2020,American Journal of Clinical Oncology: Cancer Clinical Trials,Renal Cell Cancer,Metastatic,,yes,no,yes,no,yes,yes,Pilot Study,12,Pembrolizumab,,,,PD-L1,,eligible,post-antiangiogenic therapy,Radiation Therapy,no,,,,,Interventional,,
51,Pre-operative pembrolizumab (pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC),10.1158/1538-7445.SABCS19-P3-09-09,2020,Cancer Research,Triple-negative breast cancer (TNBC),II/III,,yes,no,yes,yes,no,no,Single-institution pilot study,20,Pembrolizumab,,,,Tumor infiltrating lymphocyte (TIL) score,,eligible,Neoadjuvant,Pembrolizumab + Radiation Therapy + Chemotherapy,no,,"{'colitis_grade4': 0.055, 'nausea_grade1_2': 0.167, 'arthralgia_grade1_2': 0.667, 'fatigue_grade1_2': 0.556, 'maculopapular_rash_grade1_2': 0.055, 'diarrhea_grade1_2': 0.055, 'mucositis_grade1_2': 0.055}",,,Clinical Trial,,no
52,VEDOLIZUMAB FOR STEROID & INFLIXIMAB-REFRACTORY ICI-COLITIS,10.1093/jcag/gwz047.232,2020,Journal of the Canadian Association of Gastroenterology,Melanoma,,[],yes,no,yes,yes,no,no,Case Report,1,"Nivolumab, Ipilimumab",,,1.3,no,,yes,Adjuvant,Nivolumab +/- Ipilimumab,,,{'colitis_grade3plus': 1.3},Vedolizumab for steroid and infliximab-refractory ICI-colitis,,,,
53,"Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial",10.1007/s10147-019-01545-4,2020,International Journal of Clinical Oncology,Urothelial cancer,Advanced/metastatic,"['Pembrolizumab', 'Chemotherapy (paclitaxel, docetaxel, or vinflunine)']",yes,no,yes,no,yes,yes,"Open-label, randomized, active-controlled",52,Pembrolizumab,26.1,,,no,,eligible,Second-line,no,no,Japan,,,,Subgroup analysis of a Phase 3 trial,,
54,Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study,10.1080/2162402X.2020.1744898,2020,OncoImmunology,non-small cell lung cancer,IV,[],yes,no,yes,no,yes,no,"prospective, non-interventional",1420,nivolumab,18,,0.082,yes,,eligible,second-line or ≥third-line,,no,France,,,EGFR mutation status,observational,0-1,
55,Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer,10.1007/s10120-019-00970-8,2020,Gastric Cancer,Gastric/Gastroesophageal junction cancer,Advanced,"['Nivolumab', 'Placebo']",yes,no,no,no,yes,yes,"Randomized, double-blind, placebo-controlled, phase 3 multicenter trial",493,Nivolumab,,,,HER2 status (surrogate: prior trastuzumab use),,eligible,Third- or later-line,,,,,,,Clinical Trial,,
57,Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (Pembro) in patients with advanced hepatocellular carcinoma (HCC),10.1200/JCO.2020.38.4_suppl.518,2020,Journal of Clinical Oncology,Hepatocellular Carcinoma,Advanced,[],yes,no,yes,yes,yes,yes,Phase II,104,Pembrolizumab,31.2,73.1,26.0,no,,eligible,Second-line,,no,,{'Immune-mediated hepatitis': 2.9},,,,0-1,
58,Long-term follow-up of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC): The phase 3 Check Mate 025 trial,10.3233/KCA-200001,2020,Kidney Cancer,renal cell carcinoma,advanced,"['nivolumab', 'everolimus']",yes,no,yes,no,yes,yes,randomized controlled trial,821,nivolumab,51,,,no,,yes,previously treated,no,no,,,,,clinical trial,,no
59,The clinical activity and safety of anlotinib combined with anti-PD-1 antibodies in patients with advanced solid tumors,10.1200/JCO.2020.38.15_suppl.e15081,2020,Journal of Clinical Oncology,"lung, gallbladder, endometrial, gastric, pancreatic, penile cancers and melanoma",advanced,,yes,no,yes,no,no,no,,21,anti-PD-1 antibodies,,57.1,14.3,no,,eligible,,anlotinib + anti-PD-1 antibodies,,,"{'hand-foot syndrome grade 3': 1, 'hypertension grade 3': 2}",,,,,
60,"FRACTION-RCC: Innovative, highthroughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)",10.1200/JCO.2020.38.15_suppl.5007,2020,Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,[],yes,no,yes,yes,no,yes,"Open-label, randomized, phase 2",46,Nivolumab + Ipilimumab,8.9,47.8,,no,,eligible,Post-checkpoint inhibitor progression,Nivolumab + Ipilimumab,yes,,"{'rash': 19.6, 'diarrhea': 17.4, 'alanine aminotransferase increased': 8.7}",,,Clinical Trial,,
61,,10.1200/JCO.2020.38.15_suppl.6071,2020,Journal of Clinical Oncology,Ovarian Cancer,Advanced,"['nab-paclitaxel + cisplatin + sintilimab + inhalable MnCl', 'nab-paclitaxel + cisplatin + sintilimab']",yes,no,yes,no,yes,yes,"Randomized, Open-label, Phase II",27,Sintilimab,,,,,,eligible,Platinum-resistant/refractory,Chemoimmunotherapy,,,,,,Clinical Trial,,
62,,10.1200/JCO.2020.38.15_suppl.4051,2020,Journal of Clinical Oncology,squamous cell anal carcinoma,locally advanced or metastatic,"['avelumab alone', 'avelumab + cetuximab']",yes,no,yes,no,yes,yes,randomized phase 2 trial,60,avelumab,8.7,,,no,,eligible,second line or later,avelumab + cetuximab,no,,,,,clinical trial,,
63,A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01),10.1200/JCO.2020.38.15_suppl.4582,2020,Journal of Clinical Oncology,Biliary tract cancer,Advanced unresectable or metastatic,"['Nivolumab + Gemcitabine/Cisplatin', 'Nivolumab + Ipilimumab']",yes,no,no,no,yes,yes,Randomized Phase II,71,"Nivolumab, Ipilimumab",,,,yes,,eligible,First-line,"Chemotherapy + Immunotherapy, Immunotherapy + Immunotherapy",no,US,,,whole exome/transcriptome and immune cell subsets,Clinical Trial,0-1,
64,Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive stage small cell lung cancer (ESSCLC): ECOG-ACRIN EA5161,10.1200/jco.2020.38.15_suppl.9000,2020,Journal of Clinical Oncology,small cell lung cancer,extensive stage,"['nivolumab + CE', 'CE']",yes,no,yes,no,yes,yes,randomized phase II,160,nivolumab,,,,no,,eligible,first line,chemotherapy,no,,,,,clinical trial,0 or 1,
65,,10.1200/jco.2020.38.15_suppl.9011,2020,Journal of Clinical Oncology,non-small cell lung cancer,early stage,,yes,no,yes,yes,no,no,Phase I,20,atezolizumab,,,,PD-L1 expression,,eligible,,atezolizumab + SABR,no,,{'rash_grade3': 0.05},,,,,
66,,10.1200/jco.2020.38.15_suppl.9567,2020,Journal of Clinical Oncology,NSCLC,metastatic,"['Pembrolizumab monotherapy', 'Pembrolizumab + Vorinostat']",yes,no,yes,yes,yes,yes,"Randomized, open-label, phase II",49,Pembrolizumab,,,,"PD-L1, CD8+ TIL",,yes,first-line,Pembrolizumab + Vorinostat,no,,"{'hepatitis_grade3plus': 1, 'pneumonitis_grade3plus': 2, 'rash_grade3plus': 1}",,PD-L1 expression ≥ 1%,Clinical Trial,0/1,no
67,,10.1200/jco.2020.38.15_suppl.9035,2020,Journal of Clinical Oncology,NSCLC,"early stage (T1-T3: < 7 cm, including multi-primary tumors), isolated recurrence","['SABR', 'I-SABR (SABR + Nivolumab)']",yes,no,yes,yes,no,no,randomized phase II,92,Nivolumab,14.5,,,no,,eligible,,SABR + Nivolumab,no,,"{'dyspnea_grade3': 1, 'skin_rash_grade3': 1, 'fatigue_grade3': 2, 'pneumonitis_grade2': 2, 'fatigue_grade2': 2, 'pruritus_grade2': 2, 'hyperthyroidism_grade2': 1, 'arthralgia_grade2': 1}",All symptoms resolved with or without treatment.,,clinical trial,,
69,Non-pneumonitis immunemediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC),10.1200/jco.2020.38.15_suppl.9048,2020,Journal of Clinical Oncology,NSCLC,III,"['durvalumab', 'placebo']",yes,yes,yes,yes,no,no,double blind trial,709,durvalumab,,11.0,11.0,no,,eligible,,durvalumab after chemoradiotherapy,no,,"{'thyroid disorders': 11.0, 'rash/dermatitis': 2.0, 'diarrhea/colitis': 1.0}","endocrine replacement therapy (73%), systemic corticosteroids (34%), high dose corticosteroids (16%), and discontinuation (10%)",,,,
70,Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018,10.1200/JCO.2020.38.15_suppl.e19310,2020,Journal of Clinical Oncology,Melanoma,Metastatic,"['pembrolizumab', 'ipilimumab', 'nivolumab', 'ipilimumab + nivolumab']",yes,yes,no,yes,yes,no,Retrospective,2322,"Pembrolizumab, Ipilimumab, Nivolumab",,,,no,,yes,1st line,Ipilimumab + Nivolumab,no,England,"{'colitis_ipinivo': 0.25, 'colitis_pembro': 0.04}",Efficient and effective management of complications,,Real-world data,yes,no
72,,10.1200/JCO.2020.38.15_suppl.10015,2020,Journal of Clinical Oncology,Melanoma,III,"['2x IPI3+NIVO1 Q3W', '2x IPI1+NIVO3 Q3W', '2x IPI3 Q3W followed by 2x NIVO3 Q2W']",yes,no,yes,yes,no,yes,Phase 2 multi-center randomized trial,86,"Ipilimumab, Nivolumab",24.6,,20.0,no,,eligible,Neoadjuvant,Ipilimumab + Nivolumab,no,,"{'vitiligo': 35.0, 'fatigue': 14.0, 'sicca syndrome': 11.0, 'rash': 10.0, 'arthralgia': 7.0, 'endocrine toxicities': 20.0}",17 pts need hormone replacement therapy: 11 (14%) thyroid hormone and 7 (9%) hydrocortisone.,,Clinical Trial,,
73,Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: Analysis of Japanese patients in CheckMate 214 with extended follow-up,10.1093/jjco/hyz132,2019,Japanese Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['Nivolumab + Ipilimumab', 'Sunitinib']",yes,no,yes,no,yes,yes,Randomized Controlled Trial,1096,"Nivolumab, Ipilimumab",30,,58,no,,yes,First-line,Nivolumab + Ipilimumab,no,Japan,,,,Clinical Trial,,
74,Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study,10.1111/1346-8138.15103,2019,Journal of Dermatology,Melanoma,III/IV,"['Nivolumab', 'Ipilimumab']",yes,no,no,no,no,yes,Subgroup analysis of a phase 3 trial,28,"Nivolumab, Ipilimumab",,,,no,,eligible,Adjuvant,no,no,Japan,,,,Clinical Trial,,
75,Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130),10.1093/jjco/hyz135,2019,Japanese Journal of Clinical Oncology,triple-negative breast cancer,advanced,"['atezolizumab + nab-paclitaxel', 'placebo + nab-paclitaxel']",yes,no,no,no,yes,yes,randomized Phase 3,65,atezolizumab,,,,PD-L1,,yes,first-line,nab-paclitaxel,no,Japan,,,PD-L1-positive,subgroup analysis,,
76,"Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma",10.1182/blood-2019-129347,2019,Blood,Non-Hodgkin Lymphoma,First Relapse or Progression,['Nivolumab plus (R)-GemOx'],yes,no,yes,yes,no,no,"Safety run-in phase of a randomized, open-label study",16,Nivolumab,,,,no,,eligible,first relapse or progression,"Gemcitabine, Oxaliplatin (GemOx) plus Rituximab (R)",no,,"{'rash_grade_3_4': 2, 'pneumonitis_grade_2': 1, 'leptomeningeal_vasculitis_grade_4': 1}",Treatment discontinuation due to leptomeningeal vasculitis,,clinical trial,,no
77,Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study,10.1182/blood-2019-124339,2019,Blood,Multiple Myeloma,Relapsed/Refractory,"['Nivolumab-Daratumumab (ND)', 'Nivolumab-Daratumumab-Cyclophosphamide (NDc)']",yes,no,yes,yes,no,no,Prospective multicenter phase 2 trial,40,"Nivolumab, Daratumumab",8.6,,,no,,yes,≥2 prior therapies,Daratumumab + Nivolumab +/- Cyclophosphamide,no,,{'hypothyroidism': 2},,,Clinical Trial,0-2,no
78,,10.1093/neuonc/noz175.043,2019,Neuro-Oncology,Malignant Glioma,recurrent,"['pembrolizumab alone', 'LITT plus pembrolizumab']",yes,no,yes,yes,no,yes,Phase 1/2,9,Pembrolizumab,,,,,,eligible,,LITT,no,,"{'rash': 0.11, 'diarrhea': 0.11, 'pneumonitis': 0.11, 'hypotension': 0.11}",,,,,
80,Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study],10.1111/ajco.13263,2019,Asia-Pacific Journal of Clinical Oncology,Merkel Cell Carcinoma,metastatic,"['avelumab + 177Lu-DOTA-octreotate (LuTate)', 'avelumab + external beam radiation therapy (EBRT)']",no,no,no,no,no,yes,"prospective, open-labelled, multiinstitutional, three-arm, phase Ib/II trial",,avelumab,,,,yes,,eligible,,177Lu-DOTA-octreotate (LuTate) or external beam radiation therapy (EBRT),,Australia,,,somatostatin receptor (SSTR) expression,clinical trial,,
81,"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial",10.1016/S1470-2045(19)30413-9,2019,The Lancet Oncology,Renal Cell Carcinoma,Advanced/Metastatic,"['Nivolumab plus ipilimumab', 'Sunitinib']",yes,no,yes,yes,yes,yes,"Randomised, controlled, phase 3 trial",1096,"Nivolumab, Ipilimumab",32.4,,,no,,eligible,First-line,Nivolumab + Ipilimumab,no,28 countries,"{'increased lipase (grade 3-4)': 0.1, 'increased amylase (grade 3-4)': 0.06, 'increased alanine aminotransferase (grade 3-4)': 0.05}",,,Clinical Trial,,
82,MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226,10.1016/j.jtho.2019.08.586,2019,Journal of Thoracic Oncology,NSCLC,advanced,,yes,yes,yes,yes,yes,yes,Phase IB,73,"durvalumab, tremelimumab",,,,PD-L1,,eligible,,platinum-doublet chemotherapy,no,,"{'fatigue_any_grade': 64, 'rash_any_grade': 42, 'diarrhea_colitis_any_grade': 34, 'anorexia_any_grade': 22, 'thyroid_dysfunction_any_grade': 19, 'nausea_any_grade': 21, 'vomiting_any_grade': 12, 'diarrhea_colitis_grade3plus': 11, 'fatigue_grade3plus': 10, 'rash_grade3plus': 5}",,"PD-L1 status, EGFR mutations",multi-centre,,
83,OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer,10.1016/j.jtho.2019.08.423,2019,Journal of Thoracic Oncology,Squamous Cell Lung Cancer,IV,"['nivolumab and ipilimumab (N+I)', 'nivolumab (N)']",yes,no,yes,no,yes,yes,Phase III randomized trial,252,"Nivolumab, Ipilimumab",17.4,,,"PD-L1, TMB",,eligible,previously treated,Nivolumab + Ipilimumab,immunotherapy-naïve,,,,,,0-1,
84,MA02.07 A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer,10.1016/j.jtho.2019.08.507,2019,Journal of Thoracic Oncology,Non-Small Cell Lung Cancer,Early Stage,[],yes,no,yes,yes,no,no,3+3 dose finding design,15,atezolizumab,,,,no,,eligible,"neoadjuvant, concurrent, and adjuvant",atezolizumab + SABR,no,,"{'rash': 3, 'lymphopenia': 3, 'pneumonitis': 2, 'hypothyroidism': 2, 'hyperthyroidism': 2}",,,Phase I,<=2,no
85,Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH),10.1093/annonc/mdz252.010,2019,Annals of Oncology,squamous cell carcinoma of head and neck,locally advanced,"['IMRT + high dose cisplatin', 'IMRT + cetuximab', 'IMRT + cetuximab + avelumab']",yes,no,yes,no,no,no,randomized multicenter phase III trial,82,avelumab,,,12,no,,eligible,,avelumab + cetuximab + radiotherapy,no,,,,,clinical trial,,
86,"BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study",10.1093/annonc/mdz246.011,2019,Annals of Oncology,Colorectal cancer,Metastatic,"['Capecitabine + Bevacizumab + Placebo (Arm A)', 'Capecitabine + Bevacizumab + Atezolizumab (Arm B)']",yes,no,yes,yes,yes,yes,"Randomized, double-blind, multicenter, placebo-controlled phase II",128,Atezolizumab,12.35,,,MMR/MSS,,eligible,Refractory,"Capecitabine, Bevacizumab",no,,"{'Hypertension_grade3plus': 0.09, 'Hand-foot syndrome_grade3plus': 0.06, 'Diarrhea_grade3plus': 0.07}",No new or increased safety signals are identified.,MMR proficient or MSS,Clinical Trial,0,no
87,Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis,10.1093/annonc/mdz249.052,2019,Annals of Oncology,renal cell carcinoma,advanced,"['avelumab + axitinib', 'sunitinib']",yes,no,yes,yes,yes,yes,Randomized Phase III,67,avelumab,,,,PD-L1,,eligible,first-line,avelumab + axitinib,no,Japan,,,PD-L1+,clinical trial,0-1,no
88,CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC),10.1093/annonc/mdz394.044,2019,Annals of Oncology,Prostate Cancer,Metastatic Castration Resistant,"['Durvalumab', 'Durvalumab + Tremelimumab']",yes,no,yes,yes,no,no,Randomized Phase II,52,"Durvalumab, Tremelimumab",,,,yes,,eligible,,Durvalumab + Tremelimumab,no,Canada,"{'fatigue_any_grade': 46, 'anorexia_any_grade': 28, 'rash_any_grade': 24, 'diarrhea_any_grade': 23, 'nausea_any_grade': 21, 'vomiting_any_grade': 18, 'thyroid_dysfunction_any_grade': 15, 'LFTs_grade3plus': 8, 'diarrhea_grade3plus': 8}",Six patients discontinued treatment due to AEs.,"PD-L1/CD8 IHC, cfDNA",Interventional,0-1,Pain improved in three of four patients with OR.
89,"A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report",10.1093/annonc/mdz255.010,2019,Annals of Oncology,Merkel cell carcinoma,metastatic or recurrent,"['Nivolumab + Ipilimumab', 'Nivolumab + Ipilimumab + SBRT']",yes,no,yes,yes,no,no,"Randomized, Phase II",16,"Nivolumab, Ipilimumab",,,,no,,eligible,,Nivolumab + Ipilimumab,yes,,"{'myocarditis_G3': 1, 'colitis_G3': 1, 'arthritis_G2': 1, 'cough_G2': 1, 'dermatitis_G2': 3, 'neurotoxicity_G2': 1, 'blurred vision_G2': 1, 'abdominal pain_G2': 1, 'hypothyroidism_G2': 2, 'renal insufficiency_G2': 1}",1 patient was taken off the trial due to toxicity.,,clinical trial,0-1,no
90,Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial,10.1001/jamaoncol.2019.1588,2019,JAMA Oncology,Pancreatic Ductal Adenocarcinoma,Metastatic,"['durvalumab plus tremelimumab', 'durvalumab monotherapy']",yes,no,yes,no,no,no,Phase 2 randomized clinical trial,65,"Durvalumab, Tremelimumab",,,,yes,,eligible,Second-line,durvalumab + tremelimumab,no,multicenter (6 countries),,,"PD-L1 expression, microsatellite instability status",Clinical Trial,,
91,CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC),10.1093/annonc/mdz394.044,2019,Annals of Oncology,Prostate Cancer,Metastatic Castration-Resistant Prostate Cancer (mCRPC),"['Durvalumab', 'Durvalumab + Tremelimumab']",yes,no,yes,yes,no,no,Randomized Phase II,52,"Durvalumab, Tremelimumab",,,,"PD-L1/CD8 IHC, 74-gene panel sequencing of plasma cell-free DNA (cfDNA)",,eligible,,Durvalumab + Tremelimumab,no,,"{'fatigue': 46, 'anorexia': 28, 'rash': 24, 'diarrhea': 23, 'nausea/vomiting': 21, 'thyroid dysfunction': 15, 'LFTs (grade 3/4)': 8, 'diarrhea (grade 3/4)': 8}",Six patients discontinued treatment due to AEs.,,Clinical Trial,0/1,
92,,10.1093/annonc/mdz249.052,2019,Annals of Oncology,renal cell carcinoma,advanced,"['avelumab + axitinib', 'sunitinib']",yes,no,yes,no,yes,yes,Randomized phase III trial,67,avelumab,,,,PD-L1,,eligible,first-line,avelumab + axitinib,no,Japan,,,PD-L1+,,≤1,
94,Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH),10.1093/annonc/mdz252.010,2019,Annals of Oncology,Head and Neck Squamous Cell Carcinoma,Locally advanced,"['IMRT + Cisplatin', 'IMRT + Cetuximab', 'IMRT + Cetuximab + Avelumab']",yes,no,yes,no,no,yes,Randomized controlled trial,82,Avelumab,,,12.0,no,,eligible,,Avelumab + Cetuximab + Radiotherapy,no,,,,,Phase 3,,
95,"A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report",10.1093/annonc/mdz255.010,2019,Annals of Oncology,Merkel cell carcinoma,metastatic,"['NIVO + IPI', 'NIVO + IPI + SBRT']",yes,no,yes,yes,no,no,"Randomized, Phase II",16,"Nivolumab, Ipilimumab",,,,no,,eligible,,Nivolumab + Ipilimumab,yes,,"{'myocarditis_grade3plus': 1, 'colitis_grade3plus': 1, 'arthritis_grade2': 1, 'cough_grade2': 1, 'dermatitis_grade2': 3, 'neurotoxicity_grade2': 1, 'blurred_vision_grade2': 1, 'abdominal_pain_grade2': 1, 'hypothyroidism_grade2': 2, 'renal_insufficiency_grade2': 1}",1 patient taken off trial due to toxicity.,,clinical trial,0-1,no
96,Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial,10.1002/cncr.32190,2019,Cancer,squamous cell carcinoma of the head and neck,recurrent or metastatic,[],yes,no,no,no,yes,no,"randomized, open-label, phase 3",240,nivolumab,,,,immune cell biomarkers,,eligible,,,,,,No new safety signals were observed with TBP.,,subgroup analysis,,
97,"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study",10.1016/S1470-2045(19)30388-2,2019,The Lancet Oncology,Melanoma,Advanced,"['Pembrolizumab 10 mg/kg every 2 weeks', 'Pembrolizumab 10 mg/kg every 3 weeks', 'Ipilimumab 3 mg/kg every 3 weeks']",yes,no,yes,yes,yes,yes,"Randomized, controlled, phase 3",834,"Pembrolizumab, Ipilimumab",57.7,,0.17,BRAFV600 status,,eligible,First-line,,no,Multicentre (16 countries),"{'colitis_grade3plus': 0.02, 'diarrhoea_grade3plus': 0.02, 'fatigue_grade3plus': 0.0}",,,Clinical Trial,0-1,no
98,"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies",10.1016/j.lungcan.2019.07.004,2019,Lung Cancer,non-small-cell lung cancer,advanced,"['pembrolizumab', 'docetaxel', 'platinum-based chemotherapy']",yes,yes,yes,no,yes,no,pooled analysis of randomized controlled trials,264,pembrolizumab,,24.8,9.4,PD-L1,,eligible,first-line; second-line or later,monotherapy,no,,{},,PD-L1 positive (TPS ≥1% and TPS ≥50%),clinical trial,,no
100,"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial",10.1016/S2352-3026(19)30109-7,2019,The Lancet Haematology,Multiple Myeloma,Newly diagnosed,"['Pembrolizumab plus lenalidomide and dexamethasone', 'Lenalidomide and dexamethasone']",yes,no,yes,no,no,yes,"Randomized, open-label, phase 3 trial",301,Pembrolizumab,6.6,,,no,,yes,First-line,Lenalidomide and dexamethasone,no,"Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, New Zealand, Norway, Russia, South Africa, Spain, UK, USA",,,,Clinical Trial,0 or 1,no
101,Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial,10.1001/jamaoncol.2019.1478,2019,JAMA Oncology,Non-Small Cell Lung Cancer,Advanced,"['Pembrolizumab alone', 'Pembrolizumab after stereotactic body radiotherapy']",yes,no,no,no,yes,yes,"Multicenter, randomized phase 2 study",92,Pembrolizumab,,,,PD-L1,,yes,,Radiotherapy,no,,,,,Clinical Trial,,
102,"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study",10.1016/S1470-2045(19)30274-8,2019,The Lancet Oncology,Melanoma,III/IV,"['epacadostat plus pembrolizumab', 'placebo plus pembrolizumab']",yes,no,yes,no,yes,yes,"randomized, placebo-controlled, double-blind, parallel-group, phase 3",706,pembrolizumab,12.4,,,"PD-L1 expression, BRAFV600 mutation status",,eligible,previously untreated with PD-1 or PD-L1 checkpoint inhibitors,epacadostat plus pembrolizumab,no,international,{'lipase increase grade 3 or worse': 0.04},,,clinical trial,0 or 1,no
103,,10.1007/s00270-019-02282-x,2019,CardioVascular and Interventional Radiology,Hepatocellular Carcinoma,Advanced,,yes,no,yes,yes,no,no,"Single-arm, two-stage Phase II",11,Nivolumab,,,,no,,eligible,,Y90-radioembolization + Nivolumab,,Asia,"{'Steven Johnson syndrome': 1, 'Grade 3 fever': 1, 'Grade 3/4 ALT/AST rise': 1}",,,Clinical Trial,0,
104,A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study,10.1093/annonc/mdz158,2019,Annals of Oncology,Triple-negative breast cancer,cT1b-cT4a-d,"['durvalumab + nab-paclitaxel + EC', 'placebo + nab-paclitaxel + EC']",yes,no,yes,yes,no,no,"Randomized, phase II, double-blind, placebo-controlled",174,Durvalumab,,47,,yes,,eligible,Neoadjuvant,"nab-paclitaxel, EC",no,,{'thyroid dysfunction': 47},,"sTILs, PD-L1",Clinical Trial,,no
106,"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial",10.1016/S1470-2045(19)30027-0,2019,The Lancet Oncology,Colorectal Cancer,Metastatic,"['atezolizumab plus cobimetinib', 'atezolizumab monotherapy', 'regorafenib']",yes,no,yes,no,yes,no,Randomized Controlled Trial,363,Atezolizumab,7.3,,,Microsatellite instability,,yes,Third-line,Atezolizumab + Cobimetinib,no,Multi-country,,,Microsatellite-stable,Clinical Trial,0-1,no
107,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up",10.1093/annonc/mdz127,2019,Annals of Oncology,Urothelial Cancer,Advanced,"['Pembrolizumab', 'Paclitaxel', 'Docetaxel', 'Vinflunine']",yes,no,yes,no,yes,yes,Randomized Phase III,542,Pembrolizumab,27.7,62,16.5,no,,eligible,Second-line,no,no,,,,,Clinical Trial,,
109,Immunotherapy-induced bronchitis/bronchiolitis: A new pattern of lung toxicity of immune checkpoint inhibitors,10.1159/000499887,2019,Respiration,,,,yes,no,no,yes,no,no,Case Report,2,"nivolumab, ipilimumab",,,,no,,eligible,,nivolumab +/- ipilimumab,,,,"ICIs were stopped in both cases and high-dose prednisone was administered, together with inhaled corticosteroids and bronchodilators.",,,,
110,"Extended follow-up of a phase i trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: A trial of the ecog-acrin research group (E4412)",10.1002/hon.83_2629,2019,Hematological Oncology,Hodgkin lymphoma,Relapsed/refractory,"['B-I (Brentuximab vedotin + Ipilimumab)', 'B-N (Brentuximab vedotin + Nivolumab)', 'B-N-I (Brentuximab vedotin + Nivolumab + Ipilimumab)']",yes,no,yes,yes,yes,yes,Phase 1,61,"Ipilimumab, Nivolumab",35.76,,,no,,eligible,,"Brentuximab vedotin + Ipilimumab, Brentuximab vedotin + Nivolumab, Brentuximab vedotin + Nivolumab + Ipilimumab",,,"{'pneumonitis_grade5': 2, 'pneumonitis_DLT': 1, 'typhlitis_DLT': 1, 'diabetic_ketoacidosis_grade4': 1, 'hyperglycemia_grade4': 1, 'AST_elevation_grade3': 1, 'GVHD_grade4': 1, 'rash_grade3': 0.12, 'colitis_grade3': 1, 'gastritis_grade3': 1, 'pancreatitis_grade3': 1, 'arthritis_grade3': 1, 'fatigue_any_grade': 0.28, 'transaminitis_any_grade': 0.36, 'rash_any_grade': 0.25, 'peripheral_neuropathy_any_grade': 0.53, 'diarrhea_any_grade': 0.43}",,,Clinical Trial,,no
111,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up",10.1093/annonc/mdz127,2019,Annals of Oncology,Urothelial Cancer,Advanced,"['Pembrolizumab', 'Paclitaxel', 'Docetaxel', 'Vinflunine']",yes,no,yes,no,yes,yes,Randomized Phase III,542,Pembrolizumab,27.7,62.0,16.5,no,,eligible,Second-line,no,no,,,,,Clinical Trial,,
112,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up",10.1093/annonc/mdz127,2019,Annals of Oncology,Urothelial Cancer,Advanced,"['pembrolizumab', 'paclitaxel', 'docetaxel', 'vinflunine']",yes,no,yes,no,yes,yes,Randomized Phase III,542,pembrolizumab,27.7,,,no,,eligible,Second-line,,no,,,,,Clinical Trial,,
113,,10.1093/jjco/hyz026,2019,Japanese Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['Nivolumab', 'Everolimus']",yes,no,yes,no,yes,yes,Randomized Controlled Trial,821,Nivolumab,36,80,,no,,eligible,,,,Japan,,,,,,
114,"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial",10.1016/S0140-6736(18)32409-7,2019,The Lancet,non-small-cell lung cancer,locally advanced or metastatic,"['pembrolizumab', 'platinum-based chemotherapy']",yes,no,yes,no,yes,yes,"randomised, open-label, controlled, phase 3",1274,pembrolizumab,12.8,,18.0,PD-L1 TPS,,eligible,first-line,monotherapy,no,multinational,,,PD-L1 TPS >=1%,clinical trial,0 or 1,no
115,Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081,10.1200/JCO.2019.37.15_suppl.8535,2019,Journal of Clinical Oncology,NSCLC,IIIA/IIIB,"['nivolumab', 'nivolumab + ipilimumab']",yes,yes,yes,yes,no,no,"randomized, multi-center, phase II",20,"nivolumab, ipilimumab",,,,no,,yes,,nivolumab + ipilimumab,no,,"{'pneumonitis_grade2': 3, 'pneumonitis_grade3': 1, 'colitis_grade3': 1, 'pancreatitis_grade3': 1, 'amylase_elevation_grade4': 1}",manageable with established guidelines,,clinical trial,,
116,"A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952)",10.1200/JCO.2019.37.15_suppl.9014,2019,Journal of Clinical Oncology,squamous cell lung cancer,IV,"['nivolumab plus ipilimumab', 'nivolumab']",yes,no,yes,no,yes,yes,randomized trial,252,"nivolumab, ipilimumab",17.4,,,PD-L1,,eligible,previously treated,nivolumab + ipilimumab,immunotherapy-naïve,,,,,Phase III,0-1,no
118,Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC),10.1200/JCO.2019.37.15_suppl.4515,2019,Journal of Clinical Oncology,Renal Cell Carcinoma,Metastatic,"['Atezolizumab', 'Atezolizumab + Bevacizumab', 'Sunitinib']",yes,no,no,no,no,yes,Phase 2,,Atezolizumab,,,,PD-L1,,eligible,First-line,Atezolizumab + Bevacizumab,no,,,,PD-L1+,Clinical Trial,,yes
119,,10.1200/jco.2019.37.15_suppl.e14145,2019,Journal of Clinical Oncology,colorectal cancer,"relapsed/refractory, metastatic","['eFT508 (tomivosertib) alone', 'eFT508 (tomivosertib) in combination with avelumab']",yes,no,yes,no,no,no,"Phase II, open label, randomized, noncomparative study",45,avelumab,,,,microsatellite stable (MSS),,eligible,≥2 prior therapies for metastatic disease,eFT508 (tomivosertib) + avelumab,no,,,,MSS,clinical trial,,
120,A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma,10.1200/jco.2019.37.15_suppl.6082,2019,Journal of Clinical Oncology,Adenoid cystic carcinoma,Recurrent or metastatic,"['Pembrolizumab alone', 'Pembrolizumab with hypofractionated radiation']",yes,no,yes,no,no,yes,Randomized Phase II,20,Pembrolizumab,,,0,PD-L1,,yes,,Radiation,no,,,,,Clinical Trial,,
121,,10.1200/jco.2019.37.15_suppl.5582,2019,Journal of Clinical Oncology,Endometrial Carcinoma,,"['Durvalumab', 'Durvalumab + Tremelimumab']",yes,no,yes,no,no,yes,Phase II,56,"Durvalumab, Tremelimumab",,,,"MSI-H, MSS",,eligible,,Durvalumab + Tremelimumab,,,,,,,,
123,A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST),10.1200/JCO.2019.37.15_suppl.11017,2019,Journal of Clinical Oncology,Gastrointestinal Stromal Tumor (GIST),Advanced/metastatic,"['Nivolumab monotherapy', 'Nivolumab + Ipilimumab']",yes,no,yes,no,no,yes,"Randomized, parallel group, unblinded Phase 2 trial",29,"Nivolumab, Ipilimumab",,,,KIT Exon 17 mutation,,eligible,Second line and beyond (refractory to at least imatinib),Nivolumab + Ipilimumab,no,,,,,Clinical Trial,,
124,,10.1200/JCO.2019.37.15_suppl.e21056,2019,Journal of Clinical Oncology,cutaneous squamous cell cancer of the head and neck,high risk,,yes,no,yes,yes,no,no,Phase II,15,Pembrolizumab,,,0,no,,eligible,postoperative,IMRT,no,,"{'bullous pemphigoid': 1, 'lymphopenia': 1, 'peripheral neuropathy': 1}",Both responded to steroids and recovered completely.,,,,
125,An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238),10.1200/JCO.2019.37.15_suppl.9584,2019,Journal of Clinical Oncology,Melanoma,III/IV,"['Nivolumab', 'Ipilimumab']",yes,yes,no,yes,no,yes,Clinical Trial,453,Nivolumab,,,,no,,eligible,Adjuvant,no,no,,"{'fatigue': 0.28, 'pruritus': 0.16, 'diarrhea': 0.15}","Most TRAEs resolved within 3 months, except endocrine AEs (required hormone supplementation) and skin AEs (median resolution 22 weeks).",,Clinical Trial,,
126,"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study",10.1016/S2213-2600(18)30500-9,2019,The Lancet Respiratory Medicine,non-small-cell lung cancer,advanced,[],yes,no,yes,yes,yes,yes,"multicohort, open-label, phase 1 study",550,pembrolizumab,34.5,,12.0,PD-L1,,eligible,first-line and second-line,,no,,"{'pneumonitis': 2.0, 'fatigue': 1.0}",,PD-L1 tumor proportion score ≥50%,clinical trial,,
127,Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma,10.1056/NEJMoa1816047,2019,New England Journal of Medicine,renal-cell carcinoma,advanced,"['avelumab plus axitinib', 'sunitinib']",yes,no,yes,no,yes,yes,randomized controlled trial,886,avelumab,11.6,99.5,71.2,PD-L1,,eligible,first-line,avelumab + axitinib,no,,,,PD-L1-positive,phase 3,,
128,Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma,10.1056/NEJMoa1816714,2019,New England Journal of Medicine,renal-cell carcinoma,advanced,"['pembrolizumab plus axitinib', 'sunitinib']",yes,no,yes,no,yes,yes,"open-label, phase 3 trial",861,pembrolizumab,12.8,,75.8,yes,,eligible,first-line,pembrolizumab + axitinib,no,,,,programmed death ligand 1 expression,clinical trial,,
129,Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma,10.1016/j.ejca.2018.12.015,2019,European Journal of Cancer,Melanoma,Advanced or metastatic,"['Trametinib', 'Chemotherapy (dacarbazine or paclitaxel)']",no,no,no,no,yes,yes,"Open-label, phase 3, randomized controlled trial",322,Trametinib,,,,BRAF V600 E/K mutation,,yes,,Monotherapy,no,,,,BRAF V600 E/K mutant,Clinical Trial,,
130,,10.1158/2159-8290.CD-18-0774,2019,Cancer Discovery,Acute Myeloid Leukemia,Relapsed/Refractory,[],yes,no,yes,no,yes,no,"Single-arm, phase II",70,Nivolumab,,,0.11,yes,,eligible,,Azacitidine + Nivolumab,no,,,,"CD3, CD8, CTLA4",,,
131,Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial,10.1186/s40425-019-0508-1,2019,Journal for ImmunoTherapy of Cancer,Gastric/Gastroesophageal junction cancer,Advanced,,yes,no,yes,no,yes,yes,Phase 1b expansion cohort,150,Avelumab,36,,8.7,no,,eligible,First-line switch-maintenance or second-line,,no,,"{'infusion-related reaction': 20.7, 'fatigue': 10, 'nausea': 6.7}",,,,,
132,Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032,10.1016/j.jtho.2018.10.003,2019,Journal of Thoracic Oncology,SCLC,limited-stage or extensive-stage,[],yes,no,yes,no,yes,yes,"phase 1/2, multicenter, open-label",109,nivolumab,28.3,,11.9,no,,eligible,third-line or later,,no,,,,,clinical trial,,
134,Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial,10.1001/jamaoncol.2018.4514,2019,JAMA Oncology,Melanoma,III or IV,"['Nivolumab', 'Dacarbazine']",yes,no,yes,no,yes,no,Randomized Phase 3,418,Nivolumab,38.4,,15.0,BRAF mutation status,,eligible,first-line,,no,,,,BRAF wild-type,clinical trial,0 or 1,
135,Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial,10.1001/jamaoncol.2018.4628,2019,JAMA Oncology,Head and Neck Squamous Cell Carcinoma (HNSCC),Recurrent or Metastatic,"['Durvalumab + Tremelimumab', 'Durvalumab monotherapy', 'Tremelimumab monotherapy']",yes,no,yes,no,yes,no,"Phase 2, randomized, open-label",267,"Durvalumab, Tremelimumab",,,0.06,PD-L1,,eligible,after 1 platinum-containing regimen,Durvalumab + Tremelimumab,no,"North America, Europe, Asia Pacific",{},,PD-L1-low/negative,Clinical Trial,,
136,"Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4)",10.1093/annonc/mdy540,2019,Annals of Oncology,Gastric/Gastroesophageal Junction (G/GEJ) cancer,Advanced or recurrent,"['nivolumab + S-1 + oxaliplatin (SOX)', 'nivolumab + capecitabine + oxaliplatin (CapeOX)']",yes,no,yes,yes,yes,yes,"Randomized, Phase II",40,Nivolumab,,,,HER2,,eligible,First-line,Chemotherapy (SOX/CapeOX),no,,"{'neutropenia': 14.3, 'anemia': 11.1, 'peripheral sensory neuropathy': 11.1, 'decreased appetite': 11.1, 'type 1 diabetes mellitus': 11.1, 'nausea': 11.1}",,HER2-negative,Interventional,,
137,ASCO 2019 Meeting Abstracts,,2019,Journal of Clinical Oncology,"Esophageal cancer, Gastric cancer, Gastroesophageal junction adenocarcinoma","Advanced, Metastatic, Locally advanced, Clinical stage I","['Pembrolizumab versus chemotherapy', 'Trifluridine/tipiracil (FTD/TPI) with or without prior gastrectomy', 'Andecaliximab combined with mFOLFOX6 versus placebo', 'Durvalumab following trimodality therapy', 'Esophagectomy versus chemoradiotherapy']",no,no,no,no,no,no,"Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group controlled trial",,"Pembrolizumab, Durvalumab, Andecaliximab",,,,,,no,"Second-line, First-line","Andecaliximab combined with mFOLFOX6, Durvalumab following trimodality therapy",,,,,,Clinical Trial,,
139,Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care,10.1080/15384047.2018.1507260,2019,Cancer Biology and Therapy,Renal Cell Carcinoma,Metastatic,"['Nivolumab + Ipilimumab', 'Sunitinib']",no,no,no,no,yes,no,,,"Nivolumab, Ipilimumab",,,,no,,eligible,First-line,Nivolumab + Ipilimumab,no,,,,,,,
140,Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study,10.1016/j.ejca.2018.11.020,2019,European Journal of Cancer,non-small-cell lung cancer,advanced,"['atezolizumab', 'docetaxel']",yes,no,no,no,yes,no,"randomized, phase III",,atezolizumab,26,,,PD-L1,,eligible,previously treated,,no,,,,,,,
141,Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater,10.1200/JCO.18.00149,2019,Journal of Clinical Oncology,non-small-cell lung cancer,advanced,"['pembrolizumab', 'platinum-based chemotherapy']",yes,no,yes,no,yes,yes,"randomized, open-label, phase III",305,pembrolizumab,25.2,,31.2,PD-L1,,eligible,first-line,monotherapy,no,,,,PD-L1 tumor proportion score of 50% or greater,,,
142,Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 trial,10.1200/JCO.18.01998,2019,Journal of Clinical Oncology,Melanoma,III/IV,"['Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg (NIVO3+IPI1)', 'Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg (NIVO1+IPI3)']",yes,no,yes,no,yes,yes,Randomized controlled trial,360,"Nivolumab, Ipilimumab",12,,0.34,no,,yes,First-line,Nivolumab + Ipilimumab,no,,,,,Phase IIIb/IV,,
143,Clinical analysis for head and neck cancer cases treated with nivolumab in osaka international cancer institute,10.5981/jjhnc.45.46,2019,Japanese Journal of Head and Neck Cancer,Head and Neck Cancer,,[],yes,yes,yes,no,yes,yes,Retrospective,28,Nivolumab,,46.4,7.1,no,,eligible,,Monotherapy,,Japan,{},,,,,
144,,10.1200/JCO.18.02151,2019,Journal of Clinical Oncology,Hodgkin lymphoma,relapsed/refractory,"['camrelizumab monotherapy', 'decitabine plus camrelizumab']",yes,no,no,no,no,no,"Phase II, two-arm, open-label",86,camrelizumab,14.9,,,no,,eligible,at least two lines of previous therapy,decitabine + camrelizumab,yes,,,,,,,
145,Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody,10.1200/JCO.19.00318,2019,Journal of Clinical Oncology,Urothelial cancer,Metastatic or locally advanced,,yes,yes,no,no,yes,no,Retrospective analysis of seven trials,1747,Anti-PD-1/L1 antibodies,,0.64,,no,,eligible,Prior platinum-based therapy or cisplatin ineligible,,,,,ImAEs were defined as AESIs treated with topical or systemic corticosteroids. Systemic corticosteroid use did not appear to affect the duration of response.,,Retrospective analysis,,
146,Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis,10.3892/ol.2018.9724,2019,Oncology Letters,NSCLC,metastatic,"['pembrolizumab monotherapy', 'pembrolizumab + weekly low-dose carboplatin and paclitaxel']",no,no,no,no,no,no,randomized,20,pembrolizumab,,,,yes,,eligible,,chemotherapy,no,,,,"circulating immune cell phenotyping, sPD-L1, immune-modulatory microRNAs",interventional,2,
147,KEYNOTE-022 part 3: Phase 2 randomized study of 1L dabrafenib and trametinib plus pembrolizumab or placebo for BRAF-mutant advanced melanoma,10.1186/s12967-018-1745-7,2019,Journal of Translational Medicine,Melanoma,III/IV,"['pembrolizumab + dabrafenib + trametinib', 'placebo + dabrafenib + trametinib']",yes,no,yes,yes,yes,yes,"Randomized, double-blind, phase 2",120,Pembrolizumab,9.6,43.0,,BRAFV600E/K-mutant,,eligible,First-line,"Dabrafenib, Trametinib",no,,"{'pneumonitis': 15.0, 'hypothyroidism': 8.0, 'skin disorders': 7.0, 'hyperthyroidism': 5.0, 'uveitis': 5.0}",Most resolved with treatment discontinuation/modification.,BRAFV600E/K-mutant,Clinical Trial,0/1,no
148,A changing of the guard: Immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer,10.3389/fonc.2019.00195,2019,Frontiers in Oncology,Non-small cell lung cancer,Metastatic,,no,no,no,no,yes,yes,,,"Pembrolizumab, Atezolizumab",,,,"PD-L1, ALK, EGFR",,eligible,First-line,Chemo-immunotherapy,no,,,,,Review,,
150,The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis,10.3389/fphar.2018.01430,2018,Frontiers in Pharmacology,Advanced Cancer,,"['Immune checkpoint inhibitors', 'Standard therapies']",yes,yes,yes,yes,no,no,Meta-analysis,,PD-1/PD-L1 inhibitors,,,,no,,yes,,,,,"{'pneumonitis_any_grade_NSCLC': 3.1, 'pneumonitis_any_grade_other_tumors': 2.0, 'pneumonitis_grade3plus_NSCLC': 1.4, 'pneumonitis_grade3plus_other_tumors': 0.6}",,,,,
152,Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study,10.1016/j.lungcan.2018.08.019,2018,Lung Cancer,non-small-cell lung cancer,advanced,"['pembrolizumab 2 or 10 mg/kg Q3W + carboplatin AUC 6 mg/mL/min + paclitaxel 200 mg/m2 (cohort A)', 'pembrolizumab 2 or 10 mg/kg Q3W + carboplatin AUC 6 mg/mL/min + paclitaxel 200 mg/m2 + bevacizumab 15 mg/kg (cohort B)', 'pembrolizumab 2 or 10 mg/kg Q3W + carboplatin AUC 5 mg/mL/min + pemetrexed 500 mg/m2 (cohort C)']",yes,no,yes,no,no,no,multicohort phase 1/2 study,74,pembrolizumab,18.4,,,no,,eligible,first-line,platinum-based chemotherapy,no,,,,,clinical trial,,
153,"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial",10.1016/S1470-2045(18)30700-9,2018,The Lancet Oncology,Melanoma,III/IV,"['nivolumab plus ipilimumab', 'nivolumab alone', 'ipilimumab alone']",yes,no,yes,yes,yes,yes,"Randomized, controlled, phase 3 trial",945,"Nivolumab, Ipilimumab",46.9,,,"BRAF mutation status, PD-L1 status",,eligible,First-line,Nivolumab + Ipilimumab,no,,"{'diarrhoea_grade3': 0.09, 'colitis_grade3': 0.07, 'increased_lipase_grade4': 0.05}",,"BRAFV600 mutation status, PD-L1 status",Clinical Trial,0 or 1,no
154,Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma,10.1038/s41591-018-0198-0,2018,Nature Medicine,Melanoma,III,"['neoadjuvant ipilimumab + nivolumab', 'adjuvant ipilimumab + nivolumab']",yes,no,yes,no,no,yes,Randomized controlled trial,20,"Ipilimumab, Nivolumab",25.6,,90,T cell clones,,yes,Adjuvant/Neoadjuvant,Ipilimumab + Nivolumab,no,,,,,Clinical Trial,,
155,,10.1182/blood-2018-99-113685,2018,Blood,Classical Hodgkin Lymphoma,,[],yes,no,yes,yes,yes,yes,"Phase 2, multi-center, single-arm study",30,Pembrolizumab,,36.67,10.0,"PD-1, PD-L1",,yes,Post-ASCT,,no,,"{'pneumonitis_grade2': 6.67, 'pneumonitis_grade3': 3.33, 'thyroid_dysfunction_grade2': 3.33, 'transaminitis_grade3': 6.67, 'colitis/diarrhea_grade2': 3.33, 'colitis/diarrhea_grade3': 6.67, 'rash_grade2': 6.67, 'pulmonary_hemorrhage_grade3': 3.33, 'arthritis_grade2': 3.33, 'increased_creatinine_grade2': 3.33, 'neutropenia_grade4': 10.0, 'diarrhea_grade3': 3.33, 'eosinophilic_colitis_grade3': 3.33, 'leukopenia_grade3': 6.67, 'ALT_elevation_grade3': 3.33, 'AST_elevation_grade3': 3.33}",,,Clinical Trial,,
156,"Pembrolizumab Randomized, Phase 1 Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032",10.1016/j.jtho.2018.08.663,2018,Journal of Thoracic Oncology,NSCLC,advanced,"['pembrolizumab 2 mg/kg', 'pembrolizumab 10 mg/kg', 'pembrolizumab 200 mg']",yes,no,yes,yes,yes,yes,open label phase 1 study,42,pembrolizumab,7.9,69.0,10.0,PD-L1,,eligible,1L and 2L settings,,,China,"{'hypothyroidism': 2, 'hyperthyroidism': 1, 'anaphylactic reaction': 1, 'rash': 1, 'eyelid ptosis': 1, 'fatigue': 1, 'dermatitis acneiform': 1}",,PD-L1 TPS ≥1%,clinical trial,0/1,
157,CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer,10.1200/JCO.2017.76.6212,2018,Journal of Clinical Oncology,Esophagogastric cancer,Metastatic,"['nivolumab 3mg/kg', 'nivolumab 1mg/kg plus ipilimumab 3mg/kg', 'nivolumab 3 mg/kg plus ipilimumab 1 mg/kg']",yes,no,yes,no,yes,yes,Clinical Trial,160,"Nivolumab, Ipilimumab",24.67,,,PD-L1,,yes,Chemotherapy-refractory (after second-line chemotherapy failure),Nivolumab + Ipilimumab,no,"United States, Europe",,,,Clinical Trial,,
159,KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma,10.1093/annonc/mdy289,2018,Annals of Oncology,Melanoma,Stage III/IV,"['pembrolizumab + dabrafenib + trametinib', 'placebo + dabrafenib + trametinib']",yes,no,yes,yes,yes,yes,"Randomized, double-blind, phase 2",120,Pembrolizumab,9.6,43.0,,BRAF V600E/K mutation,,eligible,First-line,Dabrafenib + Trametinib,no,,"{'pneumonitis': 15.0, 'hypothyroidism': 8.0, 'skin disorders': 7.0, 'hyperthyroidism': 5.0, 'uveitis': 5.0}",Most resolved with treatment discontinuation/modification.,BRAF V600E/K-mutant,,0/1,
160,Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma,10.1093/annonc/mdy289.022,2018,Annals of Oncology,Melanoma,Metastatic,"['dabrafenib/trametinib', 'pembrolizumab', 'bemcentinib + dabrafenib/trametinib', 'bemcentinib + pembrolizumab']",yes,no,yes,no,no,no,Randomized Phase Ib/II,23,Pembrolizumab,,,30,yes,,eligible,First-line,Bemcentinib + Dabrafenib/Trametinib; Bemcentinib + Pembrolizumab,no,,{'rash': 3},,AXL upregulation,Interventional,,no
161,Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC),10.1093/annonc/mdy424.059,2018,Annals of Oncology,Non-small cell lung cancer (NSCLC),I-IIIA (single N2),"['Nivolumab', 'Nivolumab plus Ipilimumab']",yes,no,yes,yes,no,no,Randomized Phase 2,33,"Nivolumab, Ipilimumab",,,,yes,,yes,Neoadjuvant,Nivolumab + Ipilimumab,no,,"{'G5 death due to BPF post steroid-treated pneumonitis': 1, 'G3 pneumonia': 1, 'G3 hypoxia': 1, 'G2 cough': 3, 'G2 rash': 1, 'G2 fatigue': 1}",Steroid-treated pneumonitis,"Immune infiltrates (Ki67+, ICOS+, CD8+, CD4+, CD27+, CD28+, CD103+, Tregs)",Clinical Trial,0-1,no
163,Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma,10.1038/s41416-018-0164-0,2018,British Journal of Cancer,renal cell carcinoma,advanced,"['cabozantinib', 'everolimus']",no,no,no,no,yes,yes,Phase 3,,,,,,,,eligible,,,yes,,,,,Clinical Trial,,
164,Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy,10.1053/j.seminoncol.2018.06.003,2018,Seminars in Oncology,Non-small cell lung cancer,Advanced,"['Patients ≥70 years', 'Patients <70 years']",yes,yes,no,no,no,no,Pooled analysis of three randomized controlled trials,,anti-PD-1/PD-L1 therapy,3,,,no,,eligible,,,,,,,,Retrospective analysis,,yes
165,"The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600- mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i",10.1158/1538-7445.AM2018-CT182,2018,Cancer Research,Melanoma,Stage III/IV,,yes,no,yes,yes,no,no,"Phase 3, biomarker cohort",23,Spartalizumab (PDR001),2,91,22,yes,,yes,First-line,Dabrafenib + Trametinib,no,,"{'pyrexia': 61, 'arthralgia': 17, 'fatigue': 17, 'rash': 17, 'vomiting': 17}",Pyrexia managed with dose interruption.,BRAF V600-mutant,Clinical Trial,,no
166,"APACHE: An open label, randomized, phase II study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage",10.1158/1538-7445.AM2018-CT102,2018,Cancer Research,Germ Cell Tumors (GCT),advanced,"['Durvalumab alone', 'Durvalumab plus Tremelimumab']",yes,no,yes,yes,no,no,"open-label, randomized, phase 2",18,"Durvalumab, Tremelimumab",,,5.6,yes,,yes,chemorefractory (failed >=2 chemotherapy regimens),Durvalumab + Tremelimumab,no,,{'pneumonitis': 5.6},,"PD-L1 expression, KRAS amplification",Clinical Trial,,
167,Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer,,2018,clinicaltrials.gov,Pancreatic Cancer,Resectable or Borderline Resectable,[],yes,no,yes,no,yes,yes,Interventional,,Durvalumab,,,,yes,,eligible,Neoadjuvant and Adjuvant,Chemoradiotherapy (CCRT) with Gemcitabine,no,,{},,"immune cells (TIL, macrophage)",Interventional,,
168,Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma,10.1038/s41591-018-0053-3,2018,Nature Medicine,renal cell carcinoma,metastatic,"['atezolizumab', 'atezolizumab + bevacizumab', 'sunitinib']",no,no,no,no,no,yes,randomized phase 2,305,atezolizumab,,,,yes,,eligible,treatment-naive,bevacizumab,no,,,,"PD-L1+, tumor mutation burden, neoantigen burden, angiogenesis, T-effector/IFN-γ response, myeloid inflammatory gene expression signatures",,,
169,"Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab1cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer",10.1093/annonc/mdy208,2018,Annals of Oncology,colorectal cancer,metastatic,"['atezolizumab + cobimetinib', 'atezolizumab monotherapy', 'regorafenib']",yes,no,yes,no,yes,yes,randomised Phase III trial,363,atezolizumab,,,,"MSI status, RAS mutation status",,eligible,chemotherapy-refractory,atezolizumab + cobimetinib,no,,,,"MSS/MSI-L, RAS mutant",clinical trial,,
170,Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden,10.1056/NEJMoa1801946,2018,New England Journal of Medicine,non-small-cell lung cancer (NSCLC),IV or recurrent,"['nivolumab plus ipilimumab', 'nivolumab monotherapy', 'nivolumab plus chemotherapy', 'chemotherapy']",yes,no,yes,no,no,yes,"open-label, multipart, phase 3 trial",,"nivolumab, ipilimumab",,,31.2,yes,,eligible,first-line,nivolumab plus ipilimumab,no,,,,"tumor mutational burden (TMB) >= 10 mutations per megabase, PD-L1 expression",,,
171,,10.1056/NEJMoa1802357,2018,New England Journal of Medicine,Melanoma,III,"['pembrolizumab', 'placebo']",yes,no,yes,yes,no,yes,"Phase 3, double-blind, randomized controlled trial",1019,Pembrolizumab,15,,14.7,PD-L1,,eligible,Adjuvant,,no,,{'myositis_grade_5': 1},,PD-L1 positive,RCT,,
172,Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study,10.1016/S1470-2045(18)30139-6,2018,The Lancet Oncology,Melanoma,Metastatic,"['Nivolumab plus ipilimumab', 'Nivolumab monotherapy']",yes,no,yes,no,yes,no,Multicentre open-label randomised phase 2 trial,79,"Nivolumab, Ipilimumab",17,0.97,0.54,no,,eligible,First-line,Nivolumab + Ipilimumab,no,Australia,,,,Clinical Trial,,
173,Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma,10.1038/s41416-018-0061-6,2018,British Journal of Cancer,Renal Cell Carcinoma,Advanced,"['cabozantinib', 'everolimus']",no,no,no,no,yes,yes,Randomized Controlled Trial,658,,,,,,,eligible,after prior antiangiogenic therapy,,,,,,,,,
174,Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial,10.1001/jamaoncol.2018.0013,2018,JAMA Oncology,Gastric cancer,Advanced,[],yes,no,yes,no,no,no,"Phase 2, open-label, single-arm, multicohort",259,Pembrolizumab,5.8,,17.8,PD-L1,,eligible,Third-line or later,Monotherapy,no,Global,,,,Clinical Trial,,
175,FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response,10.1200/jco.2018.36.15_suppl.8008,2018,Journal of Clinical Oncology,Multiple Myeloma,Relapsed/Refractory; Newly Diagnosed,"['pembrolizumab + pomalidomide + dexamethasone', 'pomalidomide + dexamethasone', 'pembrolizumab + lenalidomide + dexamethasone', 'lenalidomide + dexamethasone']",yes,yes,no,no,yes,no,Randomized Controlled Trial,550,Pembrolizumab,8.1,0.58,,no,,eligible,,pomalidomide + dexamethasone; lenalidomide + dexamethasone,,,,,,Clinical Trial,,
176,A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185,10.1200/jco.2018.36.15_suppl.8010,2018,Journal of Clinical Oncology,Multiple Myeloma,Newly diagnosed,"['pembrolizumab + lenalidomide + low-dose dexamethasone', 'lenalidomide + low-dose dexamethasone']",yes,no,yes,yes,yes,yes,"Randomized, Phase 3",301,Pembrolizumab,6.4,,,no,,eligible,First-line,"Lenalidomide, Dexamethasone",no,,"{'hypothyroidism': 0.07, 'hyperthyroidism': 0.06, 'colitis': 0.02, 'skin reactions': 0.13}",,,Clinical Trial,,
177,A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183,10.1200/jco.2018.36.15_suppl.8021,2018,Journal of Clinical Oncology,Multiple Myeloma,Relapsed/Refractory,"['Pembrolizumab + Pomalidomide + Dexamethasone', 'Pomalidomide + Dexamethasone']",yes,no,yes,yes,yes,yes,Randomized Phase 3,249,Pembrolizumab,7.8,18.0,,no,,eligible,,Pomalidomide + Dexamethasone,,,"{'skin reaction': 5.0, 'pneumonitis': 4.0, 'hyperthyroidism': 3.0, 'infusion reaction': 2.0, 'myopathy': 2.0, 'myocarditis': 1.0, 'iridocyclitis': 1.0, 'hepatitis': 1.0, 'Steven-Johnson syndrome (SJS)': 1.0}",,,Clinical Trial,yes,no
178,,10.1200/jco.2018.36.15_suppl.9548,2018,Journal of Clinical Oncology,Melanoma,Metastatic,"['Dabrafenib/Trametinib', 'Pembrolizumab', 'Bemcentinib + Dabrafenib/Trametinib', 'Bemcentinib + Pembrolizumab']",yes,no,yes,no,no,no,Randomized Phase Ib/II,19,Pembrolizumab,,,16,yes,,eligible,First-line,Bemcentinib + Dabrafenib/Trametinib; Bemcentinib + Pembrolizumab,no,,,,Axl,Interventional,,
179,,10.1200/jco.2018.36.15_suppl.9017,2018,Journal of Clinical Oncology,NSCLC,advanced,"['M7824 500 mg q2w', 'M7824 1200 mg q2w']",yes,no,yes,no,no,no,"Phase 1, expansion cohort",80,M7824 (bifunctional fusion protein targeting TGF-β and PD-L1),8.8,,25.0,PD-L1,,eligible,second-line,monotherapy,no,,,,,,,
180,"A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial",10.1200/JCO.2018.36.15_suppl.6018,2018,Journal of Clinical Oncology,squamous cell carcinoma of the head and neck (SCCHN),"III, IVa, IVb","['cetuximab + RT', 'pembrolizumab + RT']",yes,no,yes,no,no,no,randomized phase II,133,pembrolizumab,,,,p16 status,,eligible,,radiotherapy,no,,,,,clinical trial,,
181,"Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage",10.1200/JCO.2018.36.15_suppl.4547,2018,Journal of Clinical Oncology,Germ Cell Tumors (GCT),advanced,"['Durvalumab (Durva)', 'Durvalumab (Durva) plus Tremelimumab (Treme)']",yes,no,yes,yes,no,no,"open-label, randomized, phase 2",18,"Durvalumab, Tremelimumab",,,5.6,yes,,eligible,"chemorefractory, failed >=2 chemotherapy regimens",Durvalumab + Tremelimumab,no,,{'pneumonitis': 5.6},,"PD-L1 expression, tumor mutational burden (TMB)",clinical trial,,no
182,"Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer",10.1200/JCO.2018.36.15_suppl.4031,2018,Journal of Clinical Oncology,Gastric cancer,Advanced,"['Durvalumab + Tremelimumab', 'Durvalumab monotherapy', 'Tremelimumab monotherapy']",yes,no,yes,yes,yes,yes,Phase Ib/II,94,"Durvalumab, Tremelimumab",9.2,,0.29,PD-L1,,eligible,"Second-line, Third-line",Durvalumab + Tremelimumab,no,,{'colitis': 0.05},,PD-L1 expression,Clinical Trial,,
183,Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo),10.1200/jco.2018.36.15_suppl.tps9606,2018,Journal of Clinical Oncology,Melanoma,III,"['Arm A: 2x IPI 3mg/kg plus NIVO 1mg/kg q3wks', 'Arm B: 2x IPI 1mg/kg plus NIVO 3mg/kg q3wks', 'Arm C: 2x IPI 3mg/kg q3wks directly followed by 2x NIVO 3mg/kg q2wks']",yes,no,yes,no,yes,yes,Multicenter phase 2 randomized trial,90,"Ipilimumab, Nivolumab",24,,0.9,no,,eligible,Neo-adjuvant,Ipilimumab + Nivolumab,no,,,,,Interventional,,
184,Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 Study,10.1158/1078-0432.CCR-17-3436,2018,Clinical Cancer Research,Melanoma; Renal Cell Carcinoma,Advanced,"['Pembrolizumab + Ipilimumab', 'Pembrolizumab + PEG-IFN']",yes,no,yes,no,no,no,Phase Ib,39,Pembrolizumab; Ipilimumab,,,0.59,no,,eligible,,Pembrolizumab + Ipilimumab; Pembrolizumab + PEG-IFN,,,,,,,,
185,Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma,10.1056/NEJMoa1712126,2018,New England Journal of Medicine,renal-cell carcinoma,advanced,"['nivolumab plus ipilimumab', 'sunitinib']",yes,no,yes,no,yes,yes,randomized controlled trial,1096,"nivolumab, ipilimumab",25.2,93.0,46.0,no,,eligible,first-line,nivolumab + ipilimumab,no,,,,,Phase 3,,
186,Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases,10.1093/annonc/mdy041,2018,Annals of Oncology,non-small-cell lung cancer,advanced,"['nivolumab', 'docetaxel']",yes,no,yes,yes,yes,no,randomized controlled trial,854,nivolumab,40.3,,,no,,yes,previously treated,,no,,{'hepatic adverse events': 0.1},,,clinical trial,,
188,"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial",10.1200/JCO.2017.74.7352,2018,Journal of Clinical Oncology,Renal Cell Carcinoma,Advanced,"['Cabozantinib', 'Everolimus']",no,no,no,no,yes,yes,Randomized controlled trial,658,,,,,yes,,no,,,,,,,bone biomarkers,,,
189,"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials",10.1016/S1470-2045(18)30006-8,2018,The Lancet Oncology,Sarcoma,"Metastatic, locally advanced, or unresectable","['Nivolumab monotherapy', 'Nivolumab plus ipilimumab']",yes,no,yes,no,no,no,"Multicentre, open-label, non-comparative, randomised, phase 2",85,"Nivolumab, Ipilimumab",,,,no,,eligible,At least one previous line of systemic therapy,Nivolumab + Ipilimumab,no,USA,,,,Clinical Trial,0-1,no
190,Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience,10.1177/1756287217748867,2018,Therapeutic Advances in Urology,Renal Cell Carcinoma,Advanced,"['Cabozantinib', 'Everolimus']",no,no,no,no,yes,yes,Phase III randomized controlled trial,658,,,,,"MET, AXL",,eligible,Second-line,,no,,,,,RCT,,
191,Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: Analyses from the Ph III study OAK,10.1055/s-0037-1619265,2018,Pneumologie,NSCLC,advanced,"['atezolizumab', 'docetaxel']",yes,yes,yes,no,yes,yes,randomized Ph III study,850,atezolizumab,,31.0,6.2,PD-L1 expression,,eligible,post-platinum therapy,,no,,,corticosteroid treatment,,clinical trial,,
192,"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial",10.1016/S0140-6736(17)33297-X,2018,The Lancet,Urothelial Carcinoma,Locally advanced or metastatic,"['Atezolizumab', 'Chemotherapy (vinflunine, paclitaxel, or docetaxel)']",yes,no,yes,no,yes,no,Randomized controlled trial,931,Atezolizumab,,,20,PD-L1,,yes,After progression with platinum-based chemotherapy,,no,"Europe, North America, Asia-Pacific region",,,PD-L1 expression on <1% (IC0) or 1% to <5% (IC1) of tumour-infiltrating immune cells vs ≥5% of tumour-infiltrating immune cells (IC2/3),Clinical Trial,,
193,A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study,10.1200/jco.2018.36.4_suppl.217,2018,Journal of Clinical Oncology,pancreatic ductal adenocarcinoma,metastatic,"['durvalumab monotherapy', 'durvalumab + tremelimumab']",yes,no,yes,yes,yes,yes,randomized phase 2,65,"durvalumab, tremelimumab",,,,yes,,yes,second-line,durvalumab + tremelimumab,no,,"{'diarrhea_grade3plus': 9.4, 'fatigue_grade3plus': 6.3, 'ascites_grade3plus': 3.1, 'hepatitis_grade3plus': 3.1, 'increased lipase_grade3plus': 3.1}",,"tumor mutation burden, PD-L1, microsatellite status",,,
194,"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial",10.1016/S0140-6736(17)31827-5,2017,The Lancet,Gastric or gastro-oesophageal junction cancer,Advanced,"['Nivolumab', 'Placebo']",yes,no,yes,no,yes,no,"Randomized, double-blind, placebo-controlled, phase 3 trial",493,Nivolumab,8.87,,0.1,no,,yes,Third-line or later,no,no,"Japan, South Korea, Taiwan",{},,,Clinical Trial,0-1,
195,Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?,10.1016/j.clsc.2017.06.003,2017,Clinical Skin Cancer,Melanoma,Metastatic,"['Ipilimumab combined with PD-1 inhibitor', 'PD-1 inhibitor alone']",yes,no,yes,no,yes,no,Review,,"Ipilimumab, Pembrolizumab, Nivolumab",,,,no,,eligible,First-line,Ipilimumab + Nivolumab,no,,,,,,,
196,Cutting the Brakes: Immunotherapy With PD-1 Inhibitors,10.1016/j.clsc.2017.09.001,2017,Clinical Skin Cancer,Melanoma,Metastatic,,yes,no,no,no,yes,no,,,PD-1 inhibitors,,,,no,,eligible,,,,,,yes,,Review,,
198,Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer,10.1056/NEJMoa1709937,2017,New England Journal of Medicine,NSCLC,III,"['durvalumab', 'placebo']",yes,no,yes,yes,yes,yes,"Randomized, controlled, phase 3",713,durvalumab,,,29.9,no,,eligible,consolidation,no,no,,{'pneumonia': 4.4},,,clinical trial,,
199,Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma,10.1056/NEJMoa1709030,2017,New England Journal of Medicine,Melanoma,"III, IV","['Nivolumab', 'Ipilimumab']",yes,no,yes,no,no,yes,"Randomized, double-blind, phase 3 trial",906,"Nivolumab, Ipilimumab",18,,,no,,yes,Adjuvant,no,no,,,,,Clinical Trial,,
200,Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma,10.1016/j.ejca.2017.07.022,2017,European Journal of Cancer,Melanoma,Advanced,"['Pembrolizumab 2 mg/kg', 'Pembrolizumab 10 mg/kg', 'Investigator-choice chemotherapy']",yes,no,yes,no,yes,yes,"Randomized, phase II",540,Pembrolizumab,28,,,BRAFV600 mutant-positive,,eligible,,,Ipilimumab,,,,,,,
203,"Early results of a multicenter phase I and open-label, randomized phase ii study testing the toxicities and efficacy of MK-3475 (pembrolizumab) in combination with MRI-guided laser interstitial thermal therapy (LITT) in recurrent malignant gliomas",10.1093/neuonc/nox168,2017,Neuro-Oncology,Malignant Glioma,Recurrent,"['LITT plus pembrolizumab', 'pembrolizumab alone']",yes,no,yes,yes,no,yes,"Phase 1/2, randomized",9,Pembrolizumab,,,0.22,no,,yes,,LITT,no,,"{'rash': 0.11, 'diarrhea': 0.11, 'pneumonitis': 0.11, 'hypotension': 0.11}",,,Clinical Trial,,
204,,,2017,Journal of Thoracic Oncology,NSCLC,recurrent/metastatic,"['pembrolizumab monotherapy', 'pembrolizumab + low dose weekly carboplatin/paclitaxel']",yes,no,yes,yes,no,no,randomized,20,pembrolizumab,,,,PDL-1,,yes,second line,carboplatin/paclitaxel,no,,"{'fatigue_grade3': 0.11, 'allergic_reactions': 0.33, 'hypothyroidism': 0.11, 'complete_AV_block': 0.1}",One patient discontinued therapy due to grade 3 fatigue. Three patients discontinued carboplatin due to allergic reactions but continued pembrolizumab and paclitaxel. One patient on hormone replacement therapy due to treatment-induced hypothyroidism. One patient discontinued treatment due to complete A-V block successfully resolved with pacemaker insertion. Two patients on hormone replacement therapy due to treatment-induced hypothyroidism.,,,2,
205,Nivolumab for patients with advanced melanoma treated beyond progression analysis of 2 phase 3 clinical trials,10.1001/jamaoncol.2017.1588,2017,JAMA Oncology,Melanoma,Advanced,"['TBP group (treated beyond progression)', 'non-TBP group (not treated beyond progression)']",yes,no,yes,no,yes,no,Retrospective analysis of pooled phase 3 trials,526,Nivolumab,,,,no,,eligible,Frontline,Monotherapy,no,,,,,Clinical Trial,,
206,,,2017,clinicaltrials.gov,Breast Cancer,Metastatic or Locally Recurrent,"['SV-BR-1-GM regimen + retifanlimab (original sequence)', 'SV-BR-1-GM regimen + retifanlimab (alternative sequence - retifanlimab skipped in Cycle 1)']",yes,no,yes,no,yes,no,"Phase I/II, open-label, double arm, randomized",36,Retifanlimab (anti-PD-1),,,,yes,,eligible,Failed standard therapy,"SV-BR-1-GM regimen (cyclophosphamide, SV-BR-1-GM inoculation, interferon) + Retifanlimab",no,,,,CD8 ImmunoPET,Interventional,,
207,"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)",10.1016/S0140-6736(17)31601-X,2017,The Lancet,Melanoma,III/IV,"['Pembrolizumab every 2 weeks', 'Pembrolizumab every 3 weeks', 'Ipilimumab']",yes,no,no,no,yes,yes,"Randomized, open-label, phase 3",834,"Pembrolizumab, Ipilimumab",22.9,,,no,,eligible,,,no,Multicentre (16 countries),{},,,Clinical Trial,0 or 1,
208,Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer,10.1200/JCO.2016.71.7629,2017,Journal of Clinical Oncology,non-small-cell lung cancer,IV or recurrent,"['ipilimumab + paclitaxel + carboplatin', 'placebo + paclitaxel + carboplatin']",yes,no,yes,no,yes,yes,"randomized, double-blind, phase III",956,ipilimumab,,,,no,,yes,first-line,"paclitaxel, carboplatin",no,,,,,clinical trial,,
209,Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma,10.1056/NEJMoa1709684,2017,New England Journal of Medicine,Melanoma,Advanced,"['Nivolumab + Ipilimumab', 'Nivolumab + Placebo', 'Ipilimumab + Placebo']",yes,no,yes,no,yes,yes,Randomized Controlled Trial,,"Nivolumab, Ipilimumab",36,,0.59,"PD-L1, BRAF mutation",,yes,First-line,Nivolumab + Ipilimumab,no,,,,,Clinical Trial,,
210,"A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141",10.1016/j.oraloncology.2017.07.023,2017,Oral Oncology,squamous cell carcinoma of the head and neck (SCCHN),recurrent or metastatic,"['nivolumab', ""investigator's choice of therapy (IC)""]",yes,no,no,no,yes,yes,"randomized, open-label, Phase III clinical trial",34,nivolumab,,,,no,,yes,,,,"Japan, Taiwan, Hong Kong, and Korea",,,,clinical trial,,
212,FDA Approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma,10.1158/1078-0432.CCR-16-0663,2017,Clinical Cancer Research,Melanoma,Metastatic,[],yes,no,no,yes,no,no,"Phase 1, randomized, multicenter, open-label, dose-finding, and activity-estimating trial",89,Pembrolizumab,6,,,BRAF V600 mutation,,eligible,Second-line,,Ipilimumab,,,,BRAF V600 mutation positive,,,
213,Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK,10.1093/annonc/mdx380.016,2017,Annals of Oncology,NSCLC,advanced,"['atezolizumab', 'docetaxel']",yes,no,yes,yes,yes,no,randomized Ph III,1225,atezolizumab,,25.0,6.2,PD-L1,,eligible,prior platinum therapy failure,,no,,"{'hypothyroidism': 3.9, 'pneumonitis': 1.5, 'hepatitis': 1.1, 'colitis': 0.3, 'pneumonitis_grade3plus': 0.7, 'hepatitis_grade3plus': 0.7, 'meningoencephalitis': 0.7, 'AST/ALT elevation': 0.3, 'diarrhea': 0.8}",Majority of irAEs were manageable; 5.9% required corticosteroid treatment; 2.1% discontinued atezo; 4.3% had dose interruptions.,,clinical trial,,no
214,Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: Analyses from the phase III study OAK,10.1093/annonc/mdx380.017,2017,Annals of Oncology,NSCLC,advanced,"['atezolizumab', 'docetaxel']",yes,yes,yes,no,yes,yes,randomized Ph III,850,atezolizumab,,31.0,6.2,PD-L1 expression,,eligible,post-platinum therapy,,no,,,corticosteroid treatment,,clinical trial,,
216,"Efficacy and safety of nivolumab in routine NSCLC treatment-an observational study in 5 lung cancer centers in Berlin, Germany",10.1183/1393003.congress-2017.OA1477,2017,European Respiratory Journal,NSCLC,,[],yes,no,yes,yes,no,no,Observational,148,Nivolumab,,,,no,,eligible,"1st, 2nd, 3rd, or later",,,"Berlin, Germany",,,,Observational Study,,
217,Eosinophilia during immunotherapy of metastatic melanoma: A warning signal for possible side effects?,10.1111/ddg.13300,2017,JDDG - Journal of the German Society of Dermatology,Melanoma,Metastatic,,yes,yes,yes,no,yes,yes,Observational,64,"Ipilimumab, Nivolumab, Pembrolizumab",,69,55,Eosinophils,,yes,,Ipilimumab + Nivolumab,,,,Early recognition and early steroid treatment,Eosinophilia (>4%),,,Quality of life
218,FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma,10.1158/1078-0432.CCR-16-0714,2017,Clinical Cancer Research,Melanoma,Unresectable or metastatic,"['Nivolumab', 'Dacarbazine']",yes,no,no,no,yes,yes,"Double-blind, randomized",418,Nivolumab,,,,BRAFV600 wild-type,,eligible,First-line,no,no,International (outside US),,,BRAFV600 wild-type,Clinical Trial,,
219,U.S. FDA approval summary: Nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab,10.1158/1078-0432.CCR-16-0712,2017,Clinical Cancer Research,Melanoma,Metastatic,[],yes,no,no,no,no,no,Non-comparative analysis,268,Nivolumab,6,,,BRAF V600 mutation,,eligible,,,Ipilimumab,US,{},"Systematic approaches to the identification, description, and patient management for imARs in product labeling.",,Clinical Trial,,
220,Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study,10.1093/jjco/hyx049,2017,Japanese Journal of Clinical Oncology,renal cell carcinoma,advanced,"['nivolumab', 'everolimus']",yes,yes,yes,yes,yes,yes,randomized controlled trial,821,nivolumab,26,78,19,no,,eligible,previously treated,no,no,Japan,"{'diarrhea': 19, 'anemia': 5}",,,subgroup analysis,,Quality of life was stable in the nivolumab arm.
224,Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab,10.1093/jnci/djw260,2017,Journal of the National Cancer Institute,Melanoma,,[],yes,yes,yes,yes,no,no,Retrospective study,119,Nivolumab + Ipilimumab,,,,yes,,eligible,,Nivolumab + Ipilimumab,,,{'pancreatitis': 0.0168},,"amylase, lipase",,,
225,,10.1093/annonc/mdx008,2017,Annals of Oncology,Non-small cell lung cancer,Advanced,[],yes,no,yes,no,yes,yes,"Phase 1b, open-label",101,Pembrolizumab,,,11.9,PD-L1,,eligible,First-line,,no,,,,PD-L1 positive,Clinical Trial,,
226,,10.1245/s10434-017-5854-y,2017,Annals of Surgical Oncology,Ductal carcinoma in situ (DCIS) of the breast,,"['pembrolizumab', 'control (surgery alone)']",yes,no,yes,no,no,no,Dose escalation and dose expansion study,39,Pembrolizumab,,,,CD8+ T cells,,yes,,,no,"University of California, San Francisco",,,,Interventional,,
227,"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",10.1016/S0140-6736(16)32517-X,2017,The Lancet,non-small-cell lung cancer,IIIB or IV,"['atezolizumab', 'docetaxel']",yes,no,yes,no,yes,no,"randomised, open-label, phase 3",1225,atezolizumab,,,15.0,PD-L1,,yes,second-line or later,,no,multicentre (31 countries),,,,clinical trial,0 or 1,
228,"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study",10.1016/S1470-2045(16)30624-6,2017,The Lancet Oncology,non-small-cell lung cancer,IIIb or IV,"['nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks', 'nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks', 'nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks']",yes,no,yes,yes,no,no,"open-label, phase 1, multicohort study",77,"nivolumab, ipilimumab",12.8,,,PD-L1,,eligible,first-line,nivolumab plus ipilimumab,no,US,"{'increased lipase grade 3-4': 8, 'pneumonitis grade 3-4': 5, 'adrenal insufficiency grade 3-4': 5, 'colitis grade 3-4': 5}",Treatment-related adverse events (any grade) prompted treatment discontinuation in 11% and 13% of patients in the respective cohorts. No treatment-related deaths occurred.,PD-L1 >= 1%,clinical trial,,no
229,Intra-and inter-observer reproducibility study of PD-L1 biomarker in Non-Small Cell Lung Cancer (NSCLC)-The dream study,,2017,Journal of Thoracic Oncology,Non-Small Cell Lung Cancer (NSCLC),,[],no,no,no,no,no,no,Reproducibility study,789,pembrolizumab,,,,PD-L1,,eligible,,,,,,,,,,
230,,,2017,Journal of Thoracic Oncology,NSCLC,advanced,,no,no,no,no,yes,yes,,,"nivolumab, pembrolizumab",,,,"PD-L1, EGFR, ALK, ROS1",,no,"first-line, second-line, subsequent-line",,,,,,,,,
231,,,2017,Colombia Medica,"melanoma, glioblastomas, prostate tumors",advanced,,no,no,no,no,no,no,,,ipilimumab,,,,,,no,,HSV-TK gene therapy + ganciclovir,,,,,,,,
232,"LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure",,2016,clinicaltrials.gov,Non-small Cell Lung Cancer (NSCLC),Stage 4,"['Docetaxel or immune checkpoint inhibitor in combination with TTFields using the NovoTTF-100L System', 'Docetaxel or immune checkpoint inhibitor without TTFields']",yes,no,no,no,yes,yes,Randomized Controlled Trial,,Immune checkpoint inhibitor,,,,,,yes,Second line or later,TTFields + Docetaxel or Immune Checkpoint Inhibitor,no,,,,,Interventional,,
233,Nivolumab for recurrent squamous-cell carcinoma of the head and neck,10.1056/NEJMoa1602252,2016,New England Journal of Medicine,squamous-cell carcinoma of the head and neck,recurrent or metastatic,"['nivolumab', 'standard, single-Agent systemic therapy (methotrexate, docetaxel, or cetuximab)']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 3 trial",361,nivolumab,,,13.1,no,,eligible,after platinum-based chemotherapy,,,,,,,,,no
234,"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial",10.1016/S1470-2045(16)30366-7,2016,The Lancet Oncology,Melanoma,III/IV,"['nivolumab + ipilimumab', 'ipilimumab + placebo']",yes,no,yes,yes,yes,yes,Randomized controlled trial,142,"Nivolumab, Ipilimumab",24.5,,0.54,BRAF mutation status,,eligible,first-line,nivolumab + ipilimumab,no,"France, USA","{'colitis': 0.13, 'increased alanine aminotransferase': 0.11, 'diarrhoea': 0.11, 'hypophysitis': 0.04}",,BRAFV600 wild-type,clinical trial,0 or 1,no
235,Survival and efficacy data for patients with glioblastoma treated with ipilimumab in combination with bevacizumab,10.1093/neuonc/now212.073,2016,Neuro-Oncology,Glioblastoma,,,yes,no,no,no,yes,yes,,37,Ipilimumab,,,,no,,eligible,first-line; recurrent,Ipilimumab + Bevacizumab,,,,,,,,
236,Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?,10.1080/14737140.2016.1227706,2016,Expert Review of Anticancer Therapy,Hepatocellular Carcinoma,,,no,no,no,no,no,no,Review,,,,,,,,no,,,,,,,,,,
237,Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma,10.1093/annonc/mdw373.03,2016,Annals of Oncology,renal cell carcinoma,advanced,,yes,no,yes,yes,no,no,"Phase 1b, dose-finding",,avelumab,,,,,,eligible,treatment-naïve,avelumab + axitinib,no,,,,,,,
238,"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial",10.1016/S1470-2045(16)30126-7,2016,The Lancet Oncology,Melanoma,III or IV,"['nivolumab followed by ipilimumab', 'ipilimumab followed by nivolumab']",yes,no,yes,yes,yes,no,"Randomized, open-label, phase 2",140,"Nivolumab, Ipilimumab",19.8,,0.46,no,,yes,treatment-naive or progressed after no more than one previous systemic therapy,sequential nivolumab and ipilimumab,no,USA,"{'colitis': 0.175, 'increased lipase': 0.16, 'diarrhoea': 0.095}",,,Clinical Trial,0 or 1,no
239,Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C,,2016,Journal of Clinical Oncology,NSCLC,advanced,"['pembrolizumab + carboplatin + paclitaxel', 'pembrolizumab + carboplatin + paclitaxel + bevacizumab', 'pembrolizumab + carboplatin + pemetrexed']",yes,no,yes,yes,no,no,randomized controlled trial,74,Pembrolizumab,12,,,PD-L1,,yes,front-line,chemotherapy,no,,"{'rash': 1, 'AST elevation': 3, 'anemia': 4, 'neutropenia': 4, 'febrile neutropenia': 4, 'pericardial effusion': 1}",,,clinical trial,0-1,no
240,"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study",,2016,Journal of Clinical Oncology,Malignant Mesothelioma,,"['Tremelimumab', 'Placebo']",yes,no,yes,yes,yes,yes,Randomized Controlled Trial,571,Tremelimumab,,,,no,,eligible,second-line; third-line,monotherapy,no,global,"{'diarrhea': 0.47, 'dyspnea': 0.32, 'decreased appetite': 0.29, 'fatigue': 0.24, 'nausea': 0.28, 'constipation': 0.17, 'pruritus': 0.27, 'rash': 0.21, 'colitis': 0.07}",,,clinical trial,,
241,Toxicity profile of approved anti-PDI monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials,,2016,Journal of Clinical Oncology,"Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer",Advanced,"['Nivolumab monotherapy', 'Pembrolizumab monotherapy', 'Standard of care']",yes,yes,yes,yes,no,no,Systematic Review and Meta-Analysis,5666,"Nivolumab, Pembrolizumab",,,,no,,eligible,,,,,"{'hypothyroidism_any_grade': 0.065, 'rash_any_grade': 0.125, 'pneumonitis_any_grade': 0.026, 'colitis_any_grade': 0.01}",,,Meta-analysis,,
242,Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA- 4 and PD-1 inhibitors in cancer patients,,2016,Journal of Clinical Oncology,not specified,,"['single-agent ICB arms (nivolumab, pembrolizumab, ipilimumab)', 'non-ICB arms']",yes,yes,yes,yes,no,no,meta-analysis,6133,"nivolumab, pembrolizumab, ipilimumab",,,,no,,eligible,,,,,"{'colitis_any_grade': 3.1, 'increased_AST_any_grade': 7.8, 'rash_any_grade': 16.7, 'hypothyroidism_any_grade': 4.2, 'pneumonitis_any_grade': 2.4, 'colitis_grade3plus': 2.0, 'increased_AST_grade3plus': 2.0, 'rash_grade3plus': 1.0, 'hypothyroidism_grade3plus': 0.3, 'pneumonitis_grade3plus': 0.9}",,,randomized phase II/III trials,,
243,Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1,,2016,Journal of Clinical Oncology,Melanoma,IV M1c,['short-term IPI followed by NIV or PEM'],yes,no,yes,yes,no,no,Retrospective analysis,41,"Ipilimumab, Nivolumab, Pembrolizumab",6,,29.3,BRAFV600 mutation,,eligible,,Ipilimumab followed by Nivolumab/Pembrolizumab,,Netherlands,"{'colitis_grade3plus': 17, 'increased ALT/AST_grade3plus': 5, 'maculopapular rash_grade3plus': 5, 'nephritis_grade3plus': 2}",Treatment was discontinued in 17% of patients due to toxicity.,BRAFV600 mutation 56%,Observational,,
244,Association of pembrolizumab with tumor response and survival among patients with advanced melanoma,10.1001/jama.2016.4059,2016,JAMA - Journal of the American Medical Association,Melanoma,Advanced or metastatic,,yes,no,yes,no,yes,yes,"Open-label, multicohort, phase 1b clinical trials",655,Pembrolizumab,21,,0.14,no,,eligible,,,Ipilimumab,"Australia, Canada, France, United States",,,,Clinical Trial,,
245,FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy,10.1634/theoncologist.2015-0507,2016,Oncologist,non-small cell lung cancer,metastatic,"['nivolumab', 'docetaxel']",yes,no,yes,yes,yes,yes,randomized trial,582,nivolumab,,,,programmed cell death ligand 1,,eligible,after platinum-based chemotherapy,,no,international,{'limbic encephalitis grade 5': 1},,programmed cell death ligand 1-negative,clinical trial,,
246,,10.7573/dic.212297,2016,Drugs in Context,Melanoma,Advanced,"['Nivolumab + Ipilimumab (N+I)', 'Dabrafenib + Trametinib (D+T)']",no,no,no,no,yes,yes,Cost-benefit model,,"Nivolumab, Ipilimumab",,,,BRAF V600 mutation,,eligible,,"Nivolumab + Ipilimumab, Dabrafenib + Trametinib",,US,,,BRAF V600 mutation,Economic analysis,,
247,,10.1093/annonc/mdw373.3,2016,Annals of Oncology,renal cell carcinoma,advanced,[],yes,no,yes,yes,no,no,Phase 1b,6,avelumab,,,,no,,eligible,treatment-naïve,avelumab + axitinib,no,,"{'proteinuria_grade3': 1, 'hypertension_grade3-4': 2, 'palmar-plantar erythrodysaesthesia syndrome_grade3-4': 1, 'lipase increased_grade3-4': 1, 'dysphonia_any_grade': 4, 'hypertension_any_grade': 4, 'fatigue_any_grade': 3, 'headache_any_grade': 3}",,,,<=1,
248,Single center experience on patients with advanced melanoma treated with short-term anti-CTLA4 directly followed by anti-PD-1,10.1093/annonc/mdw379.15,2016,Annals of Oncology,Melanoma,IV M1c,"['short-term IPI followed by NIVO/PEM', 'concurrent IPI + NIVO']",yes,no,yes,yes,no,no,Retrospective analysis,40,"Ipilimumab, Nivolumab, Pembrolizumab",7,,0.33,BRAFV600 mutation,,eligible,,Ipilimumab followed by Nivolumab/Pembrolizumab,,Netherlands,"{'colitis': 0.18, 'increased ALT/AST': 0.08, 'maculopapular rash': 0.05}",Treatment permanently discontinued due to toxicity in 15% of patients.,BRAFV600 mutation 58%,Observational,,
249,Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma,10.1056/NEJMoa1504030,2015,New England Journal of Medicine,Melanoma,III/IV,"['nivolumab alone', 'nivolumab plus ipilimumab', 'ipilimumab alone']",yes,no,yes,no,yes,yes,"randomized, double-blind, phase 3",945,"nivolumab, ipilimumab",,,,PD-L1,,eligible,first-line,nivolumab + ipilimumab,no,,,,"PD-L1 positive, PD-L1 negative",clinical trial,,
250,Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial,10.1200/JCO.2014.59.0703,2015,Journal of Clinical Oncology,Renal Cell Carcinoma,Metastatic,"['Nivolumab 0.3 mg/kg', 'Nivolumab 2 mg/kg', 'Nivolumab 10 mg/kg']",yes,no,yes,no,yes,yes,Randomized Phase II,168,Nivolumab,,,11,no,,yes,Second-line or later,no,no,,,,,Clinical Trial,,
251,Nivolumab in previously untreated melanoma without BRAF mutation,10.1056/NEJMoa1412082,2015,New England Journal of Medicine,Melanoma,Metastatic,"['Nivolumab', 'Dacarbazine']",yes,no,yes,no,yes,yes,Randomized controlled trial,418,Nivolumab,,,11.7,yes,,eligible,First-line,,no,,,,"BRAF mutation negative, PD-L1 status",,,
252,Nivolumab and ipilimumab versus ipilimumab in untreated melanoma,10.1056/NEJMoa1414428,2015,New England Journal of Medicine,Melanoma,Metastatic,"['Nivolumab + Ipilimumab', 'Ipilimumab + Placebo']",yes,no,yes,yes,no,yes,"Double-blind, randomized",142,"Nivolumab, Ipilimumab",,,54,BRAF V600,,eligible,First-line,Nivolumab + Ipilimumab,no,,,Most events resolved with immune-modulating medication.,"BRAF V600 wild-type, BRAF mutation-positive",Clinical Trial,,
253,"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial",10.1016/S1470-2045(15)00083-2,2015,The Lancet Oncology,Melanoma,,"['pembrolizumab 2 mg/kg', 'pembrolizumab 10 mg/kg', 'investigator-choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide)']",yes,no,yes,yes,no,yes,Randomized controlled phase 2 trial,540,Pembrolizumab,,,11,BRAFV600 mutation status,,eligible,,,ipilimumab,multinational (12 countries),"{'fatigue': 1, 'generalised oedema': 1, 'myalgia': 1, 'hypopituitarism': 1, 'colitis': 1, 'diarrhoea': 1, 'decreased appetite': 1, 'hyponatremia': 1, 'pneumonitis': 1}",,BRAFV600 mutant-positive,clinical trial,0 or 1,no
254,,10.1056/NEJMoa1503093,2015,New England Journal of Medicine,Melanoma,Advanced,"['Pembrolizumab (10 mg/kg every 2 weeks)', 'Pembrolizumab (10 mg/kg every 3 weeks)', 'Ipilimumab (3 mg/kg every 3 weeks)']",yes,no,yes,no,yes,yes,"Randomized, controlled, phase 3",834,"Pembrolizumab, Ipilimumab",7.9,,,no,,eligible,,,,,,,,,,
255,,10.1056/NEJMoa1507643,2015,New England Journal of Medicine,non-small-cell lung cancer,advanced,"['nivolumab', 'docetaxel']",yes,no,yes,no,yes,yes,"randomized, open-label, international phase 3 study",582,nivolumab,,,10,PD-L1,,eligible,second-line or later,,no,,,,,,,
256,Nivolumab versus everolimus in advanced renal-cell carcinoma,10.1056/NEJMoa1510665,2015,New England Journal of Medicine,renal-cell carcinoma,advanced,"['nivolumab', 'everolimus']",yes,no,yes,no,yes,yes,"randomized, open-label, phase 3",821,nivolumab,,,19,no,,yes,second-line or later,,no,,,,,,,
257,Cabozantinib versus everolimus in advanced renal-cell carcinoma,10.1056/NEJMoa1510016,2015,New England Journal of Medicine,renal-cell carcinoma,advanced,"['cabozantinib', 'everolimus']",no,no,no,no,yes,yes,"randomized, open-label, phase 3 trial",658,,,,,,,eligible,,,,,,,,,,
258,Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial,10.1016/S0140-6736(14)60958-2,2014,The Lancet,Melanoma,Advanced,"['Pembrolizumab 2 mg/kg every 3 weeks', 'Pembrolizumab 10 mg/kg every 3 weeks']",yes,no,yes,yes,no,no,Randomized controlled trial,173,Pembrolizumab,8,,,no,,yes,,no,Ipilimumab,,"{'fatigue': 0.33, 'pruritus': 0.26, 'rash': 0.18}",,,Phase 1,,
261,Immunotherapy for melanoma,10.1097/CCO.0b013e3283436e79,2011,Current Opinion in Oncology,Melanoma,,,yes,no,no,no,yes,no,Review,,"CTLA-4 inhibitors, PD-1 inhibitors, CD40 agonists, MAGE-3 ASCI",,,,,,eligible,,,,,,The unique side-effect profile for immune checkpoint inhibitors will be a challenge but new skills for dealing with them in community based practice will be learned.,,,,
